Document:

Exhibit 10.5

 

 

Master Purchase Agreement

 

This Master Purchase Agreement (this “Agreement”),
effective as of
                    ,
2008 (the “Effective Date”), is entered into
between Applera Corporation, a Delaware corporation (“AB”),
having a place of business at 850 Lincoln Centre Drive, Foster City, California
94404, and Celera Corporation, a Delaware Corporation (“Celera”),
having a place of business at 1401 Harbor Bay Parkway, Alameda, California
94502, each individually a “Party” and
collectively the “Parties”.

 

WHEREAS, Celera desires to purchase certain products from AB, and AB,
subject to the terms and conditions of this Agreement, is willing to supply
such products to Celera;

 

NOW, THEREFORE, in consideration of the premises and mutual promises set
forth in this Agreement, the Parties agree as follows:

 

1                                         Definitions

 

1.1.        “Celera Critical Product” means a Product to be supplied by
AB to Celera pursuant to this Agreement that (i) as of the Effective Date
is manufactured by AB or for AB using AB’s IPR, (ii) is used by Celera in
the manufacture or sale of Celera Products as of the Effective Date, (iii) will
be used in Celera’s breast cancer products in development as of the Effective
Date and (iv) (x) for which IPR, owned or controlled by AB, would be
required if Celera were to make or have made such Celera Products or (y) where
there is no commercially reasonable alternative to AB as a source of supply. Products
shall be designated as Celera Critical Products by the Parties prior to the
Effective Date. In addition, Celera Critical Products will include Products
derived from the Maui Project that are used by Celera in the manufacture or
sale of Celera Products and that are manufactured by AB or for AB using AB’s
IPR and as to which clause (iv) above is applicable.

 

1.2.        “Celera Product” means a product made by or on behalf of
Celera, that is sold by Celera or its Distributor, that contains an
Intermediate purchased from AB and/or an Oligonucleotide Conjugate purchased
from AB or manufactured by or for Celera.

 

1.3.        “Defective Item” means a Product that has a manufacturing
defect or design defect under the product liability laws of the State of
Delaware.

 

1.4.        “Diagnostic Losses” means claims, losses, damages, expenses
or liabilities arising from or caused by, or alleged to have arisen from or be
caused by, any failure of a Celera Product or any component or part thereof, to
properly diagnose a disease or condition or to make a diagnosis, including
without limitation the making or reporting by a Celera Product or any component
or part thereof of an incorrect diagnosis or a false positive finding or
indication, or the failure of a Celera Product or any part or component thereof
to make or report a finding or indication that if made would result in or
support a diagnosis.

 

1.5.        “Distributor” means any distributor of Celera Products for
Celera. A Distributor of Celera Products as of the Effective Date is Abbott
Molecular.

 

1.6.        “Effective Date” means the date set forth in the preamble
above.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

1

 

 

1.7.        “Field” means Human In Vitro Diagnostics Field as defined in
the Separation Agreement.

 

1.8.        “Intellectual Property Rights” or “IPR”
means all intangible property rights worldwide arising under statutory or
common law, whether or not perfected, including, without limitation, all (1) patents,
patent applications and patent rights; (2) divisions, continuations,
continuations-in-part, renewals, reissues, re-examinations, continuing
prosecutions, and extensions of the foregoing existing at a time in question,
or thereafter filed, issued or acquired; (3) rights associated with works
of authorship including copyrights, copyright applications, copyright
registrations, and derivative works; and (4) Know-how.

 

1.9.        “Instrument” means an Applied Biosystems CE sequencer
instrument previously purchased by Celera or Abbott for the Abbott Alliance (as
defined in the Operating Agreement) as listed on Exhibit B attached
hereto.

 

1.10.      “Intermediate” means the materials that are sold by AB,
including AB catalog products and materials that were produced and/or
configured on a custom basis for Celera and any New Products that are added,
but excluding Raw Materials, that are listed in Exhibit A.1.

 

1.11.      “Know-how” means confidential and/or proprietary technical
and other information, whether patentable or not, including, without
limitation, concepts, discoveries, inventions, modifications, improvements,
data, results, designs, formulae, ideas, analyses, methods, techniques, assays,
research plans, procedures, tests, processes (including manufacturing processes,
specifications and techniques), laboratory records, chemical, pharmacological,
toxicological, clinical, analytical and quality control data, reports, and
summaries.

 

1.12.      “Knowledge”
means, and is limited to, the actual knowledge, as of the Effective Date, of a
Party’s Named Representatives, of facts, documents or information, without
investigation on the part of such Named Representatives. Knowledge may not be
imputed, and there shall be no duty to conduct further inquiry, from the fact
that particular documents, contracts, patents, licenses or the like
(collectively, “document files”) are possessed by a Party’s Named
Representatives, where such Named Representatives have not investigated such
document files.

 

1.13.        “Named Representative” means, with respect to AB, the patent
attorneys and patent agents, senior director attorneys and technology
transaction attorneys in the Applied Biosystems Legal Department and the Senior
Director of Strategic Technology Licensing in the Applied Biosystems Strategy
and Business Development Department, and, with respect to Celera, any officer
or employee.

 

1.14.      “New Product” means a product to be supplied by AB to Celera
that is not listed on Exhibit A as of the Effective Date.

 

1.15.      “New Product Pricing” means the price assigned to a New
Product at the time such New Product is added to the list of Products on Exhibit A
and any New Product derived from the Maui Project (as defined in the Operating
Agreement). For AB products in existence at the time such AB product becomes a

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

2

 

 

New Product by its addition to Exhibit A
and any New Product derived from the Maui Project, New Product Pricing will be
established using a trailing 12 month weighted average of the sales price, less
customary trade discounts and allowances and excluding in all cases, sales to
Celera and sales involving promotional or early access discounts or special
pricing as part of a collaborative exchange with a Third Party (all of the
foregoing collectively, “net sales price”) to AB’s top five customers (or a
smaller number if there are less than five customers) receiving the lowest
global net sales price for such New Products (“AB’s Top
Five”).

 

If the New Product has not been previously sold by AB at the time such
AB product is to become a New Product, the initial sales price to Celera will
be based on AB’s established list price for such New Product less a discount of
10%. An interim New Product Pricing will be determined using the weighted
average of the net sales price to AB’s Top Five for the next 2 full AB fiscal
quarters following the addition of the New Product to Exhibit A and any
New Product derived from the Maui Project A final New Product Pricing will be
determined using the weighted average of the net sales price to AB’s Top Five
for the next four full AB fiscal quarters following the determination of the
interim New Product Pricing. Such final New Product Pricing will be effective
immediately thereafter for 1 full fiscal year, subject to the provisions of
Sections 5.2 and 5.3. In no event will retroactive adjustments be made for any
sales from AB to Celera using the initial sales price for a New Product.

 

1.16.      “Oligonucleotide Conjugate” means an oligonucleotide that
has been chemically combined with a Raw Material.

 

1.17.      “Products” means Intermediates and Raw Materials listed on Exhibit A.1
(Intermediates) and on Exhibit A.2 (Raw Materials), respectively, and
Instruments on Exhibit B, including any New Products added thereto
subsequent to the Effective Date.

 

1.18.      “Raw Materials” means materials that are not sold by AB as
standalone products or as components of products but that are used by AB to
make Oligonucleotide Conjugates and other chemical derivatives of such
materials. Raw Materials include those that are listed in Exhibit A.2, and
any New Products that are Raw Materials and are added to Exhibit A.2.

 

1.19.      “Separation Agreement” means the agreement between AB and
Celera dated May 8, 2008. Capitalized terms used but not defined in this
Agreement will have the meaning given to such terms in the Separation
Agreement.

 

1.20.      “Specifications” means, with respect to a Product listed on Exhibit A
or Exhibit B as of the Effective Date, AB’s written specifications for
such Product or, if there are no written specifications for a Product,
specifications agreed to in writing by the Parties.

 

1.21.      “Third Party” means any person or entity other than Celera
or AB or an Affiliate of Celera or AB.

 

1.22.      “Third Party Manufacturer” means a Third Party that is a
contract manufacturer for a Party. For the avoidance of doubt, a Third Party
Manufacturer does not include a Third Party who supplies a Party with products
or materials according to the specifications of that Third Party.

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

3

 

2                                         Products

 

2.1.        Product List. Subject to the terms and conditions of this
Agreement, AB will use commercially reasonable efforts to deliver to Celera or
Distributor, as ordered by Celera pursuant to this Agreement, the Products
listed on and further described in Exhibits A.1 and A.2, at prices to be
determined by the Parties prior to the Effective Date based on historical
prices, and Exhibit B, attached hereto.

 

2.2.        Adding Products. From time to time, New Products may be
added to Exhibits A or B, at which time such New Products will become subject
to the terms of this Agreement.

 

(a)       If
a New Product is offered by AB to its customers, then 30 days after Celera’s
written request, such New Product will be added to Exhibit A, subject to Section 2.8,
at the New Product Price. In the event that AB must pay a royalty to a Third
Party in order to sell such New Product to Celera pursuant to this Agreement,
and such royalty is not already included in the New Product Price, the amount
of such royalty due with respect to a sale of such New Product by Celera will
be paid by Celera to AB (defined herein as a “Pass-Through
Royalty”). The New Product Price and any applicable Pass-Through
Royalty will be determined by AB within 30 days of such New Product being added
to Exhibit A. For the avoidance of doubt, no Pass-Through Royalty will be
applicable to Products listed on Exhibit A as of the Effective Date to the
extent AB has breached its representations and warranties set forth in Section 2.8
with respect to such Products.

 

(b)      Notwithstanding
Section 2.2(a) above, if Celera can demonstrate that it has
previously ordered a product that is not listed on Exhibit A, such product
will be added to Exhibit A, subject to Section 2.8, at the price
previously paid by Celera, as adjusted pursuant to Section 5.2, and will
be deemed a Product hereunder as of the Effective Date.

 

(c)       If
a New Product is not offered by AB to its customers at the time of Celera’s
request, such New Product will be deemed a custom product and will be addressed
as described in Section 2.7.

 

(d)      If
a New Product is derived from the Kauai Project (as defined in the Operating
Agreement) it will be added to Exhibits A or B, as the case may be, at a price
determined as set forth in the agreement between the Parties for the Kauai
Project.

 

(e)       If
a New Product is derived from the Maui Project it will be added to Exhibits A
or B, as the case may be, at the New Product Price. In the event that AB must
pay a royalty to a Third Party in order to sell such New Product to Celera
pursuant to this Agreement, and such royalty is not already included in the New
Product Price, the Pass-Through Royalty will be paid by Celera to AB. The New
Product Price and any applicable Pass-Through Royalty will be determined by AB
within 30 days of such New Product being added to Exhibit A.

 

(f)       If
a New Product is an Instrument and is not covered by clauses (d) and (e) above,
it will be added to Exhibit B at a price agreed to by the Parties.

 

2.3.        Removing Products. AB will be able to remove Products from Exhibit A
or B if AB ceases to manufacture Products and/or have manufactured for it
Products using AB’s IPR.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

4

 

 

AB will give
Celera six months prior written notice of the date of removal, provided that if
AB is legally compelled to withdraw a product no prior notice need be given,
but notice will be given to Celera as soon as practicable thereafter, and
further provided that if a Third Party Manufacturer ceases manufacture of a
Product it supplies to AB, AB need only provide the notice period it receives
from such Third Party Manufacturer. AB will afford Celera an opportunity to
make an “end of life” purchase of such Product, provided a purchase order for
same is received within 30 days after delivery of written notice of proposed
discontinuance to Celera. Such end of life purchase will not exceed the volume
of that Product Celera estimates it will need for the following two years. AB
will use commercially reasonable efforts to manufacture, or have manufactured,
and deliver the amount of such Product ordered by Celera.

 

2.4.        Celera’s Right to Continue Production. In the event AB
elects to remove a Celera Critical Product from Exhibit A or is prevented
from supplying a Celera Critical Product due to a Force Majeure Event (as
defined in Section 22.6) applicable to AB that continues for 60 days
beyond the delivery date for such Celera Critical Product, AB will have the option
of (i) securing an alternative source of
supply for such Celera Critical Product, subject to
Celera’s approval, such approval not to be unreasonably withheld or delayed, or (ii) granting Celera the right to
manufacture such Celera Critical Product itself or through a Third Party
Manufacturer selected by Celera, subject to AB’s approval, such approval not to be
unreasonably withheld or delayed. Notwithstanding anything to contrary herein,
AB will not be obligated to transfer any IPR to Celera or a Third Party
Manufacturer if AB is prohibited from doing so by an injunction. Any
alternative source of supply of a Celera Critical Product to Celera pursuant to
clause (i) above will be on terms substantially similar with the terms of
this Agreement, including price. Celera’s supply through a Third Party
Manufacturer pursuant to clause (ii) above will be subject to the
representations set forth in Section 2.8.

 

If Celera is granted the
right to manufacture the Celera Critical Product itself as provided herein or
through a Third Party Manufacturer, AB will in a timely manner (as is reasonable under
the circumstances) grant to Celera a limited,
non-exclusive, royalty-free license, subject to Section 2.8, (without the
right to sublicense or transfer except as provided herein) to use Intellectual
Property Rights owned or controlled by AB necessary to enable Celera or the
approved Third Party Manufacturer to manufacture the Celera Critical Product.
AB will also provide  technical, product and
manufacturing documentation that Celera or the Third Party Manufacturer may
request as is reasonably necessary to allow Celera continued supply of the
Celera Critical Product so that the availability of the Celera Critical Product
is not interrupted or any interruption is minimized. In addition, any
additional assistance, such as training, that Celera or the Third Party
Manufacturer requests will be provided at AB’s then prevailing rates. Celera
will require any Third Party Manufacturer to agree in writing to treat AB’s
technical, product and manufacturing documentation and Intellectual Property
Rights as Confidential Information of AB, and Celera will restrict disclosure
to those employees and contractors to whom it is necessary to disclose such
Confidential Information in connection with the performance of the duties under
this Section 2.4.

 

AB may notify and demonstrate to Celera that it is again willing and
able to supply the Celera Critical Product. Upon such notice from AB, Celera
will, in a time frame that is commercially reasonable under the circumstances,
commence purchasing the Celera Critical Product from AB and Celera’s rights
under this Section 2.4 will terminate.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

5

 

 

2.5.        Intermediates and Components for Further Manufacturing

 

(a) Intermediates.  Subject
to the restrictions and obligations on Celera’s use of the Intermediates set
forth in this Agreement, Celera will sell Intermediates, directly or through a
Distributor, only (i) to end users who purchase or use Celera diagnostic
products and (ii) for use only with Celera diagnostic products. For the
avoidance of doubt, the foregoing will not restrict Celera’s or its bona fide
collaborators’ use of Intermediates for research, development or in Celera’s
clinical laboratory testing services business, subject in each case to the
restrictions and obligations on Celera herein.

 

(b) Components for Further
Manufacturing. Intermediates and Raw Materials will be deemed to be
and will be components for further manufacturing, and Celera will be deemed to
be and will be the finished device manufacturer, or the manufacturer of any
Celera Product that is a diagnostic product, within the meaning of the U.S.
Food and Drug Administration (“FDA”) laws, rules and
regulations and foreign laws, rules and regulations governing the
manufacture, sale and distribution of diagnostic and other medical devices. AB
may label or refer to Intermediates and Raw Materials as components for further
manufacturing. In the event that any Intermediate or Raw Material is
accompanied by a label or statement stating that such Intermediate or Raw
Material is “For Research Use Only. Not for use in diagnostic procedures” or
words of the same import, such label will not be deemed to restrict Celera’s
use of such Intermediate or Raw Material as a component for further
manufacturing of Celera Products for use in the Field.

 

2.6.        Raw Materials. Celera will have the right to use Raw
Materials purchased from AB, to make, or have made by a Third Party
Manufacturer, Oligonucleotide Conjugates and to use such Oligonucleotide
Conjugates to make, have made, use, sell, offer for sale and/or import Celera
Products that incorporate such Oligonucleotide Conjugates; provided that such
Third Party Manufacturer is not infringing (i) the 5’ Nuclease IPR of
Roche, a partial list of which is as follows: 5,538,848, 5,723,591, 5,876,930,
6,030,787, 6,258,569, 5,804,375, 5,210,015 and 5,487,972; or (ii) AB’s dye
patents, a partial list of which is as follows: 6,649,598, 6,096,723,
6,303,775, 6,020,481, 6,008,379, 6,221,604. Celera will notify AB when it
selects such Third Party Manufacturer and AB will have 30 days to notify Celera
whether or not there is a reasonable and good faith basis to believe that the
Third Party Manufacturer is infringing the AB dye or 5’ Nuclease technology. AB
agrees that it will not commence an infringement action against such Third
Party Manufacturer by reason of its activities conducted for Celera pursuant to
this Section 2.6. Except for permitted transfers to Third Party
Manufacturers solely for the purpose of making Oligonucleotide Conjugates for
Celera, any sale or transfer of Raw Materials to a Third Party is specifically
prohibited. All agreements pursuant to which Raw Materials are transferred to a
Third Party Manufacturer will contain provisions providing that: (i) all
Raw Materials transferred will be deemed confidential information of AB; (ii) the
Third Party Manufacturer will not reverse-engineer any Raw Materials for so
long as they remain confidential information of AB; (iii) the Third Party
Manufacturer will not sell, re-sell, donate or otherwise transfer Raw Materials
to any Third Party; (iv) Celera will have the right, upon reasonable
notice and at its expense, to audit all use of the Raw Materials by the Third
Party Manufacturer to determine compliance with these provisions; and (v) all
Raw Materials will be and remain property of Celera, be subject to removal at
any time upon demand by Celera, be at all times clearly identified by the Third
Party Manufacturer as the property of Celera and be kept

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

6

 

 

free of liens
and/or encumbrances of any kind. Scandinavian Gene Synthesis, Celera’s current
Third Party Manufacturer using Raw Materials, is approved by AB as a Third
Party Manufacturer.

 

2.7.        Custom Products. Celera may request AB to create customized
products. AB may accept or reject such a request at its discretion. In the
event AB agrees to create a customized product for Celera, the Parties will
amend this Agreement, or otherwise agree in writing, to include appropriate
special terms and conditions and thereafter such customized product will be
added as a New Product.

 

2.8           Grant of Rights.
(a) AB hereby grants to Celera, under AB’s IPR and, without AB having to
pay any additional consideration, under AB’s existing rights in any Third Party
IPR as of the Effective Date, all rights necessary (i) to make, have made,
use, sell, offer for sale and/or import Celera Products that incorporate
Products, and (ii) to convey to end-users all rights necessary to use
Celera Products that incorporate Products in the Field.

 

(b) Celera
will be responsible for securing access, at Celera’s cost and without any
contribution from AB, to any additional Third Party IPR Celera needs.

 

(c) AB
represents and warrants, to its Knowledge, that AB’s grant of the rights set
forth in Section 2.8(a) are free and clear of any additional
obligations of Celera to AB or a Third Party as to the Products on Exhibits A
and B and that, subject to the provisions of the next sentence, AB has the
necessary rights to sell such Products for use in Celera Products in the Field.
AB makes no representation and warranty with respect to Third Party IPR (i) where
AB’s patent attorneys and patent agents have a good faith, well reasoned legal
basis to believe that the claims of any Third Party IPR are invalid,
unenforceable or not infringed, or (ii) as to the matters set forth on
Schedule 2.8, or (iii) where any Named Representative of Celera has
Knowledge that AB does not have the rights set forth in Section 2.8(a) as
of the Effective Date free and clear of any additional obligations to a Third
Party. For the avoidance of doubt, AB would not be required to convey or obtain
any Third Party IPR for the Field where it does not have such rights to convey
as of the Effective Date, including in those instances where AB has prior to
the Effective Date procured a license to any Third Party IPR for fields other
than the Field, provided that AB’s representation and warranty in this Section 2.8(c) is
true.

 

(d) Notwithstanding
Section 2.8(b), in the event that AB breaches the foregoing representation
and warranty, AB’s sole obligation and Celera’s sole remedy (except for AB’s
indemnity obligations pursuant to Section 15.1) with respect to such
breach will be, at AB’s option, (a) to reimburse Celera for the
consideration paid by Celera to obtain the rights that are the subject of AB’s
breach of such representation and warranty, (b) to use commercially
reasonable efforts at AB’s cost to obtain such rights for Celera as soon as
reasonably feasible, or (c) if AB concludes that obtaining such rights for
Celera is not possible or commercially feasible, paying Celera such damages to
which Celera may be entitled under law for breach of such representation and
warranty, provided that in no event shall such amount exceed lost profits of
Celera as reasonably estimated by Celera for Celera’s inability to sell the
subject Celera Product during the [***] period commencing on the date Celera
ceased exercising the rights that are the subject of such breach.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

7

 

 

3                                         Term

 

3.1.        Initial Term. The term of this Agreement will commence on
the Effective Date and will, unless sooner terminated as provided herein, be in
full force and effect for seven years thereafter (the “Initial
Term”).

 

3.2.        Renewal. Following the Initial Term, this Agreement may be
renewed for consecutive one year terms by mutual agreement of the Parties
reached not later than 90 days prior to the expiration of the then-current
term. If after the Initial Term (or any renewal term) AB elects to terminate
this Agreement, Celera may thereafter reasonably demonstrate to AB that rights
to certain patents or patent applications owned or controlled by AB as to any
Product previously supplied to Celera are required for Celera to continue to
make, use or sell Celera Products. In such event, AB and Celera will discuss
and negotiate in good faith Celera’s access to such AB patents and patent
applications. For the avoidance of doubt, the preceding sentence is not a
binding commitment by either Party to conclude an agreement.

 

4                                         Termination

 

4.1                                 Default. Either Party may terminate this Agreement in the event
the other Party breaches any material obligation hereunder, other than for
non-payment of undisputed amounts past due, and, if such breach is capable of
being cured, such breach remains uncured for 90 days after receipt by the
defaulting Party of written notice of such default; provided,
however, that if such breach is amenable of cure but not within 90 days, and if the breaching
Party begins diligent efforts to
cure such breach promptly after
receipt of written notice thereof, then the breaching Party will have an
additional 90 days within which to cure
such breach provided that the breaching Party continues to use diligent efforts to cure such breach as soon as reasonably
possible. Notwithstanding the foregoing, where the breach is non-payment of
amounts due when payable, the cure period will be 30 days after receipt of
written notice of breach.

 

4.2                                 Acts of Insolvency. Either Party may terminate this
Agreement by written notice if the other Party becomes insolvent, makes a
general assignment for the benefit of creditors, suffers or permits the
appointment of a receiver for its business or assets, or has wound up or
liquidated, voluntarily or otherwise.

 

4.3                                 Challenge to AB Patents. AB may terminate sales of a Product
pursuant to this Agreement in the event Celera initiates any proceeding for the
purpose of challenging AB’s IPR in that Product. Celera will not be deemed to
have initiated such a proceeding if Celera challenges AB’s patent rights in a
Product as a defense or compulsory counterclaim in a proceeding initiated
against Celera by AB or as in a declaratory judgment action brought by Celera
against AB.

 

4.4                                 Force Majeure Event. If a Force Majeure Event (as defined in
Section 22.6) causing AB to fail to supply a Product continues for 60
consecutive days beyond the delivery date for such Product, Celera will have
the right to terminate its obligations under the Agreement with respect to that
Product on 30 days written notice to AB, or provide AB with written notice of
its intent to invoke the provisions of Section 2.4.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

8

 

 

4.5                                 Effect of Termination. Obligations incurred, including
purchase orders accepted, prior to the effective date of termination will not
be affected by termination, provided, however, that if the basis for
termination is non-payment of invoices or acts of insolvency, the terminating
Party may cancel all outstanding purchase orders without penalty or restocking
fee.

 

4.6                                 Effect of Third Party Acquisition. In the event Celera is acquired by a Third
Party during the term or any extended term of this Agreement, then the
purchasing volume of Products and Instruments on Exhibits A and B will be
limited to increases determined by the reasonable requirements to support
Celera’s or a
successor’s on-going business. Such reasonable requirements will be based on the
size of Celera’s business as of the Effective Date of the Separation Agreement,
as increased to take into account subsequent increases in Celera’s or a Third
Party acquirer’s sales volume because of: (i) increased sales of existing
products; (ii) sales of newly introduced products in the Field; and (iii) the
acquisition of other companies or their assets.

 

4.7                                 Return of Confidential Information. Upon cancellation,
termination or expiration of this Agreement, upon written request of a Party,
each Party agrees to immediately deliver to the other Party or destroy all
documents, data, records, notebooks, and similar writings relating in any way
to any Confidential Information of the other Party, including copies then in
such Party’s possession, whether prepared by that Party or others. If any such
documents are destroyed, the Party destroying same will certify to such
destruction in writing. Neither Party will retain any such documents, data, or
other items originated by the other Party, except one copy may be retained for
legal archive purposes.

 

4.8                       Surviving Provisions. The rights and obligations of the
Parties set forth under Sections
                                                      
and any other provisions that are expressly stated to survive termination of
this Agreement will survive termination of this Agreement for any reason. All
other rights and obligations of the Parties will cease on termination of this
Agreement.

 

5                                         Price

 

5.1                                 Price. The price of each Product will be the price set forth
on Exhibit A. The price applicable to a Product may be adjusted pursuant
to the terms of Section 5.2.

 

5.2                                 Price
Changes. The prices set forth in Exhibit A are firm for
the first year following the Effective Date. After the first year of the
Initial Term, AB may increase the prices set forth in Exhibit A not more
frequently than once in any twelve (12) month period, provided that the maximum
percentage change for a Product over the previous price for such Product shall
be limited to a percentage which is calculated as provided below. Any such
change in the Product prices will be effective for all Products ordered after July 1st
of the next July 1 to June 30 fiscal year (the “Fiscal Year”). Each annual change to
the Product prices will be determined using one of the following formulas
depending on type of Product using calculations to one decimal place.

 

5.2.1  Price
Change Formula for BDT Products Containing the [***] Enzyme. The Parties agree to calculate price changes for BDT
Products containing the [***] enzyme using a

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

9

 

 

formula
based on the Employment Cost Index for Total Compensation for the Pacific
Region (“ECI”) as it appears on http://www.bls.gov/ro9/eciwest.htm, and the
annual change, if any, in the AB purchase price of the enzyme [***]. The price
of Products may change by an amount determined by AB in its sole discretion,
provided that any increase for such Product from one Fiscal Year to the next
will not exceed the price for that Product in effect during the preceding
Fiscal Year increased by a percent equal to the weighted average percent
increase of two pricing components over the same period.  By the first 15th of May following
the Effective Date and by each May 15th thereafter during the term
of the Agreement, the Parties will calculate a pricing adjustment determined by
the combined percentage of: i) a weighting of 20.0% times the annual percentage
of change from the previous 12 month average from April 1st to March 31st
in the ECI and ii) a weighting of 80.0% times the annual change in the AB
purchase price of the Roche Enzyme [***], with an example as follows.

 

20% (12
month avg percent change of ECI) plus 80% (annual price change in purchase price of [***]
enzyme) = % of maximum price increase/yr

 

Example - Price Change Formula for BDT
Products containing the enzyme [***]

 

A.     Establish: Appropriate Index and Weighted Averages

 

	
   

  	
  20%

  	
  BLS - Employment Cost Index for
  the Pacific Region

  
	
   

  	
  80%

  	
  AB Purchase Price of [***]

  

 

B.     Establish: Timing, Index Base values, and Annual Index Change

 

         1.             Establish Timing Convention

 

	
   

  	
  Period Start

  	
   

  	
  4/1/2007

  	
   

  	
  4/1/2008

  	
   

  	
  4/1/2009

  	
   

  
	
   

  	
  Period End

  	
   

  	
  3/31/2008

  	
   

  	
  3/312009

  	
   

  	
  3/31/2010

  	
   

  
	
   

  	
  Known As:

  	
   

  	
  Base
  Yr.

  	
   

  	
  Year
  1

  	
   

  	
  Year
  2

  	
   

  

 

         2.             Establish Monthly
Average of the 12 Months in the Period

 

	
   

  	
   

  	
   

  	
  Base Yr.

  	
   

  	
  Year 1

  	
   

  	
  Year 2

  	
   

  
	
   

  	
  ECI-Pacific

  	
   

  	
  160

  	
   

  	
  170

  	
   

  	
  190

  	
   

  
	
   

  	
  [***]

  	
   

  	
  $

  	
  2,000

  	
   

  	
  $

  	
  2,200

  	
   

  	
  $

  	
  2,300

  	
   

  
												

 

         3.             Establish Percentage
Change from the Prior Period

 

	
   

  	
   

  	
   

  	
  Base Yr.

  	
   

  	
  Year 1

  	
   

  	
  Year 2

  	
   

  
	
   

  	
  ECI-Pacific

  	
   

  	
   

  	
   

  	
  6.3

  	
  %

  	
  11.8

  	
  %

  
	
   

  	
  [***]

  	
   

  	
   

  	
   

  	
  10.0

  	
  %

  	
  4.5

  	
  %

  

 

C.      Calculate for Year 1 -
Annual Blended Index Pricing Change

 

         1.             Establish Percentage Change from the Prior
Period

 

	
   

  	
   

  	
   

  	
  Year 1

  % Blend

  	
   

  	
  Year 1% of

  Index Change

  	
   

  	
  Year 1 Weighted%

  	
   

  
	
   

  	
  ECI-Pacific

  	
   

  	
  20.0

  	
  %

  	
  6.3

  	
  %

  	
  1.3

  	
  %

  
	
   

  	
  [***]

  	
   

  	
  80.0

  	
  %

  	
  10.0

  	
  %

  	
  8.0

  	
  %

  

 

	
   

  	
  2.

  	
  Pricing on Products can
  change up to:

  	
  9.3

  	
  %

  

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

10

 

 

5.2.2 Price
Change Formula for BDT Products containing enzymes other than [***]. The
following formula will govern price changes for BDT Products containing enzymes
other than [***] on Exhibit A. The Parties agree to use weighted average
percentage method of price adjustment such that the price of Products will change
by an amount determined by AB in its sole discretion, provided that any
increase for a Product from one Fiscal Year to the next will not exceed the
price for the Product in effect during the preceding Fiscal Year increased by a
percent equal to the weighted average percent increase of two published indexes
over the same period. The Parties agree to use a composite index based on the
weighted average of the previous 12-month average, from April 1st to March 31st,
of both the ECI and the Producer Price Index for In vitro Manufacturing
Substances (“PPI”). By the first 15th of May following the
Effective Date and by each May 15th thereafter during the Term
of the Agreement, the Parties will calculate a straight line average of the
previous 12 months (April through March of each annual period) for
each of the PPI (as defined above) as it appears on the Bureau of Labor
Statistics website  http://www.bls.gov/ppi/home.htm under In
Vitro Diagnostic Substances Manufacturing PPI code 06371402 and the ECI
as it appears in the Bureau of Labor Statistics website
http://www.bls.gov/ro9/eciwest.htm, or if discontinued such equivalent index as
is mutually agreed to by the Parties. AB will notify Celera of any increase in
price of a Product at least thirty (30) days prior to the date on which the
increase will take effect. The pricing adjustment will be determined by the
combined percentage of: i) a weighting of 70.0% of the average percent change
of the previous 12 months from April 1st to March 31st in the ECI
plus ii) a weighting of 30.0% of the average percent change of the previous 12
months from April 1st to March 31st in the PPI, with an example as
follows.

 

70% (12 month avg percent change of ECI) plus 30%
(12 month avg change of PPI) = % of maximum price increase/yr

 

Example - Price Change Formula for BDT Products
containing enzymes other than [***]

 

A.    Establish:
Appropriate Index and Weighted Averages

 

	
   

  	
  70%

  	
  BLS - Employment Cost Index for the Pacific Region

  
	
   

  	
  30%

  	
  BLS - PPI for In Vitro Manufactured Substances

  

 

B.     Establish:
Timing, Index Base values, and Annual Index Change

 

         1.             Establish Timing Convention

 

	
   

  	
  Period Start

  	
   

  	
  4/1/2007

  	
   

  	
  4/1/2008

  	
   

  	
  4/1/2009

  	
   

  
	
   

  	
  Period End

  	
   

  	
  3/31/2008

  	
   

  	
  3/31/2009

  	
   

  	
  3/31/2010

  	
   

  
	
   

  	
  Known As:

  	
   

  	
  Base Yr.

  	
   

  	
  Year 1

  	
   

  	
  Year 2

  	
   

  

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

11

 

 

         2.              Establish Monthly
Average of the 12 Months in the Period

 

	
   

  	
   

  	
   

  	
  Base Yr.

  	
   

  	
  Year 1

  	
   

  	
  Year 2

  	
   

  
	
   

  	
  ECI-Pacific

  	
   

  	
  160

  	
   

  	
  170

  	
   

  	
  190

  	
   

  
	
   

  	
  PPI Invitro Mfg.

  	
   

  	
  180

  	
   

  	
  175

  	
   

  	
  185

  	
   

  

 

         3.              Establish Percentage
Change from the Prior Period

 

	
   

  	
   

  	
   

  	
  Base Yr.

  	
   

  	
  Year 1

  	
   

  	
  Year 2

  	
   

  
	
   

  	
  ECI-Pacific

  	
   

  	
   

  	
   

  	
  6.3

  	
  %

  	
  11.8

  	
  %

  
	
   

  	
  PPI Invitro Mfg.

  	
   

  	
   

  	
   

  	
  -2.8

  	
  %

  	
  5.7

  	
  %

  

 

C.     Calculate
Annual Index-Based Pricing Change

 

         1.              Establish Percentage
Change from the Prior Period

 

	
   

  	
   

  	
   

  	
   

  	
  Year 1 

  % Blend

  	
   

  	
  Year 1 % of

  Index Change

  	
   

  	
  Year 1 Weighted %

  	
   

  
	
   

  	
   

  	
  ECI-Pacific

  	
   

  	
  70.0

  	
  %

  	
  6.3

  	
  %

  	
  4.4

  	
  %

  
	
   

  	
   

  	
  PPI Invitro Mfg.

  	
   

  	
  30.0

  	
  %

  	
  -2.8

  	
  %

  	
  -0.8

  	
  %

  

 

	
   

  	
  2.

  	
  Pricing on Products can
  change up to by:

  	
  3.5

  	
  %

  

 

5.2.3 Price
Change Formula for Other Products. The following formula will govern price
changes for all Products on Exhibit A except those Products in Section 5.2.1
and 5.2.2 above. The Parties agree to use weighted average percentage method of
price adjustment such that the price of Products will change by an amount
determined by AB in its sole discretion, provided that any increase for a
Product from one Fiscal Year to the next will not exceed the price for the
Product in effect during the preceding Fiscal Year increased by a percent equal
to the weighted average percent increase of two published indexes over the same
period. The Parties agree to use a composite index based on the weighted
average of the previous 12-month average, from April 1st to March 31st,
of both the ECI and the PPI. By the first 15th of May following
the Effective Date and each May 15th thereafter during the term
of the Agreement, the Parties will calculate a straight line average of the
previous 12 months (April through March of each annual period) for
each of the PPI as it appears on the Bureau of Labor Statistics website www.bls.gov
under In Vitro Diagnostic Substances Manufacturing, PPI code 06371402 and the ECI
as it appears in the Bureau of Labor Statistics website
http://www.bls.gov/ro9/eciwest.htm, or if discontinued such equivalent index as
is mutually agreed to by the Parties. AB will notify Celera of any increase in
price of a Product at least thirty (30) days prior to the date on which the
increase will take effect. The pricing adjustment will be determined by the
combined percentage of: i) a weighting of 40.0% of the average percent change
of the previous 12 months from April 1st to March 31st in the ECI
plus ii) a weighting of 60.0% of the average percent change of the previous 12
months from April 1st to March 31st in the PPI, with an example as
follows.

 

40% (12
month avg change of
ECI) plus 60% (12 month avg change of PPI) = % of maximum price
increase/yr

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

12

 

 

Example - Price Change Formula for all Other
AB Products

 

A.          Establish: Appropriate Index and Weighted
Averages

 

40%                         BLS - Employment Cost Index for the Pacific Region

60%                         BLS - PPI for In Vitro Manufactured Substances

 

B.            Establish:
Timing, Index Base values, and Annual Index Change

 

1.              Establish
Timing Convention

 

	
  Period Start

  	
   

  	
  4/1/2007

  	
   

  	
  4/1/2008

  	
   

  	
  4/1/2009

  
	
  Period End

  	
   

  	
  3/31/2008

  	
   

  	
  3/31/2009

  	
   

  	
  3/31/2010

  
	
  Known As:

  	
   

  	
  Base Yr.

  	
   

  	
  Year 1

  	
   

  	
  Year 2

  

 

2.              Establish
Monthly Average of the 12 Months in the Period

 

	
   

  	
   

  	
  Base Yr.

  	
   

  	
  Year 1

  	
   

  	
  Year 2

  	
   

  
	
  ECI-Pacific

  	
   

  	
  160

  	
   

  	
  170

  	
   

  	
  190

  	
   

  
	
  PPI Invitro Mfg.

  	
   

  	
  180

  	
   

  	
  175

  	
   

  	
  185

  	
   

  

 

3.              Establish
Percentage Change from the Prior Period

 

	
   

  	
   

  	
  Base Yr.

  	
   

  	
  Year 1

  	
   

  	
  Year 2

  	
   

  
	
  ECI-Pacific

  	
   

  	
   

  	
   

  	
  6.3

  	
  %

  	
  11.8

  	
  %

  
	
  PPI Invitro Mfg.

  	
   

  	
   

  	
   

  	
  -2.8

  	
  %

  	
  5.7

  	
  %

  

 

C.            Calculate
Annual Index-Based Pricing Change

 

1.              Establish
Percentage Change from the Prior Period

 

	
   

  	
   

  	
  Year 1

  % Blend

  	
   

  	
  Year 1%

  of Index Change

  	
   

  	
  Year 1 Weighted

  %

  	
   

  
	
  ECI-Pacific

  	
   

  	
  40.0

  	
  %

  	
  6.3

  	
  %

  	
  2.5

  	
  %

  
	
  PPI Invitro Mfg.

  	
   

  	
  60.0

  	
  %

  	
  -2.8

  	
  %

  	
  -1.7

  	
  %

  

 

	
  2.    Pricing on
  Products may change up to:

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  0.8

  	
  %

  

 

5.3                                Changed Costs. The Parties agree to negotiate in good faith
a reasonable adjustment to the price of a Product independent of adjustments
pursuant to Section 5.2 in the event of an increase in AB’s cost of
manufacture thereof purchased from Third Party suppliers, provided such
adjustments will occur, if ever, only once  in any 12
month period or at any time provided such costs increase by more than 10%, and
provided further that no price adjustment will be permitted to compensate AB
for royalties paid to obtain Third Party IPR, except to the extent set forth in
Section 2.8.

 

5.4                                Tax, Freight, and Insurance. The prices set forth in Exhibits A
and B are exclusive of all sales, excise or stamp taxes or similar charges,
assessments, fees or duties levied or assessed 

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

13

 

 

on or for the sale or transportation of
Products and all transportation, freight, shipping, handling and insurance
charges, all of which will be separately invoiced to Celera.

 

5.5                                Audits. Upon the written request of Celera and not more than
once in each calendar year, AB will permit an independent certified public
accounting firm selected by Celera and reasonably acceptable to AB, at Celera’s
expense, to have access during normal business hours to such of the records of
AB as may be reasonably necessary to verify the accuracy of the New Product
Pricing, Pass-Through Royalties, PPI and ECI adjustments and changed cost
adjustments hereunder for any calendar year ending not more than 36 months
prior to the date of such request, subject to AB’s reasonable health and
safety, security and confidentiality requirements. The accounting firm will
disclose to Celera only whether the foregoing items are correct or incorrect
and the amount of any discrepancy. No other information will be provided to
Celera. If such accounting firm correctly identifies a discrepancy made during
such period, the appropriate Party will pay the other Party the amount of the
discrepancy within 30 days of the date Celera delivers to AB such accounting
firm’s written report so correctly concluding, or as otherwise agreed upon by
the Parties. The fees charged by such accounting firm will be paid by Celera; provided, however, that if AB is found to have erred in AB’s
favor by the greater of (a) $1,000,000 or (b) more than 5% for the
audited period, AB will reimburse Celera for the full cost of the performance
of such audit.

 

6                                        Orders

 

6.1                                Purchase Orders. To purchase Products hereunder, Celera and
its Affiliates (through any of their respective divisions or business units) may
issue purchase orders (“Purchase Orders”), which (a) will
specify the Purchase Order number, type and quantity of Product ordered, places
of delivery, and delivery dates, and (b) may also contain instructions as
to carrier and method of shipment, packaging and labeling, and other relevant
aspects regarding the supply of Products. If Celera fails to specify a carrier
and method of shipment, AB will select a suitable carrier and method of
shipment on a commercially reasonable basis. Celera will place each Purchase
Order with AB at least 10 business days in advance of the delivery date unless
other lead times are specified in Exhibit A with respect to certain
Products. AB will promptly accept and confirm all Purchase Orders issued in
accordance with this Agreement in writing within five business days from the
date of the Purchase Order. In the absence of an acceptance within such period,
the applicable Purchase Order will be deemed accepted by AB.

 

6.2                                Shipment. AB will ship Products subject to a Purchase Order
in accordance with the lead times specified in Exhibit A. Products will be
delivered in single shipments, unless otherwise specified by Celera on a
Purchase Order. In the event that AB
cannot deliver Products in a single shipment or a delay will occur to provide
such single shipment, AB will notify Celera and obtain Celera’s preference as
to how Products are to be shipped.

 

7                                        Forecasts

 

7.1                                Twelve Month Forecast. Celera will provide AB with a rolling
twelve month non-binding forecast of its orders for Products listed on Exhibit A.
The initial forecast will be delivered to AB within 30 days of the Effective
Date and updated quarterly thereafter. If a Product is designated on Exhibit A
as “OTS” (“off the shelf”), no forecast is
required. If a 

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

14

 

 

Product is designated on Exhibit A as “MTO” (“made to order”), Celera will place orders for MTO
Products in concert with the lead times for such Products as set forth in Exhibit A.

 

7.2                                Changes in Purchase Orders. Celera may increase the
quantity, or request an earlier delivery date, of a Product ordered over the
quantity and delivery date specified in its firm purchase order for such
Product and AB will use commercially reasonable efforts to fill such orders
provided that the timing of the increased order falls within the agreed upon
lead time for such Product and taking into consideration AB’s obligations to
its other customers with respect to such Product. In no event is AB obligated,
nor will it be a breach of this Agreement if AB is unable, to fill an order
which is more than 125% in excess of the quantity specified in its firm
purchase order or to deliver such order earlier than originally agreed to.

 

8                                        Invoicing
and Payment

 

8.1                                Invoicing. AB will invoice Celera for Products shipped FOB
AB’s dock pursuant to Section 9 at the price per Product unit set forth on
Exhibit A. Invoices will include the applicable Purchase Order number,
quantity and part number of the Products shipped and prices therefor.

 

8.2                                Payment. Celera will pay AB for each Product shipped to
Celera no later than 30 days after receipt of an invoice therefore. AB will not
invoice Celera for a Product until a date that is on or after the date of
shipment of the Product to Celera. Invoicing and payment will be made in United
States dollars.

 

8.3                                Late Payments. If payment is not received by the due date,
AB may assess and Celera agrees to pay a late payment charge at the rate of 1%
per month (12% per year) or the maximum legal rate, whichever is less, of the
amount due from the due date to the date of payment.

 

8.4                                Collection. If AB retains a collection agency or attorney to
collect unpaid amounts, AB may invoice Celera for, and Celera will pay, all
reasonable costs of collection, including without limitation reasonable
attorneys fees.

 

9                                        Shipping,
Delivery and Packaging

 

9.1                                Shipping and Delivery. AB will ship Product so that it is
delivered to Celera on the delivery date, and Products will not be delivered
more than four calendar days prior to the delivery date without Celera’s prior
written consent. AB will notify Celera at the time of shipment as to the
quantity of Product shipped and the specific shipping information. Shipping
quantities may not vary from those established by the Purchase Order unless
otherwise mutually agreed upon in writing by the Parties. In the event any
shipment is delayed, Celera may direct AB to ship such Product by expedited
transportation designated by Celera and AB will bear the expense of any
difference in cost due to such expedited transportation. AB will promptly
notify Celera of its inability or expected inability to meet a delivery date.
AB will ship the Product to the delivery addresses set forth in the applicable
Purchase Order. Celera may, from time to time, instruct AB to deliver all or a
portion of Product ordered pursuant to a Purchase Order to non-Celera
locations. AB will at all times properly handle and store Products in
accordance with AB’s specifications and customary procedures. AB will solely
bear all risk of loss or damage and 

 

[***] indicates material that has been omitted
pursuant to a request for confidential treatment. The omitted material has been
filed separately with the Securities and Exchange Commission.

 

15

 

 

all costs and expenses incurred by Celera for
storage or return with respect to quantities of Product shipped by AB in excess
of the quantities set forth in the applicable Purchase Order.

 

9.2                                Risk of Loss. Title and risk of loss with respect to all
Products will pass from AB to Celera upon transfer of possession of the Product
to a common or other Third Party carrier at AB’s facility.

 

9.3                                Packaging. Products will be packaged and prepared for
shipment (a) in a manner which (i) follows good commercial practice
and complies with all laws and regulations, including, without limitation, the
hazardous materials regulations set forth in 49 C.F.R. Sections 100 et seq.
(and any subsequent or successor versions thereof) and any other applicable
hazardous materials regulations, and (ii) is acceptable to, and complies
with any specific requirements of, the designated carrier and/or Celera agreed
to by AB in writing, , and (b) in accordance with any reasonable specific
packaging and labeling requirements set forth in the Purchase Order or the
Specifications. Each shipment will be accompanied by a packing slip which will
include Celera’s part numbers, Purchase Order number, AB’s part number, and the
quantity of Products contained in such shipment. AB will be responsible for all
losses or damages caused by or due to any improper packaging.

 

10                                 Quality

 

10.1                          Quality Management System. AB will maintain a Quality
Management System designed to comply, at a minimum, with ISO 9001:2000 at
facilities at which Products are manufactured.

 

10.2                          Certificate of Analysis. AB will deliver certificates of
analysis with Products when delivered to Celera for those Products with respect
to which it is AB’s customary practice with its commercial customers to do so,
and for those Products with respect to which AB and Celera have developed a
certificate of analysis pursuant to the last sentence of this Section 10.2.
If a certificate of analysis has not previously been provided to Celera or is
not provided as a routine matter for a particular Product, or if Celera wishes
and AB agrees to a certificate of analysis for a Product in a format different
than the one furnished by AB to its commercial customers, the Parties will in
good faith seek to agree on the form of a certificate of analysis, and AB will
provide a certificate of analysis in the agreed upon format if the Parties do
agree, and the reasonable development expense and/or increase in cost required
to generate such certificate of analysis will be paid by Celera or reimbursed
to AB by Celera, unless otherwise agreed to by the Parties.

 

10.3                          Product Changes. AB agrees to notify Celera of a change in
composition to or method of manufacture of a Product listed on Exhibit A
or Exhibit B to the extent that AB determines that a change affects the
form, fit or function of the Product and results in a change to the final
Product Specifications (a “Material Product Change”).
Such notification may be in the form of a letter from AB distributed generally
to its customers. Notwithstanding the foregoing, if a Product is manufactured
or supplied by a Third Party, AB’s ability and agreement to provide notice of
change as set forth herein above is subject to AB receiving written change
information from the manufacturer or supplier that notifies AB of a change in
the Product’s Specifications. The parties may designate on Exhibit A
Products for which no Material 

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

16

 

 

Product Change can be knowingly made without
AB and Celera first discussing the effect of any such proposed change. If any
Product is so designated, AB will not knowingly make a Material Product Change
to the Product without first notifying Celera in writing and discussing
possible effects of such change.  Celera’s sole
and exclusive remedy, and AB’s sole and exclusive obligation and liability, for
failure to notify Celera of any Material Product Change as required by this Agreement
will be for AB to use its commercially reasonable efforts to fulfill as soon as
reasonably feasible a single order for such Product, with the Specifications in
effect prior to the Material Product Change, that is placed by Celera with AB
within 60 days of Celera’s receiving notification of the Material Product
Change. Such order will be in the amount of Product that Celera estimates it
will need for the following two years in accordance with the provisions of Section 2.3,
provided that AB will not be required to fulfill such an order placed by Celera
if, in AB’s reasonable determination, the Material Product Change would result
in health and safety concerns, and in which event AB’s sole and exclusive
obligation and liability will have been satisfied.

 

10.4                          Specifications. AB will manufacture and supply all Products
to AB’s most recent Specifications for the Product (that is, AB’s most recent
public written specifications or, with respect to Products for which AB and
Celera have agreed upon specifications, such agreed upon Specifications).
Except as may be otherwise set forth in Section 10.3, nothing in this
Agreement will be deemed restrict or limit AB from making changes to any
product specifications, including without limitation the Specifications of
Products listed on Exhibits A and B, provided that, subject to Section 10.3,
AB will give Celera prior written notice of any changes to Specifications of
Products listed on Exhibits A and B.

 

10.5                          Additional Quality Terms. Celera may request additional terms
regarding the quality of a Product. In such an event the Parties will conduct
good faith discussions regarding such additional quality terms and to the
extent that such a request is within the reasonable capabilities of AB, AB may
include at AB’s discretion such additional quality terms for the specified
Product, provided that doing so may result in the creation of a New Product
with new pricing at AB’s discretion.

 

11                                 Manufacturing
Processes

 

11.1                          Document Retention. AB will maintain all material records
documenting the manufacture, testing and shipment of the Products supplied to
Celera (“Celera Product Documents”) for a
period of five years following the shipment of the Celera Products to Celera or
its designee; provided, however, that AB will
notify Celera prior to destruction of any Celera Product Documents and send
them to Celera, at Celera’s cost, if so requested. AB will allow Celera to
review such Celera Product Documents during any site inspection conducted under
the terms of this Agreement and at other reasonable times at the request of
Celera, in all cases subject to AB’s reasonable health and safety, security,
and confidentiality requirements. Celera Product Documents will be confidential
information of AB, provided however that Celera may disclose such Celera
Product Documents to a Distributor as necessary, and to applicable regulatory
authorities if required to do so under law, subject to satisfaction of AB’s
reasonable confidentiality requirements, which may include, if AB wishes,
signing of a confidentiality agreement in form satisfactory to AB and marking
all documents to protect same under Freedom of Information Act and other
disclosure laws or regulations.

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

17

 

 

11.2                          Site Inspections. Upon reasonable prior notice, AB will,
from time to time during the term or any extended term of this Agreement, allow
representatives of Celera to tour and inspect AB facilities utilized by AB in
the manufacture or refurbishing of Celera Products, at reasonable times and
upon reasonable advance notice for the purposes of verifying compliance with
the terms of this Agreement. Any such inspections will not occur more than once
in any calendar year, and will be subject to AB’s reasonable health and safety,
security, and confidentiality requirements.

 

11.3                          Regulatory Inspections. AB will allow representatives of the
FDA or other applicable regulatory or governmental authorities to tour and
inspect all facilities utilized by AB in the manufacture, testing, packaging
and storing of Celera Products, provided that the foregoing will not be deemed
a waiver by AB of any rights or remedies it may have under law or restrict AB
from insisting on reasonable health and safety, security or confidentiality
requirements.

 

11.4                          Responsibility for Regulatory Matters.                               All regulatory matters regarding obtaining and
maintaining any necessary clearance or other permit, permission, consent or
approval, or promotion or labeling, or otherwise complying or assuring
compliance with applicable law for or relating to the importation, sale and use
of Celera Products, if any such requirements exist, from the FDA, or under the
European IVD Directive or any other body or agency, will remain under the
exclusive control of Celera and will be solely Celera’s responsibility. AB will
provide Celera access to documentation under AB’s control reasonably required
for Celera Product regulatory registration (subject to AB’s reasonable
confidentiality requirements), provided that any such registration will not
impose any duties or requirements on AB or require AB to take any action except
to permit regulatory inspections as and to the extent expressly set forth in Section 11.3
of this Agreement.

 

12                                 Defects
and Returns

 

12.1                          Rejected Products. Any claims for damaged, missing or
defective Product must be reported in writing by Celera within 15 days from the
date of Celera’s receipt of the Product, after which time the order will have
been deemed to be accepted. In addition, Celera must promptly return a rejected
Product to AB, C.O.D, unused and in a condition no worse than that delivered to
Celera and in the Product’s original containers and packing material,
accompanied by a valid return authorization number obtained from AB, which will
not be unreasonably withheld or delayed. AB may refuse any Product not timely
rejected or sought to be returned without a valid return authorization number.
For any valid claim timely made, AB, at its option, may repair the Product or
replace the Product with an identical or substantially similar Product.
Shipping charges will not be credited.

 

12.2                          Sole Remedy. THE PROVISIONS OF SECTION 12 SET FORTH
CELERA’S SOLE AND EXCLUSIVE REMEDIES FOR A DAMAGED OR MISSING PRODUCT, AND,
EXCEPT FOR EXPRESS WRITTEN WARRANTY RIGHTS, FOR A DEFECTIVE PRODUCT.

 

12.3                          Decontamination. AB may require that Celera sign and deliver
a properly completed certificate of decontamination prior to returning any
Product.

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

18

 

 

13           General Warranty

 

13.1                          Express Warranties. Except as otherwise provided herein, AB
makes only those warranties with respect to Product expressly identified as “warranties”
and set forth in AB’s current operating manual or catalog, or in a specific
written warranty included with and covering a Product, if any.

 

13.2                          No Pass Through. Warranties are made only to the Celera as
the entity purchasing the Product directly from AB, are not transferable and do
not extend to the benefit of any other person or entity, unless otherwise
expressly stated in writing by AB.

 

13.3                          “AS IS”. EXCEPT AS OTHERWISE PROVIDED HEREIN, ANY PRODUCT
NOT COVERED BY AN EXPRESS WRITTEN WARRANTY IS SOLD AND PROVIDED “AS IS,”
WITHOUT WARRANTY OF ANY KIND, STATUTORY, EXPRESS OR IMPLIED.

 

13.4                          Descriptions, Models and Samples. Any description of Product
recited in AB’s quotation is for the sole purpose of identifying Product, and
any such description is not part of any contract between AB and Celera and does
not constitute a warranty that Product will conform to that description. Any
sample or model used in connection with AB’s quotation is for illustrative
purposes only, and is not part of any contract between AB and Celera and does
not constitute a warranty that Product will conform to the sample or model. No
affirmation of fact or promise made by AB, whether or not in AB’s quotation,
will constitute a warranty that Product will conform to the affirmation or promise.
Unless otherwise specified in writing in documentation shipped with Product or
otherwise agreed by AB in writing, AB does not provide service or support for
custom products or other products made to buyer’s specifications.

 

13.5                          Sole and Exclusive. EXCEPT AS OTHERWISE PROVIDED HEREIN, THE
WARRANTIES IDENTIFIED IN SECTION 13.1 ARE APPLERA’S SOLE AND EXCLUSIVE
WARRANTIES WITH RESPECT TO THE PRODUCTS AND ARE IN LIEU OF ALL OTHER
WARRANTIES, STATUTORY, EXPRESS OR IMPLIED, ALL OF WHICH OTHER WARRANTIES ARE
EXPRESSLY DISCLAIMED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR
REGARDING RESULTS OBTAINED THROUGH THE USE OF ANY PRODUCT (INCLUDING, WITHOUT
LIMITATION, ANY CLAIM OF INACCURATE, INVALID OR INCOMPLETE RESULTS), WHETHER
ARISING FROM A STATUTE OR OTHERWISE IN LAW OR FROM A COURSE OF PERFORMANCE,
DEALING OR USAGE OF TRADE.

 

14           Limitation of Liability

 

14.1                          Disclaimer of Consequential Damages. EXCEPT AS PROVIDED
HEREIN AND FOR BREACHES OF SECTION 18 (CONFIDENTIALITY) , IN NO EVENT WILL
EITHER PARTY BE LIABLE TO THE OTHER, WHETHER IN CONTRACT, TORT, WARRANTY, OR
UNDER ANY STATUTE (INCLUDING WITHOUT LIMITATION ANY TRADE PRACTICE, UNFAIR
COMPETITION OR OTHER STATUTE OF SIMILAR IMPORT) OR ON ANY OTHER BASIS, FOR
INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, MULTIPLE, OR PUNITIVE DAMAGES OF
THE OTHER 

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

19

 

 

PARTY OR ITS AFFILIATES, WHETHER OR NOT
FORESEEABLE AND WHETHER OR NOT THE OTHER PARTY IS ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES, INCLUDING, WITHOUT LIMITATION, DAMAGES ARISING FROM OR RELATED TO
THE USE OR PERFORMANCE OF PRODUCTS, LOSS OF USE, LOSS OF DATA, FAILURE OR
INTERRUPTION IN THE OPERATION OF ANY EQUIPMENT, DELAY IN REPAIR OR REPLACEMENT,
FAILURE OF ANY PRODUCT TO OPERATE OR PERFORM AS INTENDED, OR LOSS OF
GOODWILL. For the avoidance of doubt, the provisions of this Section 14.1
are not intended to be a waiver of any damages of a Third Party subject to a
Party’s indemnification obligations under Sections 15 and 16.

 

15           General Indemnification

 

15.1                          Indemnification by AB.

 

(a)                                 AB
will defend, indemnify and hold harmless Celera, its Affiliates and their
respective directors, officers, employees and agents (“Celera
Indemnitees”) (for purposes of this Section 15 the term “Indemnitee” may refer to either or both the AB Indemnitees
and the Celera Indemnitees, as the context may indicate) from and against:

 

(i) any
and all claims for losses, damages or expenses asserted by a Third Party
against Celera or any of its Affiliates to the extent caused by the material
breach of any representation, warranty or covenant made by AB in this
Agreement, the negligence (including gross negligence) or willful misconduct of
AB, or the manufacture by AB of a Defective Item, in all cases above to the
extent the claimed loss, damage or expense is for personal injury to or death
of a human (including without limitation employees of Celera) or damage or
destruction to tangible property, but excluding in all cases above Diagnostic
Losses except to the extent subject to AB’s indemnity set forth below in
subclause (ii) of this Section 15.1;

 

(ii) Diagnostic
Losses to the extent, and only to the extent, resulting from the gross
negligence or willful misconduct of AB; and

 

(iii) any
and all claims for losses, damages or expenses asserted by a Third Party
against Celera or any of its Affiliates to the extent caused by AB’s breach of
the representations, warranties and/or covenants made by AB in Section 2.8
(Grant of Rights) of this Agreement, subject to a cap of $[***].

 

(b)                                AB
will also indemnify and hold harmless Celera from and against Celera’s
reasonable attorneys’ fees and costs in defending any claims subject to AB’s
indemnity set forth above in Section 15.1(a) with respect to which AB
has not undertaken Celera’s defense, except to the extent otherwise set forth
in Section 15.3.

 

15.2                          Indemnification by Celera.

 

(a)                                 Except
with respect to claims expressly subject to AB’s indemnity of Celera set forth
in Section 15.1, Celera will defend, indemnify and hold harmless AB, its
Affiliates and their respective directors, officers, employees and agents (“AB Indemnitees”) from and against any and all claims for
losses, damages or expenses asserted by a Third Party against AB or any of its
Affiliates caused by:

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

20

 

 

(i) the
material breach of any representation, warranty or covenant made by Celera in
this Agreement, the negligence (including gross negligence) or willful
misconduct of Celera;

 

(ii) the
possession, manufacture, sale, storage, use or transportation of Celera
Products or parts or components thereof by any person (including without
limitation by any governmental entity), including, without limiting the
generality of the foregoing, claims for personal injury to or death of any
person (including without limitation employees of AB or Celera) or damage or
destruction of tangible property, Diagnostic Losses, even if caused by or
alleged to have been caused by the negligence of AB but not to the extent
caused by the gross negligence or willful misconduct of AB, or the failure of
any Celera Product or any component thereof to be qualified, registered or
approved under any applicable law; and

 

(iii) any
and all claims for losses, damages or expenses asserted by a Third Party
against AB or any of its Affiliates to the extent caused by Celera’s breach of
the representations and warranties made by Celera in Section 2.8 (Grant of
Rights) of this Agreement, subject to a cap of $[***].

 

(b)                                Celera
will also indemnify and hold harmless AB from and against AB’s reasonable
attorneys’ fees and costs in defending any claims subject to Celera’s indemnity
set forth above in Section 15.2(a) with respect to which Celera has
not undertaken AB’s defense, except to the extent otherwise set forth in Section 15.3.

 

15.3                         Conditions of Indemnification, Procedures.

 

(a)                                 In any action for
which a Party seeks indemnity from the other Party under this Section 15,
the Party seeking indemnification will tender the defense to the other Party,
and if such other Party accepts such indemnity and agrees in writing that it
will defend, indemnify and hold harmless the Party seeking indemnification
pursuant to this Section 15, such other Party will have the sole right to
control and conduct the defense and/or settlement of such action, either in the
name of Celera or AB or both with counsel mutually satisfactory to the Parties.
In the event a Party disagrees as to whether it is obligated to indemnify the
other under Section 15.3 with respect to for one or more claims, it will
so promptly notify the other Party, and the Parties will promptly meet to
evaluate whether the evidence then available to the Parties reasonably supports
such claim. If the Parties cannot agree, the matter will be addressed and
finally determined in accordance with the dispute resolution provisions of the
Separation Agreement. Until a final determination is made, the Party seeking
indemnification hereunder may appear and defend in such action and, if the
indemnification provisions are determined to apply, the Party found to be
obligated to indemnify will reimburse the Party seeking indemnification for
such Party’s reasonable out of pocket legal fees and expenses for the defense
of such action.

 

(b)                                If
a Party or Indemnitee intends to claim indemnification under this Section 15.3,
it will promptly notify the other Party (the “Indemnitor”)
in writing of any claim, demand, action or other proceeding for which the
Indemnitee intends to claim such indemnification, and the Indemnitor may
participate in, and, to the extent the Indemnitor so desires, assume the
defense of, such claim, demand, action or proceeding with counsel mutually
satisfactory to the Parties; provided, however,
that an Indemnitee will have the right to retain its own counsel, with the fees
and expenses to be paid by the Indemnitor, if representation of such Indemnitee
by the 

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

21

 

 

counsel retained by the Indemnitor would be
inappropriate due to actual or potential differing interests between the
Indemnitee and any other Party represented by such counsel in such proceeding.
The obligations of this Section 15.3 will not apply to amounts paid in
settlement of any claim, demand, action or other proceeding if such settlement
is effected without the consent of the Indemnitor, which consent will not be
unreasonably withheld or delayed. The failure to deliver written notice to the
Indemnitor within a reasonable time after the commencement of any such action,
if materially prejudicial to its ability to defend such action, will relieve
the Indemnitor of any obligation to the Indemnitee under this Section 15.3,
but otherwise the Indemnitor will not be relieved of its indemnity and defense
obligations on account of any failure or delay to deliver notice of a claim.
The Indemnitee will reasonably cooperate with the Indemnitor and its legal
representatives in the investigation of any claim, demand, action or other
proceeding covered by this Section 15.3. An Indemnitor will not agree to
the settlement of any claim without the consent of the other Party, which will
not be unreasonably withheld or delayed.

 

16           Intellectual Property
Indemnification

 

16.1                          Indemnity by AB. Subject to the restrictions set forth in
this Section 16 and provided Celera complies with its obligations in this Section 16,
AB agrees to defend Celera, and indemnify Celera from and against any
infringement damages finally awarded, in any legal action or proceeding brought
by a Third Party against Celera to the extent that such action is based on a
claim that the manufacture and sale of a Product by AB infringes any United
States or foreign patent, copyright, trademark or other Intellectual Property
Right of such Third Party if AB had actual knowledge of such intellectual
property right and infringement at the time of delivery of the Product to
Celera. Notwithstanding the foregoing, AB will have no liability or obligation
under this Section 16 with respect to any claim of infringement based
upon: (i) modifications to any Product made by Celera or a Third Party; or
(ii) manufacture, assembly, labeling or branding of Product by AB pursuant
to specifications or designs or requests for specific labeling or branding
furnished by Celera. Notwithstanding anything herein to the contrary, AB will
have no indemnification obligations with respect to Product originating from a
Third Party and provided under this Agreement. Celera’s sole right to indemnification
with respect to such Third Party Product will be pursuant to the original
manufacturer’s or licensor’s indemnification obligations, if any, to the extent
provided by the original manufacturer or licensor.

 

16.2                          Celera’s Obligations. Celera must notify AB in writing of
any claim for which it may seek defense and indemnity from AB hereunder
promptly after becoming aware of such claim, make no admission of liability
with respect to the claim, and cooperate with and provide reasonable assistance
to AB, at AB’s expense with respect to reasonable out of pocket expenses paid
by Celera to Third Parties for such assistance, in the defense or settlement of
such claim. AB will have sole authority to defend and/or settle any claim under
this Section 16. AB’s obligations under this Section 16 are
contingent upon Celera’s compliance with all of the foregoing.

 

16.3                          Remedy for
Infringement, Rights of AB, Exceptions. If any Product or portion
thereof is subject to a suit or other legal proceeding claiming that the
Product or such portion infringes a Third Party’s Intellectual Property Right,
or in AB’s opinion is likely to become 

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

22

 

 

subject of such a claim, AB will, at its
option, have the right to either: (a) procure for Celera the right to
continue using the Product; or (b) modify the Product so that it becomes
non-infringing; or (c) require Celera to return the Product and upon
return, refund to Celera the price actually paid by Celera for the Product,
less a reasonable amount for use, damage and obsolescence; or (d) substitute
for the alleged infringing Product other suitable, non-infringing Products with
comparable functionality.

 

16.4                          ENTIRE
LIABILITY. EXCEPT AS OTHERWISE PROVIDED HEREIN, THE FOREGOING STATES THE ENTIRE
LIABILITY OF AB, AND THE EXCLUSIVE REMEDY OF CELERA, FOR ANY INFRINGEMENT OR
CLAIMED INFRINGEMENT OF PATENT, COPYRIGHT, TRADE SECRET OR ANY OTHER INTELLECTUAL
PROPERTY RIGHT BY OR IN CONNECTION WITH ANY PRODUCT.

 

16.5                          By Celera for
Celera’s Modifications or Specifications.
If Celera modifies any Product or furnishes AB with specifications or designs
or requests for specific labeling or branding, Celera agrees to defend,
indemnify and hold AB harmless against all liabilities, damages, costs,
expenses and claims asserted by a Third Party
against AB or any of its Affiliates arising from or based upon Celera’s
modifications or AB’s manufacture and sale of Product or other performance in
compliance with such specifications or designs or requests for labeling or
branding.

 

17           Product Recall

 

17.1                          Product Recall and Corrective
Actions. In the event
that: (a) any government authority issues a request, directive or order
that any Product be recalled; (b) a court of competent jurisdiction orders
such a recall; or (c) Celera and AB determine that any Product should be recalled
because of a regulatory requirement, the Product did not conform to applicable
Specifications, a manufacturing defect by
AB or a defect in materials and workmanship when the Product was delivered to
Celera, then each Party will take reasonable and appropriate corrective
actions consistent with its quality procedures and with the intent and purposes
of this Agreement. Each Party will
immediately notify the other Party telephonically, followed by notice in
writing, of any order, request or directive of a court or other governmental
authority to recall or withdraw a Product in any jurisdiction. AB will be
solely responsible and liable for the costs (including, but not limited to,
costs of notification and all costs of shipment of the recalled Products) of
implementing any recall or withdrawal of any Product, and for the cost of any replacement Products or
refunds required to be given to any end user customer of any Product, to the
extent the recall is caused by (i) a manufacturing defect by AB or a defect
in materials and workmanship when the Product was delivered to Celera or (ii) the
material breach by AB of any of its obligations, representations, warranties
(except Product warranties set forth in Section 13) and covenants set
forth in this Agreement, except for such breaches as to which the exclusive
remedies, identified as such, are expressly set forth elsewhere in this
Agreement. Celera will be responsible, at its sole cost and expense, for the
costs of implementing any recall or withdrawal of Products, in all other
circumstances. For the avoidance of doubt, AB will be responsible and liable
for such costs of recall on account of a Defective Item or such a defect in
materials and workmanship regardless of whether the date of recall was during
or after any applicable Product warranty period. Except as expressly stated
above in this Section 17.1 and elsewhere in this Agreement where AB will
indemnify Celera, it is expressly 

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

23

 

 

understood and agreed that
Celera, not AB, will be solely responsible and liable for all costs and
liability arising out of any recall not due to AB’s gross negligence or willful
misconduct, as and to the extent set forth in Section 15.1. Celera will be
solely responsible for the text of any statement to be provided to customers.
Notwithstanding the foregoing, no statement regarding any recall that
identifies AB or any of its affiliates, directly or indirectly, by name or by
any other reference (such as “as manufacturer or supplier”) will be disclosed
to any Third Party except with AB’s prior written consent, which will not be
unreasonably withheld or delayed. In the event of a recall for which AB is
responsible as set forth in this Section 17.1 with respect to which (i) Celera
is required under law or contract to, or (ii) the Parties agree in writing,
in accordance with Celera’s normal course of business consistently applied, to,
refund the full purchase price to a customer and/or provide a customer with a
substitute product, AB will reimburse to Celera the transfer price to Celera of
any Products subject to such recall and with respect to which Celera has
refunded the full purchase price of the Product to its customer. Any Products
that are recalled will be returned by Celera to AB. AB will pay Celera any
amount due pursuant to this Section 17.1 within 30 days of receipt of an
invoice from Celera therefor, or, if the amount is disputed by AB, within 30
days of a final determination of the amount due. Any such invoice will include
reasonable documentation to support such charges. If the Parties do not agree
on the amount due, the amount due will be determined under the dispute
resolution procedures set forth in the Separation Agreement.

 

18           Confidentiality

 

18.1                          Confidentiality. At any time during the course of this
Agreement the Parties may disclose to one another, whether verbally or in
documentary form, information deemed by the disclosing Party to be confidential
(“Confidential Information”). This
Confidential Information may include, without limitation, pricing, data,
specifications, formula, diagrams, schematics, Know-how, Product volumes both
current and forecasted, business and financial information and marketing plans.
Confidential Information must be either clearly marked and identified as such
upon its disclosure or, where only identified verbally at time of disclosure,
confirmed in writing to the receiving Party as Confidential Information within
30 days. The receiving Party will not disclose Confidential Information to any
Third Party or use it for any purpose, in each case except as allowed under and
consistent with this Agreement, and will take all reasonable measures to
protect its confidentiality. These obligations of confidentiality will continue
for a period of five years following termination or expiration of this
Agreement, except with respect to Confidential Information that are trade
secrets, in which case the obligation of confidentiality will continue until
the trade secrets lose their status as such due to no fault of the receiving
Party. Excluded from Confidential Information is any information that (a) is
or becomes public knowledge through no fault of the receiving Party, (b) the
receiving Party can demonstrate through clear documentary evidence was known to
it prior to receipt and not covered by an obligation of confidentiality in
favor of the disclosing Party, (c) was subsequently received from a Third
Party without any obligation of confidentiality, or (d) is independently
developed by the receiving Party without use of Confidential Information, as
can be demonstrated by clear documentary evidence. This section will survive
the termination or expiration of this Agreement.

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

24

 

 

19                                 Intellectual
Property

 

19.1                          As between the parties the
ownership of and rights in their respective intellectual property will be
determined in accordance with the provisions of the Separation Agreement.

 

20                                 Trademarks

 

20.1                          As between the parties the
ownership of and rights in their respective trademarks will be determined in
accordance with the provisions of the Separation Agreement.

 

20.2                          No rights to any AB trademark
are transferred to Celera under this Agreement.

 

21                                 Insurance

 

21.1                          AB will, at its own expense,
provide and maintain insurance for Worker’s Compensation; employer’s liability
for bodily injury suffered through accident or disease; and commercial general
liability, provided that in no event will AB carry coverage with limits of less than $2 million per occurrence for
bodily injury and $2 million per occurrence for property damage.

 

21.2                          AB will furnish Celera
certificates of insurance evidencing the required coverage and the insurer’s
agreement to provide 30 days’ prior written
notice to Celera in the event of cancellation or material change in coverage.
AB’s insurance policies will also name Celera as an additional insured with
coverage for Celera at least as broad as provided to AB for liability arising
out of Products supplied pursuant to this Agreement.

 

21.3                          The liability of AB will not
be limited to the amount of insurance which AB is required to provide by the
terms of this Section 21.

 

22                                 General

 

22.1                          Independent
Contractor. The relationship of AB to Celera hereunder is that of an
independent contactor. In no event will either Party hold itself out to others
or allow itself to be considered an agent, employee, or representative of the
other.

 

22.2                          Assignment.
Neither Party may assign or transfer its rights or obligations under this
Agreement or any document relating to this Agreement to any other entity or
person without the prior written consent of the other Party, except that
without the prior written consent of the other Party either Party after written
notice to the other Party may assign this Agreement to any Affiliate of either
Party and to any Party that is the successor to the business and operations of
such Party to which this Agreement relates, or in connection with the merger or
consolidation of the Party, provided that (i) the assigning Party will remain
primarily liable for the assignor’s obligations and covenants in this Agreement
and the assignee and assignor will agree in a writing delivered to the
non-assigning Party that the assignee and assignor will be jointly and
severally liable for the performance of the assignor’s and assignee’s covenants
and obligations in this Agreement and (ii) no Confidential Information of the
assigning Party that has been retained by the Assignor for evidentiary purposes
under Section 14, or that a Party is permitted to retain only for evidentiary
purposes under Section 14, will be delivered or made accessible to the assignee.

 

[***] indicates material that has
been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

25

 

 

Any purported assignment in violation of the above will be null and
void and of no force and effect. Subject to the foregoing, this Agreement will
be binding upon and inure to the benefit of the Parties and their respective
successors and permitted assigns.

 

22.3         Governing
Law. This Agreement is deemed to be made under and will be construed
in accordance with the laws of the State of Delaware without giving effect to
any choice of law rule that would cause the application of the laws of any
jurisdiction other than the internal laws of the State of Delaware.

 

22.4         Notices.
All notices required hereunder will be in writing and will be sent by (a) U.S.
mail (first class), (b) nationally recognized courier service (e.g., DHL,
Federal Express), with all postage or delivery charges prepaid, or (c) facsimile,
subject to confirmation via U.S. mail or nationally recognized courier service,
and will be addressed to the Parties at their addresses set forth on the cover page of
this Agreement or to such other addresses as may be furnished by written notice
in the manner set forth herein.

 

22.5         Publicity.
Neither Party will advertise or otherwise disseminate by written or oral
publication the existence of this Agreement, or its terms, without the other
Party’s prior written consent, including as to the text thereof, which consent
will not be unreasonably withheld or delayed.

 

22.6         Force
Majeure. Failure of either Party to perform its obligations under
this Agreement (except for the obligation to make payments) will not subject
such Party to any liability to the other Party and will not be deemed a breach
of this Agreement if such failure is caused or occasioned by act of God
(including, without limitation, flood, drought, earthquake), act of a public
enemy including terrorist acts, fire, explosion, war, riot, insurrection,
sabotage, embargo, strike or other labor trouble, power outages or reductions,
failure of AB’s sole sourced suppliers (except where the product supplied is
available from other suppliers on reasonable commercial terms) to deliver on
schedule materials, equipment or machinery for reasons solely due to their own
force majeure (as defined herein), compliance with any order, regulation or
request of any government, administrative or regulatory entity acting with
color of right or any officer, department, agency or committee thereof, or by
any other event or circumstance beyond the reasonable control of the Party so
failing (“Force Majeure Events”). The affected
Party will promptly notify the other Party in writing setting forth the details
of the occurrence of force majeure, its expected duration and how that Party’s
performance is affected, and will use commercially reasonable efforts to resume
performance as soon as possible.

 

22.7         Agreement
Terms Govern. Although the Parties may use a Purchase Order or
whatever other form of writing they select from time to time to quote or order
Products, this Agreement will supersede and fully replace any different,
additional or conflicting terms, including without limitation all preprinted or
other standard terms (other than the name or identity of Products purchased,
quantity, delivery dates, bill to, ship to and invoice addresses and price) on (i) any
quotations, order confirmations, invoices or related documents issued during
the term or any extended term of this Agreement by AB or (ii) any purchase
orders or other related documents issued during the term or extended term of
this Agreement by Celera. Any different, additional or conflicting terms and
conditions in any such documents will be void and of no force and effect unless
agreed to in a writing signed by an authorized representative of each of Celera

 

[***] indicates material
that has been omitted pursuant to a request for confidential treatment. The
omitted material has been filed separately with the Securities and Exchange
Commission.

 

26

 

 

and
AB that expressly states that such different, additional or conflicting terms
and conditions are intended to supersede the terms of this Agreement.

 

22.8         Entire
Agreement. No agreement or understanding in any way modifying these
terms and conditions, either before or after the execution hereof, will be
binding upon either Party unless in writing and signed by both Parties. This
Agreement and the other Separation Documents (as defined in the Separation
Agreement) constitute the entire agreement between the Parties with respect to
the subject matter of this Agreement, and supersede any prior or
contemporaneous communications, with respect to the subject matter hereof and
thereof. For the avoidance of doubt, the agreements between the Parties to be
entered for the supply of the 3100 Genetic Analyzer, among other things, and
the Kauai Project goods will not be merged into this Agreement and will remain
in full force and effect under their own distinct terms and conditions.

 

22.9         Waiver.
Failure by either Party to insist upon strict performance of any of the terms
and conditions hereof, or delay in exercising any rights or remedies provided
herein, will not release the other Party from any of the obligations of this
Agreement and will not be deemed a waiver of any rights of such other Party to
insist upon strict performance thereof.

 

22.10       Severability.
If any one or more of the provisions contained in this Agreement is, for any
reason, held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability will not affect any other provision
hereof, and this Agreement will be construed as if such invalid, illegal or
unenforceable provision had never been contained herein.

 

22.11       Headings.
Headings used in this Agreement are for convenience of reference only and will
not affect the interpretation of this Agreement.

 

22.12       Counterparts.
This Agreement may be executed in two or more counterparts, each of which
counterparts, when duly executed and delivered, will be deemed to be an
original and all of which counterparts, taken together, will constitute one and
the same Agreement.

 

IN
WITNESS WHEREOF, the Parties have caused their duly authorized representatives
to execute and deliver this Agreement as of the Effective Date.

 

	
  APPLERA
  CORPORATION

  	
   

  	
  CELERA
  CORPORATION

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Name:

  	
   

  	
   

  	
  Name:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Title:

  	
   

  	
   

  	
  Title:

  	
   

  
								

 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

27

 

 

	
  Date:

  	
   

  	
   

  	
  Date:

  	
   

  

 

 

[***] indicates material
that has been omitted pursuant to a request for confidential treatment. The
omitted material has been filed separately with the Securities and Exchange
Commission.

 

28

 

Exhibit A

 

Assumptions &
Definitions

 

	
  Attachment
  A only contains items that Celera has procured in the last [**].

  
	
   

  	
   

  
	
  Expire to Ship(ETS)

  	
  Product
  DOES NOT have an expiration date on it.

  
	
   

  	
  Product
  is warranted for 1 year from shipment date.

  
	
   

  	
   

  
	
  Expire to Use(ETU)

  	
  Product DOES have an expiration on it.

  
	
   

  	
  Product
  may ship with 2 months remaining dating.

  
	
   

  	
   

  
	
  Topfills

  	
  Items
  noted as Topfills contain multiple items.

  
	
   

  	
  Topfills
  do not have expiration or warranties.

  
	
   

  	
  Components
  of Topfills have expiration or warranties.

  
	
   

  	
  Components
  of Topfills should be added to the Master List.

  
	
   

  	
  Celera
  can order components or topfills unless otherwise stated.

  
	
   

  	
   

  
	
  Components
  of Topfills are listed under the parent and the parent part number is in the
  Celera description.

  
	
  Components
  of Topfills shaded in BLUE are duplicates

  
	
   

  	
   

  
	
  Order Types

  	
  Off the
  Shelf(OTS). Standard products that are maintained in inventory.

  
	
   

  	
  Products
  are typically available same day as order is placed.

  
	
   

  	
   

  
	
   

  	
  Make to
  Order(MTO). Products are only produced when a firm order(PO) is received.

  
	
   

  	
  Leadtimes
  vary product by product.

  

 

[**] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

 

	
  Internal Mfg

  or

  Purchased

  	
   

  	
  AB Part

  Number

  	
   

  	
  AB Description

  	
   

  	
  Celera Description

  	
   

  	
  Order

  Type

  	
   

  	
  Expiry

  	
   

  	
  Leadtime

  (Calendar

  Days)

  	
   

  	
  AB Comments

  	
   

  	
  

  

  Celera Comments

  	
   

  	
  Qty ship

  in last 5

  years

  	
   

  	
  Date of last

  shipment

  
	
  Purchased

  	
   

  	
  5402

  	
   

  	
  BUFFER,JAR 9ML

  	
   

  	
  Anode buffer reservoir

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  400060

  	
   

  	
  FG,ANHYDROUS ACETONITRILE 30mL

  	
   

  	
  Anhdrous Acetonitrile 30 mL

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  400142

  	
   

  	
  FG,DCM,PEPTIDE SYNTHESIS 4L

  	
   

  	
  Dichloromethane, HPLC Grade

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  400236

  	
   

  	
  FG,TCA (CH2-C12)/DCM, 450mL

  	
   

  	
  Deblocking Sol (TCA/Dic)

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  400326

  	
   

  	
  FG,CE-PHOSPHORAMIDITE A 1g

  	
   

  	
  CE Phosphoramidite A

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  400327

  	
   

  	
  FG,CE-PHOSPHORAMIDITE G 1g

  	
   

  	
  Phosphoramidite, G 1g (400327)

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  400328

  	
   

  	
  FG,CE-PHOSPHORAMIDITE C 1g

  	
   

  	
  CE Phosphoramidite C

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  400329

  	
   

  	
  FG,CE-PHOSPHORAMIDITE T 1g

  	
   

  	
  CE Phosphoramidite T

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  400445

  	
   

  	
  FG,TRIFLUOROACETIC ACID, 10ml

  	
   

  	
  TFA HPLC Grade

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  400613

  	
   

  	
  FG,TRIETHYLAMINE ACETATE 2M,200mL

  	
   

  	
  TRIETHYLAMINE ACETATE 2M,200mL

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  400945

  	
   

  	
  COL,1 umol A CPG

  	
   

  	
  dA CPG

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  400946

  	
   

  	
  COL,1 umol C CPG

  	
   

  	
  dC CPG

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  400948

  	
   

  	
  COL,1 umol T CPG

  	
   

  	
  T CPG

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  401087

  	
   

  	
  FG,ACETONITRILE DNA/RNA 4L

  	
   

  	
  Anhydrous Acetonitrile

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401114

  	
   

  	
  DYE PRIMER/GS MATRIX STDS

  	
   

  	
  Dye Primer Matrix Standars

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401159

  	
   

  	
  FG,CE-PHOSPHORAMIDITE A / 2.0g^

  	
   

  	
  PHOSPHORAMIDITE “A” 1g

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401160

  	
   

  	
  FG,CE-PHOSPHORAMIDITE C / 2.0g

  	
   

  	
  RM, DMT-dCytidine Amidite

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401162

  	
   

  	
  CE-PHOSPHORAMIDITE T / 2.0g

  	
   

  	
  T AMIDITE 2G

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401165

  	
   

  	
  FG,dG(DMF) FASTPHORAMIDITE 2.0g

  	
   

  	
  RM, dG (DMF) Fastphoramidite

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401183

  	
   

  	
  FG,dG(DMF) FASTPHORAMIDITE, 1.0gr

  	
   

  	
  CE Phosphoramidite G

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401438

  	
   

  	
  COLUMN, WP dA(Bz) - 1umol

  	
   

  	
  CPG Columm A

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  401445

  	
   

  	
  Anhydrous Acetonitrile, 100mL

  	
   

  	
  Anhydrous Acetonitrile, 100mL

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401527

  	
   

  	
  6-FAM AMIDITE, 85mg

  	
   

  	
  6-FAM AMidite (85mg)

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401546

  	
   

  	
  FLUOR AMIDITE MATRIX STDS

  	
   

  	
  Flourescent Amidite Matrix Standa

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401717

  	
   

  	
  PHOSPHALINK,70mg

  	
   

  	
  Phosphorylating RGNT, 5’ (401717)

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401736

  	
   

  	
  KIT,PRISM GENESCAN 350 TAMRA

  	
   

  	
  Genescan 350 TAMRa Std

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  401846

  	
   

  	
  TAQMAN,B-ACTIN DETECTION RGNTS

  	
   

  	
  TAQMAN BACTIN DET. REAGENT

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  402014

  	
   

  	
  KIT,AFLP MseI-CTT OLIGO-250uL

  	
   

  	
  MSE1-CTT primer

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  402015

  	
   

  	
  KIT,AFLP Mse-CTG OLIGO-250uL

  	
   

  	
  Mge1CTG primers

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  402017

  	
   

  	
  KIT,AFLP Mse-CTA OLIGO-250uL

  	
   

  	
  MSE1 CTA primer

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  402038

  	
   

  	
  KIT,AFLP ECO RI-ACA FAM-250uL

  	
   

  	
  EcoRI-ACA FAM

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  402045

  	
   

  	
  KIT,AFLP ECO RI-ACT FAM-250uL

  	
   

  	
  EcoRI-ACT FAM

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  402152

  	
   

  	
  FG,DCM,DNA SYNTHESIS,2L

  	
   

  	
  Dichloromethane, HPLC Grade 2L

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  402264

  	
   

  	
  AFLP ECO RI-TG FAM,250uL

  	
   

  	
  EcoRI-TG FAM

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  402824

  	
   

  	
  FG,BUFFER (10X) WITH EDTA 25ML

  	
   

  	
  10xbuffer w/EDTA ABI

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  402996

  	
   

  	
  NED MATRIX STANDARD KIT

  	
   

  	
  NED Matrix Standard Kit

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  403046

  	
   

  	
  KIT,dRHOD. MATRIX STDS

  	
   

  	
  KIT,dRHOD. MATRIX STDS

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  403055

  	
   

  	
  BOX,BDP TAQ FS RR-100-21M13

  	
   

  	
  Big Dye Primer Cycle Seq. Kit

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  403081

  	
   

  	
  9700 MicroAmp 96-well Tray/Retainer set

  	
   

  	
  Tray/retainer set

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  403170

  	
   

  	
  HEX AMIDITE,55mG

  	
   

  	
  FG HEx Amidite (55 mg)

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  403171

  	
   

  	
  TET AMIDITE,50mG

  	
   

  	
  TET Amidite 50 mg

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  450025

  	
   

  	
  TaqMan TAMRA PROBE 6,000 PMOLES

  	
   

  	
  TaqMan TAMRA PROBE 6,000 PMOLES

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom oligo

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4303326

  	
   

  	
  AmpFLSTR Profiler Plus PCR Kit

  	
   

  	
  AmpF/STR Porfiler Plus PCR Amplification Kit

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4304437

  	
   

  	
  FG,TAQMAN PCR MASTER MIX,MNL 4304449

  	
   

  	
  Taqman Universal PCR Mix

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4304470

  	
   

  	
  ASSY,SYRINGE 250UL W/SEAL KLOEHN

  	
   

  	
  ASSY,SYRINGE 250UL W/SEAL KLOEHN

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4304970

  	
   

  	
  SEQUENCE DETECTION PRIMER, 10,000 PICOMO

  	
   

  	
  primer probe (Sequence Detection Primer)

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom oligo

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4305545

  	
   

  	
  FG,ABSOLUTE RNA WASH SOLUTION

  	
   

  	
  ABSOLUTE RNA WASH 6X10ML

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4305603

  	
   

  	
  FG,5X SEQUENCING BUFFER 5400 RXN

  	
   

  	
  5X SEQ BUFFER

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4305822

  	
   

  	
  FG,SDS SPECTRAL CALIBRATON KIT

  	
   

  	
  SPECTRAL CALIB KIT FOR 7700 SDS

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4306311

  	
   

  	
  MicroAmp Clear Adhesive Film, 100 pc

  	
   

  	
  MicroAmp Clear Adhesive Film, 100 pc

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4306733

  	
   

  	
  FG, BTL 3700 DNA ANALYSIS POLYMER

  	
   

  	
  3700 POP-6 Polymer 210 ml bo

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4306733

  	
   

  	
  FG, BTL 3700 DNA ANALYSIS POLYMER

  	
   

  	
  3700 Pop 6 Polymer 210mL

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4306737

  	
   

  	
  FG,TCII REACTION PLT,96 WELL,BARCODE,KIT

  	
   

  	
  FG,TCII REACTION PLT,96 WELL,BARCODE,KIT

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4306819

  	
   

  	
  ASSY,OPTICAL CALIB PLATE GRN

  	
   

  	
  Assy, optical calib plate grn

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4306898

  	
   

  	
  FG,GA 10xPCR GLD BUFF&MgCl2,6x1.5mL

  	
   

  	
  10x PCR Gold Buffer, 6x1.5 ml

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4306902

  	
   

  	
  RM,GA 10x PCR GOLD BUFF&MgCl2,150mL

  	
   

  	
  10X PCR Gold Buffer

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4309849

  	
   

  	
  FG,384-WELL CLEAR RXN PLATE

  	
   

  	
  384 well opti. react. plate

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4311320

  	
   

  	
  FG,HI-DI FORMAMIDE 25mL BOTTLE

  	
   

  	
  Hi-Di Formamide

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4311320

  	
   

  	
  FG,HI-DI FORMAMIDE 25mL BOTTLE

  	
   

  	
  HI-DI FORMAMIDE 25mL BOTTLE

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4311806

  	
   

  	
  FG,AMPLITAQ GOLD 250U+GOLD BUFFER+MgCI2

  	
   

  	
  Ampl. Taq Gold DNA Polymerase

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4311816

  	
   

  	
  FG,AMPLITAQ GOLD 1000U+GOLD BUFFER+MgCI2

  	
   

  	
  AmpliTaq Gold DNA Poly Kit, 1000

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4311818

  	
   

  	
  FG,AMPLITAQ GOLD 5X1000U+GOLD BUFFER+MgC

  	
   

  	
  AMPLITAQ GOLD DNA POLYMERASE

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4311971

  	
   

  	
  FG,OPTICAL ADHESIVE COVERS

  	
   

  	
  Microamp optical adhesive cover

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4312063

  	
   

  	
  96-well Splash Free Support Base

  	
   

  	
  96-well base

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4313663

  	
   

  	
  FG, OPTICAL ADHESIVE COVERS STARTER KIT

  	
   

  	
  Optical Adhesive Cover Starter Ki

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4315931

  	
   

  	
  FG,CAPILLARY ARRAY 16 x 36cm

  	
   

  	
  FG,CAPILLARY ARRAY 16 x 36cm

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4315933

  	
   

  	
  SEPTA STRIP,96 WELL TRAY

  	
   

  	
  SEPTA STRIP,96 WELL TRAY

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4316032

  	
   

  	
  TaqMan MGB PROBE 50,000 PMOLES

  	
   

  	
  Taqman MGB probe 50,000

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom oligo

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4316033

  	
   

  	
  TaqMan MGB PROBE 20,000 PMOLES

  	
   

  	
  TaqMan MGB PROBE 20,000 PMOLES

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom oligo

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4316034

  	
   

  	
  TaqMan MGB PROBE 6,000 PMOLES

  	
   

  	
  Custom TagMan MGB Probes

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom oligo

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4316355

  	
   

  	
  FG,3100 POP4

  	
   

  	
  3100 PERFORMANCE OPT. POLYMER 4

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4316357

  	
   

  	
  FG,3100 POP6

  	
   

  	
  ML POP6 FOR 3100

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4316357

  	
   

  	
  FG,3100 POP6

  	
   

  	
  POP6 Polymer

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4316831

  	
   

  	
  FG,TQMN RNASE P DETECT RGTS(FAM)100 RXS

  	
   

  	
  Taqman Rnase P detection reagent

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4318157

  	
   

  	
  FG,TAQMAN UNIVERSAL PCR MSTR MX 2000 RXN

  	
   

  	
  TAQMAN UNIVERSAL PCR MMX 2000 R

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4318976

  	
   

  	
  FG,3700 RUN BUFFER,4L

  	
   

  	
  3700 Running Buffer w EDTA 4L

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4318986

  	
   

  	
  FG,PET-2 AMIDITE, 120 mg

  	
   

  	
  FG, PET-2 AMIDITE, 120 mg

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4322288

  	
   

  	
  AmpFLSTR Identifiler PCR Kit

  	
   

  	
  Amp f/STR Identifier PCR Amplification Kit

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4322682

  	
   

  	
  FG,GENESCAN-500(LIZ) SIZE STD KIT

  	
   

  	
  GeneScan 500 LIZSize

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  

 

 

	
  Internal Mfg

  or

  Purchased

  	
   

  	
  AB Part

  Number

  	
   

  	
  AB Description

  	
   

  	
  Celera Description

  	
   

  	
  Order

  Type

  	
   

  	
  Expiry

  	
   

  	
  Leadtime

  (Calendar

  Days)

  	
   

  	
  AB Comments

  	
   

  	
  

  

  Celera Comments

  	
   

  	
  Qty ship

  in last 5

  years

  	
   

  	
  Date of last

  shipment

  
	
  Internal Mfg

  	
   

  	
  4323014

  	
   

  	
  FG,3100/3130 MATRIX STD SET DS-02

  	
   

  	
  SNaPshot Matirx Standard Set

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4323032

  	
   

  	
  FG,OPTICAL CAP (8 CAPS/STRIPS)

  	
   

  	
  8 caps per strip Optical Caps

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4323306

  	
   

  	
  FG,384 WELL RNASE P INST VERIF PLATE

  	
   

  	
  384 Well Rnase Test Plate

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4323977

  	
   

  	
  FG,384 WELL DYE CALIBRATION PLATE KIT

  	
   

  	
  Spectral Calibration Kit 384

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4324018

  	
   

  	
  FG,TAQMAN UNIVERSAL PCR MSTR MIX,NO UNG

  	
   

  	
  TAQMAN UNIV.TAQMAN PCR MIX

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4328639

  	
   

  	
  FG,96 WELL DYE CALIBRATION PLATE KIT

  	
   

  	
  Sequence Detection Systems 96-Well Spectral
  Calibration Kit

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4328895

  	
   

  	
  FG,7000 SPECTRAL DYE CALIB KIT

  	
   

  	
  ABI PRISM 7000 Seqe Detect Sstms

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4329538

  	
   

  	
  FG,SNAPSHOT PRIMER FOCUS

  	
   

  	
  Primers Focus Kit

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4331182

  	
   

  	
  FG,OFF THE SHELF GX SET

  	
   

  	
  Off the Shelf GX Set

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
  [**]

  	
   

  	
  Generic part

  number for

  AOD GX.

  Actual assay

  ID’s do have

  expiration date

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4332073

  	
   

  	
  CUSTOM TaqMan SNP ASSAY HUMAN LARGESCALE

  	
   

  	
  Assays by Design

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom oligo

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4333183

  	
   

  	
  FG,ADHESIVE SEAL APPLICATOR KIT(BAG=5)

  	
   

  	
  FG, Adhesive Seal Applicator Kit (Bag=5)

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4335613

  	
   

  	
  FG,3730 Buffer(10X) with EDTA 500mL

  	
   

  	
  10x Running Buffer 500 ml

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336697

  	
   

  	
  TUBE,5X SEQ BUFFER SMALL

  	
   

  	
  Big Dye Terminator

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336699

  	
   

  	
  BTL,5X SEQ BUFFER MEDIUM

  	
   

  	
  BTL, 5 x Seq Buffer Medium (28ml)

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336774

  	
   

  	
  FG,BDT v1.1 RR-100 KIT

  	
   

  	
  BDT v1.1 Cycle Sequencing kit

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336791

  	
   

  	
  FG,BDT v1.1 SEQ STD KIT

  	
   

  	
  sequencing standard kit BDT v1.1

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336799

  	
   

  	
  FG,37XX BDT v1.1 SEQ STD KIT

  	
   

  	
  3700 Big Dye Terminator Sequence

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336935

  	
   

  	
  FG,BDT v3.1 SEQ STD KIT

  	
   

  	
  3130x1 Big Dye 3.1 Sequencing

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336943

  	
   

  	
  FG,37XX BDT v3.1 SEQ STD,KIT

  	
   

  	
  FG,37XX BDT v3.1 SEQ STD,KIT

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336974

  	
   

  	
  KIT,3100/3130 BDT v3.1 MTX STDS

  	
   

  	
  Matrix Standard Kit BDT 3.1

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336975

  	
   

  	
  KIT,3700 BDT v3.1 MTX STDS

  	
   

  	
  3700 MATRIX STANDARD

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4338543

  	
   

  	
  FG,ICAT CLEAVING REAGENT- A

  	
   

  	
  Cleavable ICAT Reagent A

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4342718

  	
   

  	
  Sample Block Module, 9700 Dual 96-w

  	
   

  	
  Sample Block Module, 9700 Dual

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4343369

  	
   

  	
  FG,384 WELL CLR RX PLT W/BRCD BULK PK

  	
   

  	
  FG, 384 well clear RX plate

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4343895

  	
   

  	
  Quantifiler Human DNA kit

  	
   

  	
  Quantifiler® Human DNA Quantification Kit

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4344409

  	
   

  	
  FG,6-FAM AMIDITE, 1.0g

  	
   

  	
  FG,6-FAM AMIDITE, 1.0g

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom. Made

  only for Celera.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4344668

  	
   

  	
  FG,6-FAM NHS ESTER 100MG

  	
   

  	
  RM, NHS ester, 6-Fam

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4344675

  	
   

  	
  FG,HUMAN DNA MALE 50mL

  	
   

  	
  FG,HUMAN DNA MALE 50mL

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4344676

  	
   

  	
  FG,LOADING BUFFER 500mL

  	
   

  	
  Loading Buffer Bulk

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4345827

  	
   

  	
  FG,DS-30 (DYE SET D) MATRIX STD KIT

  	
   

  	
  DS-30 (dye set D) matrix

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4345833

  	
   

  	
  FG,DS-33 (DYE SET G5) MATRIX STD KIT

  	
   

  	
  DS-33 matrix standard kits

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4346305

  	
   

  	
  OEM,BULK PASSIVE REFERENCE STD

  	
   

  	
  RM, Fret ROX (1 mL)

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4346498

  	
   

  	
  FG,BUFFER TAQ CSA 5X

  	
   

  	
  Buffer Taq CSA 5x (361028C)

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom. Only

  for Celera.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4346504

  	
   

  	
  FG,PASSIVE REFERENCE STD ROX

  	
   

  	
  RM, Passive Reference Standard (ROX)

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4346993

  	
   

  	
  TUBES,0.2ML WITH CAP,IVD

  	
   

  	
  MicroAmp Tubes with caps, IVD

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom. Only

  for Celera.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4349690

  	
   

  	
  TUBES,0.2ML WITH CAP, CE

  	
   

  	
  MicroAmp Tubes with caps, CE

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom. Only

  for Celera.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4350584

  	
   

  	
  FG,96 WELL RNASE P VERIF PLATE NO PAD

  	
   

  	
  7300 & 7500 Taqman RNaseP

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4351151

  	
   

  	
  7500 SPECTRAL RED DYE CAL KIT

  	
   

  	
  7500 Calibration Kit II

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4351372

  	
   

  	
  KIT,TQMN GENE EX ASSAYS, SM

  	
   

  	
  TaqMan® Gene Expression Assays

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom oligo

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4351379

  	
   

  	
  TaqMan PRE-DESIGNED SNP GENOTYPING ASSAY

  	
   

  	
  TaqMan PRE-DESIGNED SNP GENOTYPING ASSAY

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom oligo

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4351389

  	
   

  	
  FG,96 WELL MICROPLATE WITH COVERS IVD

  	
   

  	
  Optical 96-Well Plates w/Covers, IVD

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom. Only

  for Celera.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4351391

  	
   

  	
  FG,96 WELL MICROPLATE WITH COVERS CE

  	
   

  	
  Optical 96-Well Plates w/Covers, CE

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom. Only

  for Celera.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4351426

  	
   

  	
  OEM,BULK ROX PASSIVE REFERENCE STD

  	
   

  	
  RM, ROX - 6T

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4352755

  	
   

  	
  FG,3130 POP-4TM Polymer

  	
   

  	
  Pop 6 for 3130x1

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4352757

  	
   

  	
  FG,3130 POP-6TM Polymer

  	
   

  	
  PoP-6 Polymer 3170

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4352759

  	
   

  	
  FG,3130 POP-7TM Polymer

  	
   

  	
  3130 Pop-7 Performance

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4363785

  	
   

  	
  FG,3130 POP-7, 3.5ml

  	
   

  	
  POP-7 Polymer for 3130x1

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4368813

  	
   

  	
  Kit, High Capacity cDNA RT (1000 Rxns)

  	
   

  	
  High Capacity cDNA Kit

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4368814

  	
   

  	
  Kit, High Capacity cDNA RT (200 Rxns)

  	
   

  	
  Kit, High Capacity cDNA RT (200 Rxns)

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4369016

  	
   

  	
  FG,TAQMAN GEx MASTER MIX,5 ML

  	
   

  	
  FG, TaqMan Gex Master Mix, 5ml

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4371355

  	
   

  	
  FG,TAQMAN GT MASTER MIX,10 ML

  	
   

  	
  TaqMan Genotyping Master Mix

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4376486

  	
   

  	
  FG, BIGDYE XTERMINATOR KIT 2ML

  	
   

  	
  Big Dye XTerminator Purification

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4389167

  	
   

  	
  FG, BDT SEQUENCING RR MIX 245ML

  	
   

  	
  FG, BDT SEQUENCING RR MIX 245ML

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom. Only

  for Celera.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  361769C

  	
   

  	
  CUSTOM,ROX CPG

  	
   

  	
  RM, ROX CPG 1G

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom. Only

  for Celera.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4310592C

  	
   

  	
  CUSTOM,PRIMER -21M13 FWD (3.2uM)

  	
   

  	
   

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Celera was

  requesting

  internal use

  only part.

  Changed to

  custom part

  for Celera.

  Minimum &

  Maximum batch

  size is 100ml

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4310594C

  	
   

  	
  CUSTOM,PRIMER M13 REV (3.2u)

  	
   

  	
   

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Celera was

  requesting

  internal use

  only part.

  Changed to

  custom part

  for Celera.

  Minimum &

  Maximum batch

  size is 100ml

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4326320E

  	
   

  	
  FG,hu GUS MGB

  	
   

  	
  Human GUSB Endogenous Control

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4326502C

  	
   

  	
  CUSTOM,6-FAM AMIDITE

  	
   

  	
  6-FAM Amidite 1G

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom; not

  catalog.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4333767F

  	
   

  	
  FG,HUMAN GUSB

  	
   

  	
  Human GUSB Endogenous Control

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4335632C

  	
   

  	
  CUSTOM,PASSIVE REFERENCE

  	
   

  	
  FRETROX

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4346516C

  	
   

  	
  CUSTOM,BENZYLDADENOSINE CPG

  	
   

  	
  RM, DMT Benzyl dAdenosine CPG

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Custom. Made

  only for Celera.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4366266C

  	
   

  	
  FG, cICAT CUSTOM REAGENT

  	
   

  	
  Poros custom/qte 20345424

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  AM1964

  	
   

  	
  RNaseAlert Lab Test Kit 25 assays

  	
   

  	
  RNaseAlert Lab Test Kit 25 assays

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  AM2548

  	
   

  	
  Proteinase K (20 mg/ml) 5 X 1.25 ml

  	
   

  	
  Proteinase K 20mg/ml

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  AM7244

  	
   

  	
  Human Liver Tumor/NAT Ttl RNA 5 ug ea

  	
   

  	
  Hum Liv tum

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  AM7245

  	
   

  	
  Human Liver Tumor Total RNA 5 ug

  	
   

  	
  HumLivr. tum.

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  AM9530G

  	
   

  	
  1 M Magnesium Chloride 100 ml (Buf Kit)

  	
   

  	
  Magnesium chloride 1.0 M

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  AM9680

  	
   

  	
  Salmon Sperm DNA (sheared) 10 x 10 mg

  	
   

  	
  Salmon Sperm DNA

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8010055

  	
   

  	
  GENEAMP KIT WITH AMPLITAQ-FROZ

  	
   

  	
  GENEAMP PCR KIT

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  

 

 

	
  Internal Mfg

  or

  Purchased

  	
   

  	
  AB Part

  Number

  	
   

  	
  AB Description

  	
   

  	
  Celera Description

  	
   

  	
  Order

  Type

  	
   

  	
  Expiry

  	
   

  	
  Leadtime

  (Calendar

  Days)

  	
   

  	
  AB Comments

  	
   

  	
  

  

  Celera Comments

  	
   

  	
  Qty ship

  in last 5

  years

  	
   

  	
  Date of last

  shipment

  
	
  Purchased

  	
   

  	
  N8010531

  	
   

  	
  MicroAmp 96-well Support Base

  	
   

  	
  Microamp 96 well base

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8010534

  	
   

  	
  MicroAmp Caps, 12 Caps/Strip

  	
   

  	
  Optical 12-Cap Strip

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8010535

  	
   

  	
  MicroAmp Caps, 8 Caps/Strip

  	
   

  	
  MicroAmp 8-Strip Cap

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8010541

  	
   

  	
  9600/9700 MicroAmp Tray for Tubes w/Cap

  	
   

  	
  Tray MicroAmp

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8010550

  	
   

  	
  MicroAmp 96-well Full Plate Cover

  	
   

  	
  Microamp 96 well plate cover

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8010560

  	
   

  	
  MicroAmp 96-well Rxn Plate - no barcode

  	
   

  	
  MicroAmp 96-well Rxn Plate - no barcode

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8010580

  	
   

  	
  MicroAmp 8-Strip Rxn Tubes, 0.2mL

  	
   

  	
  MicroAmp 8-Tube Strip 0.2ml

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080007

  	
   

  	
  GENEAMP DNTPS-FROZEN

  	
   

  	
  10MMDCTP, 10MMDATP, 10MMDGT

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080018

  	
   

  	
  MULV REVERSE TRANSCRIPTASE

  	
   

  	
  MuLV Reverse Transcriptase

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080096

  	
   

  	
  URACIL N-GLYCOSYLASE-FROZEN

  	
   

  	
  AmpErse (UNG)

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080119

  	
   

  	
  RNase Inhibitor, 20 Units/ol, 100 Rxn

  	
   

  	
  RNase Inhibitor

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080150

  	
   

  	
  AMPLIWAX PCR GEM 50

  	
   

  	
  Ampliwax PCR em 50

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080158

  	
   

  	
  ATAQ LD + BUFFER II

  	
   

  	
  Amplitaq DNA LD w/buffer II

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080159

  	
   

  	
  AmpliTaq DNA POLYMERASE300U/uL

  	
   

  	
  Amplitaq @ 300 units/ul

  	
   

  	
  MTO

  	
   

  	
  ETU

  	
   

  	
  [**]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080160

  	
   

  	
  AMPLITAQ 250 UNIT VIAL-FRZN

  	
   

  	
  Amplitaq & buffer

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080172

  	
   

  	
  ATAQ 1000 & BUFFER II

  	
   

  	
  AMPLITAQ 1,000U W/BUFFER

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080179

  	
   

  	
  GENEAMP EZ WITH RNA PCR KIT

  	
   

  	
  Gene Amp EZ rTth RNA

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080248

  	
   

  	
  AMPLITAQ GOLD 5x100OU BUFFER I

  	
   

  	
  Amplitaq Gold

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080249

  	
   

  	
  AMPLITAQ GOLD 5x1000U BUF II

  	
   

  	
  AMPLITAQ GOLD 5 X 1,000 UNITS

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  N8080250

  	
   

  	
  BULK TAQ GOLD 25000U, 5mL

  	
   

  	
  Bulk Taq Gold 25000U, 5ml

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  N8080260

  	
   

  	
  FG,dNTP MIX w/dTTP,1mL,10mM

  	
   

  	
  GeneAmp dNTP Mix with dTTP

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  N8080270

  	
   

  	
  FG,dNTP MIX w/dUTP,1mL,12.5mM

  	
   

  	
  dNTP blend w/dUTP

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4308206

  	
   

  	
  Top Fill,GeneAmp Gold RNA PCR Reagent

  	
   

  	
  Geneamp Gold PCR kits

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4308207

  	
   

  	
  FG,GENEAMP GOLD RNA PCR CORE KIT

  	
   

  	
  4308206

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4308238

  	
   

  	
  Kit,GeneAmp RNA PCR Control Kit.

  	
   

  	
  4308206

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4310253

  	
   

  	
  PRTCL,GENEAMP GOLD RNA PCR RGNT KITZ

  	
   

  	
  4308206

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4322547

  	
   

  	
  TF,PREPMAN ULTRA

  	
   

  	
  Prep Man Reagent

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4318930

  	
   

  	
  FG,PREPMAN ULTRA

  	
   

  	
  4322547

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4367551

  	
   

  	
  QRC,ANUBIS PREPMAN ULTRA REAGENT

  	
   

  	
  4322547

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4367554

  	
   

  	
  PRTCL,ANUBIS PREPMAN ULTRA REAGENT

  	
   

  	
  4322547

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4337450

  	
   

  	
  TF,BDT v1.1 RR-100 & SEQ BUFFER

  	
   

  	
  Big Dye Terminator

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336697

  	
   

  	
  TUBE,5X SEQ BUFFER SMALL

  	
   

  	
  4337450

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336774

  	
   

  	
  FG,BDT v1.1 RR-100 KIT

  	
   

  	
  4337450

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4337451

  	
   

  	
  TF,BDT v1.1 RR-1000 & SEQ BUFFER

  	
   

  	
  BDT cycle sequencing kit. (1000 RR)

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336776

  	
   

  	
  FG,BDT v1.1 RR-1000 KIT

  	
   

  	
  4337451

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4339843

  	
   

  	
  BTL,5X SEQ BUFFER 12mL

  	
   

  	
  4337451

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4337452

  	
   

  	
  TF,BDT v1.1 RR-5000 & SEQ BUFFER

  	
   

  	
  Bot v1.1 kit 5000rxn BDT

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336699

  	
   

  	
  BTL,5X SEQ BUFFER MEDIUM

  	
   

  	
  4337452

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336778

  	
   

  	
  FG,BDT v1.1 RR-5000 KIT

  	
   

  	
  4337452

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4337455

  	
   

  	
  TF,BDT v3.1 RR-100 & SEQ BUFFER

  	
   

  	
  Big Dye Terminator 3.1

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336697

  	
   

  	
  TUBE,5X SEQ BUFFER SMALL

  	
   

  	
  4337455

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336917

  	
   

  	
  FG,BDT v3.1 RR-100

  	
   

  	
  4337455

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4337457

  	
   

  	
  TF,BDT v3.1 RR-5000 & SEQ BUFFER

  	
   

  	
  BigDye terminator v3.1 cycl. seq

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336699

  	
   

  	
  BTL,5X SEQ BUFFER MEDIUM

  	
   

  	
  4337457

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336921

  	
   

  	
  FG,BDT v3.1 RR-5000

  	
   

  	
  4337457

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4338856

  	
   

  	
  TF,AMPLITAQ GOLD LD 250U KIT

  	
   

  	
  AmpliTaq Gold DNA Polyverasl

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4338859

  	
   

  	
  FG,AMPLITAQ GOLD LD 250U KIT

  	
   

  	
  4338856

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4316866

  	
   

  	
  TF,SEQUAZYME PEPTIDE MASS STD INSTL KIT

  	
   

  	
  Voyager Installation Standard

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  2-2158-00

  	
   

  	
  FG,SEQUAZYME BSA TEST STD (EA)

  	
   

  	
   

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  GEN602151

  	
   

  	
  FG,VOYAGER IgG1 MASS STANDARD

  	
   

  	
   

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  P2-3143-00

  	
   

  	
  FG,SEQUAZYME MASS STANDARDS KIT

  	
   

  	
   

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4323151

  	
   

  	
  TF,SNAPSHOT MULTIPLEX 100 RXN

  	
   

  	
  Snapshot Multiplex Kit

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4323159

  	
   

  	
  FG,SNAPSHOT MULTIPLEX 100 RXN

  	
   

  	
  4323151

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4323357

  	
   

  	
  PRTCL,SNAPSHOT VERSION 2

  	
   

  	
  4323151

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4323975

  	
   

  	
  QSC,SNAPSHOT VERSION 2

  	
   

  	
  4323151

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  AM1975

  	
   

  	
  RecoverAll(TM) Total NA Iso 40 rxn. 2 pt

  	
   

  	
  Recoverall Total Nucleic Acid

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill. Should

  be ordered as a

  topfill as

  components are

  a matched pair.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  1975-1

  	
   

  	
  RT part of 1975 RecoverAll(TM)

  	
   

  	
  AM1975

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  1975-2

  	
   

  	
  -20C part of 1975 RecoverAll(TM)

  	
   

  	
  AM1975

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  403051

  	
   

  	
  TF,BDP TAQ FS RR-100-21M13

  	
   

  	
  Big Dye Primer Cycle -21 M13

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  403055

  	
   

  	
  BOX,BDP TAQ FS RR-100-21M13

  	
   

  	
  403051

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  403057

  	
   

  	
  PRTCL,BDP TAQ FS RR KITS

  	
   

  	
  403051

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4312765

  	
   

  	
  TF,GENEAMP GOLD RNA PCR CORE KIT + PROTC

  	
   

  	
  GENEAMP RNA PCR CORE KIT

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4308207

  	
   

  	
  FG,GENEAMP GOLD RNA PCR CORE KIT

  	
   

  	
  4312765

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4310253

  	
   

  	
  PRTCL,GENEAMP GOLD RNA PCR RGNT KITZ

  	
   

  	
  4312765

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4318739

  	
   

  	
  TF,AMPLITAQ GOLD PCR MASTER MIX + PROTO

  	
   

  	
  AmphiTagGold PCR 0.5x

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4316753

  	
   

  	
  FG,AMPLITAQ GOLD MASTER MIX

  	
   

  	
  4318739

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4317621

  	
   

  	
  PRTCL,AMPLITAQ GOLD PCR MASTER MIX

  	
   

  	
  4318739

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4324287

  	
   

  	
  TF,GS120 LIZ SIZE STD

  	
   

  	
  Genscan 120 LIZ Standard

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4322362

  	
   

  	
  FG,GS120 L1Z SIZE STD

  	
   

  	
  4324287

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4340859

  	
   

  	
  TF,4 PK ACTIVATOR 450 ML (401173)

  	
   

  	
  RM, Tetrazole/Acetonitrile

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  401173

  	
   

  	
  FG,TETRAZOLE/ACETONITRILE 450mL

  	
   

  	
  4340859

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
  Need to buy

  4 pack

  Topfill 4340859

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4340860

  	
   

  	
  TF,4 PK CAP A 450 ML (402220)

  	
   

  	
  RM, Acetic Anhydride/Pyridine/Tetrahydro

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  402220

  	
   

  	
  FG,ACETIC ANHYD/PYR/THF 450mL

  	
   

  	
  4340860

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4340861

  	
   

  	
  TF,4 PK CAP B 450 ML (401175)

  	
   

  	
  RM, 1-Mehtylimidazole/Tetrahydrofuran

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  401175

  	
   

  	
  FG,NMI/THF SOLUTION 450mL

  	
   

  	
  4340861

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
  Need to buy

  4 pack

  Topfill 4340861

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4340862

  	
   

  	
  TF,4 PK OXIDIZER 450 ML (401632)

  	
   

  	
  RM, 0.02M Iodine/Water/Pyridine/Tetrahy

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  401632

  	
   

  	
  FG,0.02M IODINE/H20/PYR/THF 450mL

  	
   

  	
  4340862

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
  Need to buy

  4 pack

  Topfill 4340862

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  

 

 

	
  Internal
  Mfg

  or

  Purchased

  	
   

  	
  AB
  Part

  Number

  	
   

  	
  AB
  Description

  	
   

  	
  Celera
  Description

  	
   

  	
  Order

  Type

  	
   

  	
  Expiry

  	
   

  	
  Leadtime

  (Calendar

  Days)

  	
   

  	
  AB
  Comments

  	
   

  	
  

  

  Celera Comments

  	
   

  	
  Qty ship

  in last 5

  years

  	
   

  	
  Date of
  last

  shipment

  
	
   

  	
   

  	
  4340864

  	
   

  	
  TF,4 PK ACTIVATOR
  180 ML (400606)

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Topfill

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  400606

  	
   

  	
  FG,TETRAZOLE/ACETONITRILE
  180mL

  	
   

  	
  4340864

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
  Need to buy 4
  pack

  Topfill 4340864

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4340865

  	
   

  	
  TF,4 PK CAP A 180
  ML (402222)

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Topfill

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  402222

  	
   

  	
  FG,ACETIC
  ANHYD/PYR/THF 180mL

  	
   

  	
  4340865

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
  Need to buy 4
  pack

  Topfill 4340865

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4340866

  	
   

  	
  TF,4 PK CAP B 180
  ML (400785)

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Topfill

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  400785

  	
   

  	
  FG,NMI SOLUTION
  DNA SYNTHESIS 180mL

  	
   

  	
  4340866

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
  Need to buy 4
  pack

  Topfill 4340866

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4340867

  	
   

  	
  TF,4 PK OXIDIZER
  200 ML (401732)

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Topfill

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  401732

  	
   

  	
  0G,0.02M
  IODINE/H2O/PYR/THF 200mL

  	
   

  	
  4340867

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
  Need to buy 4
  pack

  Topfill 4340867

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4347377

  	
   

  	
  TF,4pk 401272
  TCA/DCM (CH2-C12),2L

  	
   

  	
  RM,
  Trichloroacetic Acid/Dichloromethane

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  401272

  	
   

  	
  FG,TCA/DCM
  (CH2-C12),2L

  	
   

  	
  4347377

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4351176

  	
   

  	
  TF,7500 CHEMICAL
  INSTALL KIT

  	
   

  	
  7500 CHEMICAL
  INSTALL KIT

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4349180

  	
   

  	
  FG,7500 SPECTRAL
  DYE CAL KIT

  	
   

  	
  4351176

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4350584

  	
   

  	
  FG,96 WELL RNASE
  P VERIF PLATE NO PAD

  	
   

  	
  4351176

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4351151

  	
   

  	
  7500 SPECTRAL RED
  DYE CAL KIT

  	
   

  	
  4351176

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4352405

  	
   

  	
  KIT,TAQMAN 18S
  STARTER KIT

  	
   

  	
  4351176

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4363935

  	
   

  	
  TF,BOX OF 10
  BOTTLES POP-7

  	
   

  	
  POP7 Polym.
  3730/3730xl DNA anal

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4335615

  	
   

  	
  FG,BOX OF 5
  BOTTLES POP7

  	
   

  	
  4363935

  	
   

  	
  OTS

  	
   

  	
  ETU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  4379580

  	
   

  	
  TF,METHYlSEQR
  BISULFITE CONVERSION KIT

  	
   

  	
  methyl SEQr

  	
   

  	
  OTS

  	
   

  	
  NA

  	
   

  	
   

  	
   

  	
  Topfill.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4374960

  	
   

  	
  FG,METHYLSEQR
  REAGENT KIT

  	
   

  	
  4379580

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4374959

  	
   

  	
  FG,METHYLSEQR
  PURIFICATION COLUMNS

  	
   

  	
  4379580

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Purchased

  	
   

  	
  4374710

  	
   

  	
  PRTCL,METHYLSEQR
  BISULFITE SQNCNG

  	
   

  	
  4379580

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
  EXHIBIT
  A.2 - RAW MATERIALS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  [**]  

  [**]  

  [**]  

  [**]

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

	
   

  	
   

  	
  AB
  Part 

  Number

  	
   

  	
  AB
  Description

  	
   

  	
  Description

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Internal Mfg

  	
   

  	
  4344411

  	
   

  	
  FG,NED
  AMIDITE,1.0g

  	
   

  	
  RM, NED AMIDITE
  (1 gram)

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Celera
  is only user.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4344416

  	
   

  	
  FG,VIC-2 AMIDITE,
  1.0g

  	
   

  	
  RM, VIC - 2
  AMIDITE (1 gram)

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Celera
  is only user.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4344670

  	
   

  	
  FG,HEX NHS ESTER
  100MG

  	
   

  	
  HEX NHS Ester

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Celera
  is only user.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4345702

  	
   

  	
  FG,DMT-PEG
  AMIDITE, 745mG

  	
   

  	
  PEO
  Phosphoramidite

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Celera
  is major user.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4346490

  	
   

  	
  FG,VIC AMIDITE
  200mg

  	
   

  	
  RM, VIC Amidite

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Celera
  is only user.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4346506

  	
   

  	
  FG,NED AMIDITE
  200mg

  	
   

  	
  RM, NED Amidite

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  Celera
  is only user.

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  

 

	
   

  	
   

  	
  Part Number

  	
   

  	
   

  	
   

  	
  Description

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Additional
  Items

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4336701

  	
   

  	
  BTL,5X SEQ BUFFER
  LARGE

  	
   

  	
  BigDye® Terminator
  v1.1 & v3.1 5X Sequencing

  Buffer (233ml)

  	
   

  	
  OTS

  	
   

  	
  ETS

  	
   

  	
   

  	
   

  	
  BigDye®

  Terminator v1.1

  & v3.1 5X

  Sequencing

  Buffer (233ml)

  	
   

  	
  Celera

  PN 5002298/

  Need for BDT

  	
   

  	
  [**]

  	
   

  	
  [**]

  
	
  Internal Mfg

  	
   

  	
  4346492

  	
   

  	
  FG,6-FAM AMIDITE
  200mg

  	
   

  	
  RM, 6 - FAM
  Amidite v.2

  	
   

  	
  MTO

  	
   

  	
  ETS

  	
   

  	
  [**]

  	
   

  	
  RM, 6 - FAM

  Amidite v.2

  	
   

  	
  Celera

  PN 5000134

  	
   

  	
  [**]

  	
   

  	
  [**]

  

[**]
indicates material that has been omitted pursuant to a request for confidential
treatment. The omitted material has been filed separately with the Securities
and Exchange Commission.

 

 

Exhibit B

 

Instruments

 

ABI Prism 310

ABI Prism 3100

ABI Prism 3100
Avant

ABI Prism 3130

ABI Prism 3130
xl

ABI Prism 3730
xlExhibit 10.9

 

 

 

 

 

 

 

 

 

 

 

 

 

RESTATED ALLIANCE AGREEMENT

 

RESTATED STRATEGIC ALLIANCE
AGREEMENT

 

among

 

APPLERA CORPORATION,

 

CELERA DIAGNOSTICS, LLC

 

and

 

ABBOTT LABORATORIES

 

 

 

 

[***]
indicates material that has been omitted pursuant to a request for confidential
treatment. The omitted material has been filed separately with the Securities
and Exchange Commission.

 

 

RESTATED STRATEGIC ALLIANCE
AGREEMENT

 

Table of Contents

 

	
   

  	
   

  	
  Page

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE I DEFINITIONS

  	
   

  	
  1

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE II EXCLUSIVITY

  	
   

  	
  16

  	
   

  
	
  2.1

  	
   

  	
  Exclusivity Obligations

  	
   

  	
  16

  	
   

  
	
  2.2

  	
   

  	
  Exceptions to Exclusivity

  	
   

  	
  17

  	
   

  
	
  2.3

  	
   

  	
  Outside Exclusive Areas

  	
   

  	
  17

  	
   

  
	
  2.4

  	
   

  	
  [***]

  	
   

  	
  18

  	
   

  
	
  2.5

  	
   

  	
  QSR Claims;
  Commercialization of Non-Alliance Products and Reagents for Research Use Only

  	
   

  	
  18

  	
   

  
	
  2.6

  	
   

  	
  OEM Alliance Products

  	
   

  	
  19

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE III JOINT REVIEW
  BOARD

  	
   

  	
  20

  	
   

  
	
  3.1

  	
   

  	
  Composition

  	
   

  	
  20

  	
   

  
	
  3.2

  	
   

  	
  Responsibilities

  	
   

  	
  20

  	
   

  
	
  3.3

  	
   

  	
  Meetings

  	
   

  	
  22

  	
   

  
	
  3.4

  	
   

  	
  Decisions

  	
   

  	
  22

  	
   

  
	
  3.5

  	
   

  	
  Minutes

  	
   

  	
  22

  	
   

  
	
  3.6

  	
   

  	
  In-License Decisions

  	
   

  	
  22

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE IV ALLIANCE
  PROGRAM

  	
   

  	
  23

  	
   

  
	
  4.1

  	
   

  	
  Initial Program Efforts

  	
   

  	
  23

  	
   

  
	
  4.2

  	
   

  	
  New Product Concept
  Documents

  	
   

  	
  23

  	
   

  
	
  4.3

  	
   

  	
  Acquisition of Products or
  Companies in the Alliance Field

  	
   

  	
  24

  	
   

  
	
  4.4

  	
   

  	
  Rejected NPCD

  	
   

  	
  25

  	
   

  
	
  4.5

  	
   

  	
  Non-Alliance Product

  	
   

  	
  26

  	
   

  
	
  4.6

  	
   

  	
  Work Plans

  	
   

  	
  26

  	
   

  
	
  4.7

  	
   

  	
  R&D Plan

  	
   

  	
  26

  	
   

  
	
  4.8

  	
   

  	
  Technical Assistance

  	
   

  	
  27

  	
   

  
	
  4.9

  	
   

  	
  Conduct of the Alliance
  Program

  	
   

  	
  27

  	
   

  
	
  4.10

  	
   

  	
  Records

  	
   

  	
  28

  	
   

  
	
  4.11

  	
   

  	
  Reports

  	
   

  	
  28

  	
   

  
	
  4.12

  	
   

  	
  Commercialization of
  Alliance Products

  	
   

  	
  28

  	
   

  
	
  4.13

  	
   

  	
  Disposition of Alliance
  Product

  	
   

  	
  28

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE V REGULATORY
  APPROVALS

  	
   

  	
  29

  	
   

  
	
  5.1

  	
   

  	
  Regulatory Approvals

  	
   

  	
  29

  	
   

  
	
  5.2

  	
   

  	
  Regulatory Communications

  	
   

  	
  29

  	
   

  
	
  5.3

  	
   

  	
  Product Inserts and
  Labeling

  	
   

  	
  29

  	
   

  
	
  5.4

  	
   

  	
  Inspection and Audit of
  Supplier

  	
   

  	
  29

  	
   

  
	
  5.5

  	
   

  	
  Inspection and Audit of
  Distributor

  	
   

  	
  29

  	
   

  

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

i

 

	
  5.6

  	
   

  	
  Localization

  	
   

  	
  30

  	
   

  
	
  5.7

  	
   

  	
  Regulatory Compliance And
  Related Matters

  	
   

  	
  30

  	
   

  
	
  5.8

  	
   

  	
  Field Actions

  	
   

  	
  30

  	
   

  
	
  5.9

  	
   

  	
  Existing Products

  	
   

  	
  31

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE VI MANUFACTURING
  RIGHTS

  	
   

  	
  31

  	
   

  
	
  6.1

  	
   

  	
  Manufacturing

  	
   

  	
  31

  	
   

  
	
  6.2

  	
   

  	
  Manufacturing Practices.

  	
   

  	
  31

  	
   

  
	
  6.3

  	
   

  	
  Manufacturing Records

  	
   

  	
  32

  	
   

  
	
  6.4

  	
   

  	
  Warranty

  	
   

  	
  32

  	
   

  
	
  6.5

  	
   

  	
  Terms of Supply

  	
   

  	
  33

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE VII SALES,
  MARKETING AND SUPPORT

  	
   

  	
  33

  	
   

  
	
  7.1

  	
   

  	
  Distributor

  	
   

  	
  33

  	
   

  
	
  7.2

  	
   

  	
  Selling Price

  	
   

  	
  33

  	
   

  
	
  7.3

  	
   

  	
  Marketing

  	
   

  	
  34

  	
   

  
	
  7.4

  	
   

  	
  Diligence

  	
   

  	
  34

  	
   

  
	
  7.5

  	
   

  	
  Service and Support

  	
   

  	
  34

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE VIII INSTRUMENTS

  	
   

  	
  34

  	
   

  
	
  8.1

  	
   

  	
  Instrument
  Commercialization

  	
   

  	
  34

  	
   

  
	
  8.2

  	
   

  	
  Instrument Co-Promotion

  	
   

  	
  35

  	
   

  
	
  8.3

  	
   

  	
  Instrument Distribution

  	
   

  	
  35

  	
   

  
	
  8.4

  	
   

  	
  OEM Instruments

  	
   

  	
  35

  	
   

  
	
  8.5

  	
   

  	
  Alliance Funded Instrument

  	
   

  	
  36

  	
   

  
	
  8.6

  	
   

  	
  Instrument Funding

  	
   

  	
  36

  	
   

  
	
  8.7

  	
   

  	
  Rejected Instrument

  	
   

  	
  36

  	
   

  
	
  8.8

  	
   

  	
  OEM Opportunity

  	
   

  	
  36

  	
   

  
	
  8.9

  	
   

  	
  Instruments for Performing
  Tests in Exclusive Areas

  	
   

  	
  37

  	
   

  
	
  8.10

  	
   

  	
  Technology and Patent
  Rights

  	
   

  	
  37

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE IX SHARING OF
  COSTS AND REVENUES

  	
   

  	
  38

  	
   

  
	
  9.1

  	
   

  	
  Quarterly Cost and Revenue
  Estimate

  	
   

  	
  38

  	
   

  
	
  9.2

  	
   

  	
  Cost and Revenue
  Statements

  	
   

  	
  38

  	
   

  
	
  9.3

  	
   

  	
  Statement of Net
  Investment

  	
   

  	
  38

  	
   

  
	
  9.4

  	
   

  	
  Equalization Payments

  	
   

  	
  38

  	
   

  
	
  9.5

  	
   

  	
  Maximum Costs

  	
   

  	
  39

  	
   

  
	
  9.6

  	
   

  	
  Modifying Terms

  	
   

  	
  39

  	
   

  
	
  9.7

  	
   

  	
  Payment Terms

  	
   

  	
  39

  	
   

  
	
  9.8

  	
   

  	
  Record Keeping

  	
   

  	
  39

  	
   

  
	
  9.9

  	
   

  	
  Audits

  	
   

  	
  40

  	
   

  
	
  9.10

  	
   

  	
  Tax Matters

  	
   

  	
  40

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE X OWNERSHIP,
  LICENSE AND TECHNOLOGY TRANSFER

  	
   

  	
  45

  	
   

  
	
  10.1

  	
   

  	
  Abbott Independent Rights

  	
   

  	
   

  	
   

  
	
  10.2

  	
   

  	
  Applera Independent Rights

  	
   

  	
  45

  	
   

  
	
  10.3

  	
   

  	
  Abbott Alliance Technology
  and Alliance Patent Rights

  	
   

  	
  45

  	
   

  

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

ii

 

	
  10.4

  	
   

  	
  Applera Alliance
  Technology and Alliance Patent Rights

  	
   

  	
  45

  	
   

  
	
  10.5

  	
   

  	
  Joint Alliance Technology
  and Joint Alliance Patent Rights

  	
   

  	
  46

  	
   

  
	
  10.6

  	
   

  	
  Employee Assignment and
  Disclosure

  	
   

  	
  47

  	
   

  
	
  10.7

  	
   

  	
  Transfer of Applera Technology

  	
   

  	
  48

  	
   

  
	
  10.8

  	
   

  	
  Transfer of Abbott
  Technology

  	
   

  	
  48

  	
   

  
	
  10.9

  	
   

  	
  No Title Transfer

  	
   

  	
  49

  	
   

  
	
  10.10

  	
   

  	
  Applera License Grant to
  Abbott in the Alliance Field

  	
   

  	
  49

  	
   

  
	
  10.11

  	
   

  	
  Abbott License Grant to
  Applera in the Alliance Field

  	
   

  	
  50

  	
   

  
	
  10.12

  	
   

  	
  Abbott License Grant to
  Applera Outside the Alliance Field

  	
   

  	
  50

  	
   

  
	
  10.13

  	
   

  	
  Applera License Grant to
  Abbott Outside the Alliance Field

  	
   

  	
  51

  	
   

  
	
  10.14

  	
   

  	
  Royalty Rate Factors and
  License Terms

  	
   

  	
  51

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE XI PATENT RIGHTS
  MAINTENANCE AND ENFORCEMENT

  	
   

  	
  54

  	
   

  
	
  11.1

  	
   

  	
  Independent Patent Rights

  	
   

  	
  54

  	
   

  
	
  11.2

  	
   

  	
  Alliance Patent Rights

  	
   

  	
  54

  	
   

  
	
  11.3

  	
   

  	
  Joint Alliance Patent
  Rights

  	
   

  	
  55

  	
   

  
	
  11.4

  	
   

  	
  Alliance Patent Rights
  Enforcement Outside Exclusive Areas

  	
   

  	
  55

  	
   

  
	
  11.5

  	
   

  	
  Alliance Patent Rights
  Enforcement in the Exclusive Areas

  	
   

  	
  56

  	
   

  
	
  11.6

  	
   

  	
  Joint Alliance Patent
  Rights Enforcement

  	
   

  	
  56

  	
   

  
	
  11.7

  	
   

  	
  Defense of Third Party
  Infringement Actions

  	
   

  	
  57

  	
   

  
	
  11.8

  	
   

  	
  Non-Alliance Product
  Infringement Issues

  	
   

  	
  57

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE XII TRADEMARKS

  	
   

  	
  57

  	
   

  
	
  12.1

  	
   

  	
  Trademark Usage

  	
   

  	
  57

  	
   

  
	
  12.2

  	
   

  	
  Labels

  	
   

  	
  58

  	
   

  
	
  12.3

  	
   

  	
  Party Trademark Rights

  	
   

  	
  58

  	
   

  
	
  12.4

  	
   

  	
  New Trademark Rights

  	
   

  	
  58

  	
   

  
	
  12.5

  	
   

  	
  Trademark Challenges

  	
   

  	
  58

  	
   

  
	
  12.6

  	
   

  	
  Post-Termination Rights

  	
   

  	
  59

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE XIII COPYRIGHTS

  	
   

  	
  59

  	
   

  
	
  13.1

  	
   

  	
  Copyright License

  	
   

  	
  59

  	
   

  
	
  13.2

  	
   

  	
  Copyright Marking

  	
   

  	
  59

  	
   

  
	
  13.3

  	
   

  	
  Copyright Infringement

  	
   

  	
  59

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE XIV
  CONFIDENTIALITY

  	
   

  	
  59

  	
   

  
	
  14.1

  	
   

  	
  Confidentiality

  	
   

  	
  59

  	
   

  
	
  14.2

  	
   

  	
  Terms of Agreement

  	
   

  	
  60

  	
   

  
	
  14.3

  	
   

  	
  Permitted Disclosures

  	
   

  	
  60

  	
   

  
	
  14.4

  	
   

  	
  Disclosure to Investors
  and Rating Agencies

  	
   

  	
  61

  	
   

  
	
  14.5

  	
   

  	
  Term of Obligations

  	
   

  	
  61

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE XV REPRESENTATIONS
  AND WARRANTIES

  	
   

  	
  61

  	
   

  
	
  15.1

  	
   

  	
  Representations

  	
   

  	
  61

  	
   

  
	
  15.2

  	
   

  	
  Represented by Counsel

  	
   

  	
  62

  	
   

  
	
  15.3

  	
   

  	
  Disclaimer Of Warranties

  	
   

  	
  62

  	
   

  

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

iii

 

	
  ARTICLE XVI
  INDEMNIFICATION

  	
   

  	
  62

  	
   

  
	
  16.1

  	
   

  	
  By Abbott

  	
   

  	
  62

  	
   

  
	
  16.2

  	
   

  	
  By Applera

  	
   

  	
  63

  	
   

  
	
  16.3

  	
   

  	
  Procedure

  	
   

  	
  63

  	
   

  
	
  16.4

  	
   

  	
  Insurance

  	
   

  	
  63

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE XVII TERM AND
  TERMINATION

  	
   

  	
  64

  	
   

  
	
  17.1

  	
   

  	
  Expiration

  	
   

  	
  64

  	
   

  
	
  17.2

  	
   

  	
  Termination of an Alliance
  Product or NPCD

  	
   

  	
  64

  	
   

  
	
  17.3

  	
   

  	
  Termination by Mutual
  Agreement

  	
   

  	
  64

  	
   

  
	
  17.4

  	
   

  	
  Termination by Abbott

  	
   

  	
  64

  	
   

  
	
  17.5

  	
   

  	
  Termination by Applera

  	
   

  	
  64

  	
   

  
	
  17.6

  	
   

  	
  Other Termination

  	
   

  	
  65

  	
   

  
	
  17.7

  	
   

  	
  Rights and Obligations

  	
   

  	
  65

  	
   

  
	
  17.8

  	
   

  	
  Termination for Force
  Majeure

  	
   

  	
  69

  	
   

  
	
  17.9

  	
   

  	
  Termination for Change of
  Control

  	
   

  	
  69

  	
   

  
	
  17.10

  	
   

  	
  Termination for Insolvency

  	
   

  	
  72

  	
   

  
	
  17.11

  	
   

  	
  Product Inserts and
  Labeling

  	
   

  	
  72

  	
   

  
	
  17.12

  	
   

  	
  Return Material

  	
   

  	
  72

  	
   

  
	
  17.13

  	
   

  	
  Share Net Investment

  	
   

  	
  72

  	
   

  
	
  17.14

  	
   

  	
  Liabilities

  	
   

  	
  73

  	
   

  
	
  17.15

  	
   

  	
  Post-Termination
  Activities

  	
   

  	
  73

  	
   

  
	
  17.16

  	
   

  	
  Survival

  	
   

  	
  73

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE XVIII DISPUTE
  RESOLUTION

  	
   

  	
  73

  	
   

  
	
  18.1

  	
   

  	
  Disputes

  	
   

  	
  73

  	
   

  
	
  18.2

  	
   

  	
  JRB Resolution

  	
   

  	
  74

  	
   

  
	
  18.3

  	
   

  	
  Executive Officer
  Resolution

  	
   

  	
  74

  	
   

  
	
  18.4

  	
   

  	
  Notice of ADR

  	
   

  	
  74

  	
   

  
	
  18.5

  	
   

  	
  Designation of Neutral

  	
   

  	
  74

  	
   

  
	
  18.6

  	
   

  	
  ADR Rules

  	
   

  	
  75

  	
   

  
	
  18.7

  	
   

  	
  Hearing

  	
   

  	
  75

  	
   

  
	
  18.8

  	
   

  	
  Evidence for Hearing

  	
   

  	
  75

  	
   

  
	
  18.9

  	
   

  	
  Hearing Procedure

  	
   

  	
  75

  	
   

  
	
  18.10

  	
   

  	
  Post-Hearing Briefs

  	
   

  	
  76

  	
   

  
	
  18.11

  	
   

  	
  Ruling by Neutral

  	
   

  	
  76

  	
   

  
	
  18.12

  	
   

  	
  Allocation of Expenses

  	
   

  	
  76

  	
   

  
	
  18.13

  	
   

  	
  Binding Result

  	
   

  	
  76

  	
   

  
	
  18.14

  	
   

  	
  Statute of Limitations

  	
   

  	
  77

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  ARTICLE XIX MISCELLANEOUS

  	
   

  	
  77

  	
   

  
	
  19.1

  	
   

  	
  Governing Law

  	
   

  	
  77

  	
   

  
	
  19.2

  	
   

  	
  Publicity

  	
   

  	
  77

  	
   

  
	
  19.3

  	
   

  	
  No Implied Licenses

  	
   

  	
  77

  	
   

  
	
  19.4

  	
   

  	
  Waiver

  	
   

  	
  77

  	
   

  
	
  19.5

  	
   

  	
  Assignment

  	
   

  	
  77

  	
   

  
	
  19.6

  	
   

  	
  Independent Contractors

  	
   

  	
  78

  	
   

  

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

iv

 

	
  19.7

  	
   

  	
  Further Actions

  	
   

  	
  78

  	
   

  
	
  19.8

  	
   

  	
  Notices

  	
   

  	
  78

  	
   

  
	
  19.9

  	
   

  	
  Force Majeure

  	
   

  	
  78

  	
   

  
	
  19.10

  	
   

  	
  No Consequential Damages

  	
   

  	
  79

  	
   

  
	
  19.11

  	
   

  	
  Third Party Rights

  	
   

  	
  79

  	
   

  
	
  19.12

  	
   

  	
  Complete Agreement

  	
   

  	
  79

  	
   

  
	
  19.13

  	
   

  	
  Counterparts

  	
   

  	
  79

  	
   

  
	
  19.14

  	
   

  	
  Headings

  	
   

  	
  79

  	
   

  
	
  19.15

  	
   

  	
  Severability

  	
   

  	
  79

  	
   

  
	
  19.16

  	
   

  	
  Amendment

  	
   

  	
  80

  	
   

  
	
  19.17

  	
   

  	
  Controlling Document

  	
   

  	
  80

  	
   

  

 

Exhibits

 

	
  EXHIBIT 1.13

  	
   

  	
  Financial Terms

  
	
  EXHIBIT 1.22

  	
   

  	
  Carveouts

  
	
  EXHIBIT 1.62 (a)

  	
   

  	
  NPCD — Development

  
	
  EXHIBIT 1.62 (b)

  	
   

  	
  NPCD — Feasibility

  
	
  EXHIBIT 1.77

  	
   

  	
  R&D Plan

  
	
  EXHIBIT 1.95

  	
   

  	
  Work Plan

  
	
  EXHIBIT 2.2

  	
   

  	
  Exceptions to
  Exclusivity

  
	
  EXHIBIT 2.2(a)

  	
   

  	
  Exceptions to
  Exhibit 2.2

  
	
  EXHIBIT 2.6

  	
   

  	
  OEM Alliance Products

  
	
  EXHIBIT 4.1

  	
   

  	
  Approved NPCDs

  
	
  EXHIBIT 4.7(a)(i)

  	
   

  	
  Initial R&D Plan

  
	
  EXHIBIT 4.7(a)(ii)

  	
   

  	
  Initial R&D Plan
  Budget

  
	
  EXHIBIT 9.2

  	
   

  	
  Cost and Revenue
  Statement

  
	
  EXHIBIT 9.3

  	
   

  	
  Net Investment
  Statement

  
	
  EXHIBIT 17.7(c)

  	
   

  	
  Post-Termination Royalties

  
	
  EXHIBIT 19.12

  	
   

  	
  Further Amendments to
  Amendment Nos. 2 and 2a

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

v

 

RESTATED STRATEGIC ALLIANCE
AGREEMENT

 

THIS RESTATED STRATEGIC ALLIANCE AGREEMENT (this “Agreement”), effective as of January 9, 2006 (the “Effective Date”), is entered into among APPLERA CORPORATION, a
Delaware corporation (“Applera”),
having a place of business at 301 Merritt 7, Norwalk, Connecticut 06851, CELERA
DIAGNOSTICS, LLC, a Delaware limited liability company (“CDx”), having a place of business at 1401 Harbor Bay
Parkway, Alameda, California 94502, and ABBOTT LABORATORIES, an Illinois
corporation (“Abbott”), having a place of business at 100 Abbott Park
Road, Abbott Park, Illinois 60064-6400.

 

WHEREAS, Abbott is a global, diversified healthcare company with
expertise in the discovery, development, manufacture and marketing of
pharmaceuticals, nutritionals, and medical products, including devices and
diagnostics;

 

WHEREAS, Applera, through its business units Applied Biosystems, Celera
Genomics, and CDx, has expertise and technology applicable to genetic research
and molecular diagnostic product development;

 

WHEREAS, the Parties (as defined below) entered into a Strategic
Alliance Agreement dated June 24, 2002, as amended, to engage in a
collaborative program for the discovery, research, development and
commercialization worldwide of novel molecular in vitro diagnostic products and
services; and

 

WHEREAS, the Parties desire to modify and clarify such collaborative
program in a fully restated agreement on the terms and conditions of this
Agreement.

 

NOW THEREFORE, in consideration of the foregoing premises and the
mutual covenants set forth below, the Parties agree as follows:

 

ARTICLE I

 

DEFINITIONS

 

1.1           “Abbott Alliance Patent
Rights” means Alliance Patent
Rights that claim inventions conceived solely by employees or agents of Abbott
or any Abbott Affiliate.

 

1.2           “Abbott Alliance
Technology” means the Alliance
Technology Derived solely by employees or agents of Abbott or any Abbott
Affiliate.

 

1.3           “Abbott Independent
Patent Rights” means Independent
Patent Rights owned or Controlled by Abbott or any Abbott Affiliate.

 

1.4           “Abbott Independent
Technology” means Independent
Technology owned or Controlled by Abbott or any Abbott Affiliate.

 

1.5           “Abbott Existing
Product(s)” means the LCx
instrument system and uniquely associated accessories and consumables (“System”)
and the LCx HIV and HCV assays (collectively “Viral Assays”). 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

 

1.6           “Affiliate(s)” means, with respect to any person or entity, any
other person or entity, which controls, is controlled by or is under common
control with such person or entity. For purposes of this definition, a person
or entity is in “control” of an entity if it owns or controls more than fifty
percent (50%) of the equity securities of the subject entity entitled to vote
in the election of directors (or, in the case of an entity that is not a
corporation, for the election of the corresponding managing authority), or
otherwise has the power to control the management and policies of such other
entity. An entity only retains the rights and is subject to the obligations of
an Affiliate for so long as such entity continues to satisfy the definition in
this Section 1.6.

 

1.7           “Alliance Accounting
Policies” means the accounting
policies adopted by the JRB (as defined in Section 3.1) to be used in
determining the net of sharing of Revenue less Allowable Expenses pursuant to Article IX.

 

1.8           “Alliance Field” means the manufacture, use or Commercialization of
any product or service for the in vitro amplification, detection,
quantification, extraction or sequencing of a nucleic acid in or from a human
biological sample for the purpose of: (a)  diagnosing, detecting or
monitoring any disease, state, condition, trait or characteristic of a human
being for medical management; (b) exercising quality assurance and quality
control testing of human blood or plasma from which biological therapeutic
agents may be derived for resale; (c) [***]; or (d) screening human
organs, tissues or cells for transplantation. The Alliance Field does not
include the research, development, manufacture, use or Commercialization of any
Carveout; the internal research by either Party for therapeutic development,
including clinical trials; or research, development, manufacture, use,
Commercialization, or testing in Epidemiology or Biosecurity (as each such term
is defined below).

 

1.9           “Alliance Patent Rights” means Patent Rights that claim any Alliance
Technology.

 

1.10         “Alliance Program” means the collaborative research and Development,
manufacturing, regulatory and Commercialization activities in the Exclusive
Areas undertaken pursuant to a JRB-approved Work Plan conducted by the Parties
in accordance with this Agreement or the Prior Alliance Agreement. The Alliance
Program does not include such activities by a Party on Non-Alliance Products.

 

1.11         “Alliance Product(s)” means any product, including, without limitation,
any Reagent, kit, consumable or Instrument described in Sections 8.4 and 8.5,
or any combination or component thereof, that: (a) is Commercialized under
the Alliance Program; or (b) is the subject of a JRB-approved Work Plan;
or (c) otherwise becomes an Alliance Product pursuant to this Agreement.
An Alliance Product will include software to the extent such software is
distributed in connection with the Reagent or kit. Alliance Product does not
include: 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

2

 

(x) any
Carveout; or (y) any Non-Alliance Product. For purposes of this Agreement,
the term “Alliance
Product” will also include any
service that: (d) is Commercialized under the Alliance Program; (e) is
the subject of a JRB-approved Work Plan; or (f) is provided by or for a
Party (i) through use of an Alliance Product or (ii) in support of a
customer’s use of an Alliance Product.

 

1.12         “Alliance
Technology” means Technology and/or Materials that are Derived by or for a
Party during performance of the Alliance Program or a program approved by the
JRB under the Prior Alliance Agreement and the Derivation of which is jointly
funded by the Parties pursuant to this Agreement or pursuant to a program
approved by the JRB under the Prior Alliance Agreement.

 

1.13         “Allowable Expenses” has the meaning defined in Exhibit 1.13
hereof.

 

1.14         “Analyte Specific
Reagents” or “ASR” means nucleic acid sequences, and similar reagents
which, through specific binding or chemical reactions with substances in a
specimen, are intended for use in a diagnostic application for identification
and/or quantification of an individual chemical substance in a biological
specimen, as further defined in 21 CFR 864.4020(a), as may be amended or
replaced from time to time, or in equivalent foreign regulations.

 

1.15         “Applera Alliance Patent
Rights” means Alliance Patent Rights
that claim inventions conceived solely by employees or agents of Applera or any
Applera Affiliates.

 

1.16         “Applera Alliance
Technology” means Alliance
Technology Derived solely by employees or agents of Applera or any Applera
Affiliates.

 

1.17         “Applera Existing
Products” means: (a) ViroSeq
HIV Genotyping Kit and associated software; (b) HLA Sequencing based
typing Kits (HLA-DRB, Codon 86 for HLA-DRB, HLA-A, HLA-B) and associated
software; and (c) Cystic Fibrosis mutation screening system available as
Analyte Specific Reagents and General Purpose Reagents.

 

1.18         “Applera Independent
Patent Rights” means Independent
Patent Rights owned or Controlled by Applera or any Applera Affiliate.

 

1.19         “Applera Independent
Technology” means Independent
Technology owned or Controlled by Applera or any Applera Affiliate.

 

1.20         “Biosecurity” means the detection of biological or chemical
agents, pathogens, microorganisms or other infectious agents in the
environment, agriculture, food or water.

 

1.21         [***].

 

1.22         “Carveout(s)” means, collectively and individually, the products
described in Exhibit 1.22 hereto. For purposes of this Agreement,
Carveouts are not in the Alliance Field.

 

1.23         “Commencement Date” means January 1, 2006 with respect to matters
pertaining to budgets to be approved by the JRB.

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

3

 

1.24         “Commercial Entity” means any Third Party or its Affiliates that is
engaged in the commercial sale of products in the In Vitro Diagnostics Field.

 

1.25         “Commercialize” and cognates thereof mean the sale, transfer or
co-promotion of a product or service to a Third Party for commercial purposes.
For example, an Alliance Product will be Commercialized when it or its use is
provided to any Third Party for cash or other consideration.

 

1.26         “Competing Product(s)” means any product in the Alliance Field that (a) is,
or is intended to be, Commercialized in the current or intended Customer
Segment as, and (b) except as provided in Section 2.5(b), has or
incorporates the same Clinical Intent as, an Alliance Product. A product in the
Alliance Field may be a Competing Product despite differences in the marker
used or the technology employed. “Clinical Intent”
means providing the same clinical utility, intended use or the same clinical
information. “Customer
Segment” means distinct customer
types on a country-by-country basis, for example, clinical diagnostic labs,
blood/specimen screening labs and point of care customers. A product in the
Alliance Field having the same Clinical Intent in the same Customer Segment as
an Alliance Product will be a Competing Product despite differences in
effectiveness, efficiency or price. In no event will a product Commercialized
outside the Alliance Field be considered a Competing Product. For purposes of
this Agreement, the term “Competing Product”
will include any service in the Alliance Field that is, or is intended to be,
Commercialized in the same Customer Segment as, and, except as provided in Section 2.5(b),
has the same Clinical Intent as, a service that is an Alliance Product. As
provided in Section 2.5(e), a product sold to purchasers before
JRB-approval of an NPCD-Development for a competing Alliance Product will be a
Competing Product only for sales to new customers, which sales occur after JRB
approval of the NPCD-Development for the Alliance Product. Competing Products
will not include primers and probes labeled “For Research Use Only” or other
comparable label that are sold as reagents to an individual customer for
testing with the same Clinical Intent as an Alliance Product unless they are
used for testing in the Exclusive Areas as defined in Sections 1.39(a) — (d) or
in the Exclusive Areas as defined in Sections 1.39(e) — (g) and they
incorporate Alliance Technology. In such case the Party supplying the research
use primers and probes as reagents to the individual customer may not
Facilitate the sale of such primers and probes to additional customers.

 

1.27         “Conditionally Exclusive
Areas” means any product or service
in the Alliance Field that is [***]. “Conditionally Exclusive Areas”
specifically excludes [***] unless they are Alliance Products.

 

1.28         “Confidential Information” means non-public proprietary data, information,
Materials, Technology or Instruments (and all tangible and intangible
embodiments thereof), which is owned or Controlled by a Party, is disclosed by
such Party (“Disclosing
Party”) to the other Party (“Receiving Party”) pursuant to this Agreement, and is designated as
Confidential Information by the Disclosing Party at the time of disclosure or
pursuant to this Agreement. Confidential Information will not include data,
information, Materials, Technology or Instruments which, and only to the
extent, a Receiving Party can establish by written documentation: (a) is
part of the public domain prior to disclosure of such information by the Disclosing
Party to the Receiving Party or becomes part of the public domain, without the
fault of the Receiving Party, subsequent to disclosure of such information by
the Disclosing Party to 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

4

 

the
Receiving Party; (b) has been received by the Receiving Party at any time
from a source, other than the Disclosing Party, rightfully having possession of
and the right to disclose such information free of confidentiality obligations;
(c) has been otherwise known by the Receiving Party free of
confidentiality obligations prior to disclosure of such information by the
Disclosing Party to the Receiving Party; (d) has been independently
developed by employees or others on behalf of the Receiving Party without
access to or use of such information disclosed by the Disclosing Party to the
Receiving Party. Specific aspects or details of Confidential Information will
not be deemed to be within the public knowledge or in the prior possession of
the Receiving Party merely because the aspects or details of the Confidential
Information are embraced by general disclosures in the public domain. In
addition, any combination of Confidential Information will not be considered in
the public knowledge or in the prior possession of the Receiving Party merely
because individual elements thereof are in the public domain or in the prior
possession of the Receiving Party unless the combination and its principles are
in the public knowledge or in the prior possession of the Receiving Party. With
respect to Confidential Information which is jointly created, owned or
Controlled by the Parties under this Agreement, exceptions (a) through (d) of
this Section 1.28 will continue to apply; provided, however, that for
application of exceptions (b) through (d) of this Section 1.28,
a Party must establish that the exception applies by virtue of written
documentation from a Third Party rather than the written documentation of the
Receiving Party. Further, for avoidance of doubt, Confidential Information will
include Confidential Information received by the Disclosing Party from a Third
Party. Prior to disclosure of such Third Party Confidential Information to the
Receiving Party the Disclosing Party will determine that it has the right to
make such disclosure, advise the Receiving Party that the disclosure includes
Third Party Confidential Information and provide the Receiving Party with the
terms and conditions of any agreement between the Third Party and the
Disclosing Party respecting such Third Party Confidential Information.

 

1.29         “Contract Half Year” means a consecutive and continuous six (6)-month
period commencing on January 1, 2006 and on each subsequent July 1
and January 1 thereafter during the term of this Agreement.

 

1.30         “Contract Year” means a consecutive and continuous twelve
(12)-month period commencing on January 1, 2006 and on each subsequent January 1
during the term of this Agreement.

 

1.31         “Controls” or “Controlled”
and cognates thereof mean with respect to Technology, Patent Rights, Materials,
and/or Confidential Information, the possession of the ability to grant
licenses or sublicenses, to distribute Copyrighted Works or to otherwise
disclose, without violating the terms of any agreement or other arrangement
with, or the rights of, any Third Party.

 

1.32         “Copyrighted Works” means original works of authorship, including,
without limitation, computer programs (in source code, object code or other
form), notes, sketches, drawings and reports.

 

1.33         “Deliverable Alliance
Technology” means that portion of
Alliance Technology that is responsive to goals and deliverables specifically
identified in NPCDs.

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

5

 

1.34         “Derived” and cognates thereof mean obtained, developed,
acquired, made, invented, discovered, created, synthesized, designed, or
resulting from, based upon or otherwise generated (whether directly or
indirectly, or in whole or in part).

 

1.35         “Development” means actions or activities by a Party following
proof of feasibility to validate the design of a product or service for
eventual Commercialization.

 

1.36         “Development Costs” has the meaning defined in Exhibit 1.13
hereof.

 

1.37         “Distributor” means, with respect to an Alliance Product, the
Party that Commercializes such Alliance Product in accordance with this
Agreement.

 

1.38         “Epidemiology” means the screening or testing of groups of people
or populations for the study of the patterns, causes, or control of disease in
groups of people.

 

1.39         “Exclusive Areas” means the products and services that are used or
distributed for use in the Alliance Field in:

	
   

  	
  (a)

  	
   

  	
  detecting,
  classifying or quantifying nucleic acid sequences of any of the following
  [***];

  
	
   

  
	
   

  	
  (b)

  	
   

  	
  detecting,
  classifying or quantifying any human gene or genetic variation that causes 

  
	
  or is
  linked to [***];

  
	
   

  
	
   

  	
  (c)

  	
   

  	
  detecting,
  classifying or quantifying any human gene or genetic variation that causes 

  
	
  or is
  linked to [***];

  
	
   

  
	
   

  	
  (d)

  	
   

  	
  detecting,
  classifying or quantifying the combination of [***] genes and genetic
  variations 

  
	
  therein
  for predicting [***], or any modifications thereof approved by the JRB;

  
	
   

  
	
   

  	
  (e)

  	
   

  	
  detecting,
  classifying or quantifying human genes and expression products encoded 

  
	
  by such genes
  for predicting [***] as those products are defined in the JRB-approved Work
  Plans dated July 12, 2005, or any modifications thereof approved by the
  JRB;

  
	
   

  
	
   

  	
  (f)

  	
   

  	
  detecting,
  classifying or quantifying any human gene or genetic variation for 

  
	
  predicting
  [***] as that product is defined in the JRB-approved Work Plan dated
  July 12, 2005, or any modifications thereof approved by the JRB; and

  
	
   

  
	
   

  	
  (g)

  	
   

  	
  detecting,
  classifying or quantifying nucleic acid sequences of any other [***] 

  
	
  associated
  with a human medical condition expressly added to the Exclusive Areas by
  decision of the JRB pursuant to a JRB-approved Work Plan under this
  Agreement.

  

 

“Exclusive Areas” specifically
excludes [***] unless they are Alliance Products. The products and services
specified in this definition are subject to the provisions of Section 2.4.

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

6

 

1.40         “Existing Patent Rights” means Patent Rights that are reasonably necessary
for performance under this Agreement and that are owned or Controlled by a
Party as of the effective date of the Prior Alliance Agreement.

 

1.41         “Existing Products” means Abbott Existing Products and Applera
Existing Products.

 

1.42         “Existing Technology” means Technology and Materials that are reasonably
necessary for performance under this Agreement and that are owned or Controlled
by a Party as of the effective date of the Prior Alliance Agreement.

 

1.43         “Exploit” means: (a) with respect to a Patent Right,
making, having made, using, selling, offering for sale or importing an invention
claimed in such Patent Right or granting license rights under such Patent
Right; (b) with respect to Technology, using or transferring the
Technology or part thereof in conjunction with the making, having made, using,
selling, offering for sale and importing of a product or method or granting
license rights under such Technology; and (c) with respect to Copyrighted
Works, copying, performing or distributing the Copyrighted Work or granting
license rights under such Copyrighted Work.

 

1.44         “FDA” means the Food and Drug Administration of the
United States, or a successor thereto and any foreign equivalent.

 

1.45         “Facilitate” and cognates thereof means to sell, distribute or
promote a product or a service, or to partner with a Third Party to sell, distribute
or promote a product or service, where such product or service is promoted as a
Competing Product or distributed with knowledge of its use as a Competing
Product. In the case of Instruments, “facilitating” is distributing or loading
Instruments with software, or distributing, promoting or actively assisting in
the development of software for the Instrument, that is specific to a Competing
Product (i.e., software specific to a diagnostic application).

 

1.46         “General Purpose
Instrument” means a device which,
if introduced into the United States, is not or would not be subject to
pre-market notification or approval under then-applicable FDA regulations.

 

1.47         “General Purpose Reagent” or “GPR” means
chemical or biological reagents that (a) are not Analyte Specific Reagents
and (b) have general laboratory application.

 

1.48         “In Vitro Diagnostics
Field” means the products related
to and services associated with in vitro measuring, observing and/or
determining attributes, characteristics, diseases, traits or other conditions
of a human being for medical management.

 

1.49         “Incremental Net Sales” means:

 

	
   

  	
  (a)

  	
   

  	
  With
  respect to an Alliance Product Commercialized after rejection of the NPCD 

  
	
  as
  described in Section 4.4 (a) (“New Alliance Product”), Incremental Net Sales means:

  

 

[***]
indicates material that has been omitted pursuant to a request for confidential
treatment. The omitted material has been filed separately with the Securities
and Exchange Commission.

 

7

 

(i)    where the New Alliance Product, if sold
outside the Alliance Program, would have been a Competing Product, all sales of
such New Alliance Product less any Cannibalized Sales of Alliance Products
which were being sold at the time such New Alliance Product was first sold. “Cannibalized Sales” for purposes of this Section 1.49(a)(i) means
sales resulting solely from the switch by an existing customer from an existing
Alliance Product to the New Alliance Product where both such Alliance Products
have the same Clinical Intent, but does not include any increased sales
resulting from price or volume increases attributable to the switch by an
existing customer to the New Alliance Product; or

 

(ii)   where the New Alliance Product, if sold
outside the Alliance Program, would not have been a Competing Product, all
sales of such New Alliance Product.

 

	
   

  	
  (b)

  	
   

  	
  With respect to an OEM
  Instrument or Alliance Instrument that is Commercialized after 

  
	
  rejection as described in
  Section 8.7 (“New
  Alliance Instrument”), Incremental
  Net Sales means:

  

 

(i)    where the New Alliance Instrument, if sold
outside the Alliance Program, would have been a Competing Product, all sales of
such New Alliance Instruments, all service revenue associated with such New
Alliance Instruments, and all sales of other Alliance Products which are for
use on such New Alliance Instruments, less any Cannibalized Sales of other
Alliance Products which were being sold at the time such New Alliance
Instruments were first sold. “Cannibalized Sales”
for purposes of this Section 1.49(b)(i) means sales resulting solely
from the switch by an existing customer from an existing OEM Instrument or
Alliance Instrument to the New Alliance Instrument, but does not include any
increased sales resulting from price or volume increases attributable to the
switch by an existing customer to the New Alliance Instrument; or

 

(ii)   where the New Alliance Instrument, if sold
outside the Alliance Program, would not have been a Competing Product, all
sales of such New Alliance Instruments, all service revenue associated with
such New Alliance Instruments, and all sales of other Alliance Products which
are for use on such New Alliance Instruments.

 

1.50         “Independent Patent
Rights” means Existing Patent
Rights and Post-Signature Patent Rights.

 

1.51         “Independent Technology” means Existing Technology and Post-Signature
Technology.

 

1.52         [***].

 

1.53         “Initial Activities” means NPCDs and Work Plans for Alliance Products
that the Parties have proposed to be the focus of the first three (3) Contract
Years, including the budget for each of the first three (3) Contract
Years.

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

8

 

1.54         “Instrument” means any hardware, software, device, platform or
any combination or component thereof, including any uniquely associated
accessories and consumables, which is related to the automation of in vitro
amplification, detection, quantification, or sequencing of a nucleic acid in or
from a human biological sample for the purpose of: (i) diagnosing,
detecting or monitoring any disease, state, condition, trait or characteristic
of a human being for medical management; (ii) exercising quality assurance
and quality control testing of human blood or plasma from which biological
therapeutic agents may be derived for resale; (iii) [***]; or (iv) screening
human organs, tissues or cells for transplantation. The term “Instrument” excludes (a) Reagents and kits containing
Reagents, (b) instruments for the preparation of human biological samples
containing nucleic acids, (c) instruments which are the subject of supply
arrangements existing as of the Effective Date between a Party and a Third
Party, including modifications, amendments or extensions to such arrangements,
provided such arrangements are not inconsistent with such Party’s obligations
under this Agreement, and (d) instruments which are manufactured by Abbott
as of the Effective Date and in any subsequent modified form, provided such
instruments are not Competing Products.

 

1.55         “Joint Alliance Patent
Rights” means Alliance Patent
Rights that claim inventions jointly conceived by employees or agents of both
Parties.

 

1.56         “Joint Alliance
Technology” means Technology and
Materials that are Derived jointly by or for both Parties during performance of
the Alliance Program and the Derivation of which is jointly funded by the
Parties pursuant to this Agreement or the Prior Alliance Agreement.

 

1.57         “Licensing Revenue” means the aggregate cash or other consideration
received by a Party in consideration for a license under Alliance Technology or
Alliance Patent Rights (including, without limitation, royalties received by
such Party based on sales by a Third Party of products or services
incorporating Alliance Technology or covered by Alliance Patent Rights.) In the
event consideration for license rights under Alliance Technology or Alliance
Patent Rights is not monetary, the Parties will agree upon the monetary value
of such consideration or a means for sharing the non-monetary consideration.

 

1.58         “Major Market Country” means the United States, the member countries of
the European Patent Convention, Japan and Canada.

 

1.59         “Materials” means, individually and collectively, Reagents,
formulations, nucleic acids including DNA, RNA and PNA, plasmids,
microbiological cultures or strains, cell lines, peptides, compounds,
compositions, and combinations or components thereof.

 

1.60         “Net Investment” means, with respect to the Alliance Program, the
following net assets of a Party: (a) inventory; (b) receivables
(including any receivables from the other Party in accordance with this
Agreement); (c) equipment placed as part of a Reagent Rental Program net
of depreciation; and (d) cumulative amounts paid to the other Party
pursuant to Section 9.3(c); less (e) cumulative amounts received from
the other Party pursuant to Section 9.3(c) and payables (including
amounts payable by one Party to another in accordance with this 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

9

 

Agreement)
and other liabilities, if any. Net Investment will not include any amounts
payable by one Party to another pursuant to Section 9.3.

 

1.61         “Net Sales” means:

 

	
   

  	
  (a)

  	
   

  	
  the gross invoiced price of
  an Alliance Product or Alliance Products sold by a Party to a Third 

  
	
  Party, less the following,
  to the extent charged as part of the invoiced price, separately stated on the
  invoice and paid by or credited to, as the case may be, the Third Party:

  

 

(i)    credits, allowances, discounts and rebates
to, and charge backs from the account of, Third Parties for spoiled, damaged,
out-dated, rejected or returned Alliance Products;

 

(ii)   actual freight, postage, transportation and
insurance costs incurred in delivering Alliance Products;

 

(iii)  reasonable and customary cash, quantity and
trade discounts actually given to Third Parties;

 

(iv)  sales, use, value-added and other direct taxes
to the extent billed to and paid by the Third Party; and

 

(v)   customs duties, surcharges and other
governmental charges incurred in connection with the exportation or importation
of Alliance Products.

 

	
   

  	
  (b)

  	
   

  	
  With respect to
  Combination Products, the gross invoiced price of such 

  
	
  Combination Products billed
  to Third Parties by a Party, less: the allowances and adjustments referred to
  in Sections 1.61(a)(i)-(v), multiplied by the fraction A/A+B, where A is the
  gross selling price of the Alliance Product sold separately during the
  royalty period in question, and B is the gross selling price of the other
  diagnostic product(s) in the Combination Product having significant,
  independent utilities sold separately during the royalty period in question
  and that are not covered by Valid Claims of the non-selling Party’s Patent
  Rights or employing the non-selling Party’s Confidential Information. If
  there is no established current gross selling price for the Alliance Product
  A or for the other diagnostic product(s) B, then for the purposes of
  calculating Net Sales, the Parties agree to discuss in good faith the
  relative values of Alliance Product A and the other diagnostic
  product(s) B so as to arrive at a fair gross invoiced price for
  Combination Products upon which to base the Net Sales thereof. For purposes
  of this Agreement, “Combination
  Product” means an Alliance
  Product that is sold together in combination with one (1) or more
  diagnostic products having significant independent diagnostic utility and not
  covered by a Valid Claim of the non-selling Party’s Patent Rights or
  employing the non-selling Party’s Confidential Information.

  

 

	
   

  	
  (c)

  	
   

  	
  With respect to an
  Alliance Product for which the gross invoiced price includes an 

  
	
  amount to compensate a
  Party for the amortized cost of instrumentation, services, and/or other
  equipment supplied without charge to a customer under a RAP or other
  successor or similar plan (collectively a “RAP Product”),
  the Net Sales of such RAP Product will

  

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

10

 

first be
calculated in accordance with the definition of Net Sales under paragraph (a) of
this Section 1.61 and then will be reduced by the amount of the price
increase reasonably and demonstrably attributable solely to the amortized cost
of the instrumentation, equipment and service which is provided to customers
free of charge, in accordance with the United States Generally Accepted
Accounting Practices (“GAAP”) of such
Party consistently applied.

 

	
   

  	
  (d)

  	
   

  	
  Net Sales will not include
  Alliance Products used in clinical trials, for research or 

  
	
  other non-commercial uses,
  or supplied as commercial samples or as charitable or humanitarian donations,
  so long as a Party receives no compensation in any form for such
  use/donation.

  
	
   

  
	
   

  	
  (e)

  	
   

  	
  Net Sales for services
  will be the gross revenue received therefor.

  
	
   

  
	
   

  	
  (f)

  	
   

  	
  Net Sales for products
  other than Alliance Products will be calculated in the same 

  
	
  manner set forth in this
  Section 1.61 to the extent applicable.

  

 

1.62         “New Product Concept
Document” or “NPCD” means

 

	
   

  	
  (a)

  	
   

  	
  in the case of an “NPCD — Development”, a written description of a concept of interest 

  
	
  to a Party for Development
  of a product or service in the Alliance Field that describes the proposed
  Alliance Product including the following information: (i) test or
  service type; (ii) intended diagnostic use or expected medical
  indications or disease state for such use; (iii) target customers;
  (iv) sampling requirements; (v) testing frequency;
  (vi) expected product or service pricing; (vii) peak unit sales and
  revenues; (viii) description of freedom to operate issues or special
  technologies necessary to develop the product, service or technology;
  (ix) competitive landscape issues, including market research;
  (x) each Party’s Independent Technology and Independent Patent Rights
  expected to be applicable to the proposed product or service and its
  manufacture or use and associated royalties and milestones owed to Third
  Parties; (xi) the specific proposed study design, including identification of
  each goal and deliverable of the proposed study; (xii) the proposed Supplier;
  (xiii) the proposed Distributor; (xiv) synergies with other Alliance Products
  or Carveouts; and (xv) estimated pro-forma profit and loss statement. An NPCD
  — Development will generally be in the form attached hereto as
  Exhibit 1.62(a); and

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  (b)

  	
   

  	
  in the case of an “NPCD — Feasibility”, a written description of a concept of interest 

  
	
  to a Party for
  establishing feasibility of a product or service in the Alliance Field that
  describes the proposed Alliance Product including the following information:
  (i) test or service type; (ii) intended diagnostic use or expected
  medical indications or disease state for such use; (iii) testing
  frequency; (iv) description of freedom to operate issues or special
  technologies necessary to develop the product, service or technology; and
  (v) the details of a feasibility study including expected outcomes or
  feasibility objectives. An NPCD — Feasibility will generally be in the form
  attached hereto as Exhibit 1.62(b) and will be limited to a maximum
  of twelve (12) months of feasibility studies, unless extended by mutual
  agreement of the Parties.

  

 

(collectively, NPCD — Development and NPCD — Feasibility will be
referred to in this Agreement as “NPCD”).

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

11

 

1.63         “Non-Alliance Product” means:

 

	
   

  	
  (a)

  	
   

  	
  any [***], the research or
  Development of which involves a collaboration between a 

  
	
  Party and a Third Party
  [***]; and

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  (b)

  	
   

  	
  products and services in
  the Alliance Field which, except as provided in Section 4.5, are not 

  
	
  Competing Products and
  which (i) have been rejected as an NPCD, or (ii) are in the
  Optional Areas and were never submitted to the JRB, and (iii) the
  research, Development or Commercialization of which is conducted by a Party
  outside the Alliance Program in accordance with Article IV.

  

 

1.64         “Optional Areas” means any product or service in the Alliance Field
that is in neither the Exclusive Areas nor the Conditionally Exclusive Areas.

 

1.65         “Partnership Tax Return” means any return or report of Taxes due, any
claims for refund of Taxes, any information return with respect to Taxes, or
any other similar report, declaration or document, including any amendments
related thereto, and supporting information.

 

1.66         “Party” means Abbott or Applera and its respective
Affiliates, and “Parties” means Abbott and Applera and their respective
Affiliates.

 

1.67         “Passive Investor” means any person or entity that holds securities
other than for the purpose of changing or influencing the control or management
of the issuer of the securities, and any person or entity that files a Schedule
13 G with the Securities and Exchange Commission (or any successor form
thereto) with respect to any securities will be deemed a Passive Investor in
those securities.

 

1.68         “Patent Rights” means rights conferred by: (a) patent
applications filed in any country; (b) all patents including supplemental
protection certificates that have issued or in the future issue from any of the
foregoing, including, without limitation, utility models, design patents and
certificates of invention; and (c) all divisionals, continuations,
continuations-in-part, reissues, re-examination certificates, renewals, extensions
or additions to any such patents and patent applications.

 

1.69         “Permitted Affiliate” means a Party’s Restructuring Successor and any
entity that is Totally Controlled by a Party or its Restructuring Successor.

 

1.70         [***].

 

1.71         “Post-Signature Patent
Rights” means Patent Rights that
are reasonably necessary for performance under this Agreement and that a Party
acquires ownership or Control of at any time during the term of this Agreement
and the Prior Alliance Agreement as a result of activities by the Party outside
the Alliance Program.

 

1.72         “Post-Signature
Technology” means Technology and
Materials that are reasonably necessary for performance under this Agreement
and that a Party acquires ownership or Control of at any time during the term of
this Agreement and the Prior Alliance Agreement as a result of activities by
the Party thereof outside the Alliance Program.

 

[***] indicates material that has been omitted
pursuant to a request for confidential treatment. The omitted material has been
filed separately with the Securities and Exchange Commission.

 

12

 

1.73         “Post-Termination
Acquired Product” means any product
or service in the Alliance Field that is first acquired by a Party from a Third
Party after the Termination Date and any product or service under development
by a Third Party which product or service is first acquired by a Party after
the Termination Date through the purchase of controlling securities of the
Third Party or through a purchase of assets from the Third Party.

 

1.74         “Post-Termination
Competing Product” means any
product or service in the Alliance Field that is first Commercialized by a
Party after the Termination Date and is a Competing Product, excluding all
Post-Termination Acquired Products.

 

1.75         “Prior Alliance Agreement” means the Strategic Alliance Agreement between the
Parties dated June 24, 2002, and Amendments Nos. 1, 2, 2a and 3 to the
Strategic Alliance Agreement dated December 20, 2002, January 22,
2003, January 28, 2005, and March 31, 2004, respectively.

 

1.76         “QSR Standard” means the regulations set forth in 21 CFR Chapter
1, Part 820, et seq., as such regulations may be amended or replaced from
time to time, and any foreign law, statute or regulation relating to current
good manufacturing practices.

 

1.77         “R&D Plan” means a written description which sets forth the
plan for research and Development of products and services within the Exclusive
Areas pursuant to JRB-approved NPCDs and Work Plans. In connection with each
R&D Plan, the Parties will agree upon a budget (the “R&D Plan Budget”) in accordance with Section 4.7(a).

 

1.78         “Reagent Rental Program” or “RAP” means a
program for the Commercialization of one or more Alliance Products in
conjunction with an Instrument whereby the price for the Alliance Products
includes the acquisition cost or leasing cost of the Instrument, the cost of
servicing the Instrument and/or other items of cost recovery in connection with
supply and support of the Instrument.

 

1.79         “Reagents” means oligonucleotides, including primers and
probes, Analyte Specific Reagents, General Purpose Reagents, enzymes, proteins,
controls, substrates, co-factors, buffers or any combination thereof.

 

1.80         “Regulatory Approval” means the technical, medical and scientific
licenses, registrations, authorizations and approvals required for marketing or
use of a product (including, without limitation, approvals of Pre-Market
Approval Applications, Investigational Device Exemptions, Biologic License
Applications, Investigational New Drug Applications, 510k notices, pre- and
post- approvals, pricing and third party reimbursement approvals, and labeling
approvals and any supplements and amendments to any of such approvals) of any
national, supra-national, regional, state or local regulatory agency,
department, bureau, commission, council or other governmental entity, necessary
for the Development, manufacture, distribution, marketing, promotion, offer for
sale, use, import, export or sale of Alliance Products in a regulatory
jurisdiction.

 

1.81         “Regulatory Authority” means the FDA and/or any national, supra-national
(e.g., the European Commission, the Council of the European Union, or the
European Agency for the Evaluation of Medicinal Products), regional, state or
local regulatory agency, 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

13

 

department,
bureau, commission, council or other governmental entity in each country or
supra-national territory of the world having jurisdiction over granting a
Regulatory Approval for an Alliance Product.

 

1.82         “Regulatory Filings” means a Pre-Market Approval Application, 510(k) notice,
Biologic License Application, Investigational Device Exemption, and/or any
other comparable filings as may be required by Regulatory Authorities to obtain
Regulatory Approvals for a product in the Alliance Field.

 

1.83         “Restructuring Successor” means any entity formed by or on behalf of a Party
for purposes of reincorporation in a new jurisdiction, formation of a new
parent holding company, or otherwise, provided that the ownership of the new
entity immediately after any such event is substantially the same as the
ownership of the Party immediately prior to such event.

 

1.84         “Revenue(s)” means, with respect to each Alliance Product, the
sum of the following, determined in accordance with Alliance Accounting
Policies and GAAP, consistently applied: (a) Licensing Revenue; (b) Services
Revenue; (c) Sales Revenue; and (d) any proceeds from the sale of
capital assets included in Net Investments.

 

1.85         “Sales Revenue” means, with respect to the sale or other
disposition of any Alliance Product in an arms-length transaction, the gross
sales price, including all taxes, duties, freight, insurance and other charges
actually billed by or for a Party to Third Parties or the other Party, less the
reasonable and customary deductions from such gross amounts to the extent
actually paid by or charged to the account of the Party, including, without
limitation:

 

(a)        reasonable
and customary credits, allowances, discounts and rebates to, and chargebacks
from customers for spoiled, damaged, out-dated and returned Alliance Product;

 

(b)        reasonable
and customary cash, quantity and trade discounts, rebates and other price
reductions for such Alliance Product given to such customers; and

 

(c)        sales,
use, value-added and other direct taxes (but not income taxes of any kind)
imposed upon the sale of such Alliance Product to such customers.

 

Sales Revenue will include, without any
deductions, any amounts actually invoiced by a Party as reimbursement for costs
associated with authorized distribution of Alliance Products prior to
Regulatory Approval. Sales Revenue will not include any product furnished to
Third Parties for which no payment is receivable, such as, experimental, test
market, promotional or other free goods. On the other hand, Sales Revenue will
include any product sold, whether or not such product is for commercial,
research or other use.

 

Sale or transfer of an Alliance Product by or
for a Party to an Affiliate of that Party for re-sale by such Affiliate will
not be considered a sale for the purpose of this provision, but the resale by
such Affiliate to a Third Party or to the other Party will be a sale for such
purposes. Sale or transfer of an Alliance Product by or for a Party to an
Affiliate of that Party for end-use by such Affiliate will be considered a sale
for the purposes of this provision. The Sales 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

14

 

Revenue for any such transfer
between a Party and its Affiliate or between Affiliates of the same Party will
be handled in accordance with the following procedure:

 

(x)            if
the Supplier of an Alliance Product also uses the same Alliance Product for
clinical studies of a therapeutic product run by (i) the Supplier or its
Affiliates, or (ii) in the case of Applera only, a pharmaceutical company
which Controls the therapeutic product that is the subject of a Collaboration,
then the Supplier will transfer the Alliance Product at the Supplier’s cost; and

 

(y)           if
the Supplier of an Alliance Product is different from the Party using the same
Alliance Product for clinical studies of a therapeutic product run by (i) such
other Party or its Affiliates, or (ii) in the case of Applera only, a
pharmaceutical company which Controls the therapeutic product that is the
subject of a Collaboration, then the Supplier will transfer the Alliance
Product to the other Party at the Target Minimum Sales Price.

 

1.86         “Services Revenue” means, with respect to training, service and
support of consumers using an Alliance Product and with respect to services
rendered by a Party using an Alliance Product, all proceeds actually received
by a Party for the gross sales price, including all taxes, duties, insurance
and other charges actually billed by or for a Party to

 

Third Parties or the other Party, less the
deductions from such gross amounts to the extent actually paid by or charged to
the account of the Party, including, without limitation:

 

(a)        cash,
quantity and trade discounts, rebates and other price reductions for such
services given to such customers; and

 

(b)        sales,
use, value-added and other direct taxes (but not income taxes of any kind)
imposed upon the sale of such services to such customers.

 

1.87         “Supplier” means, with respect to an Alliance Product, the
Party that manufactures such Alliance Product in final form intended for
Commercialization in accordance with this Agreement.

 

1.88         “Target Minimum Sales
Price” means a minimum unit price
for an Alliance Product in each of the following geographic territories: North
America, Japan, Europe (to the extent of the member countries of the European
Union and Switzerland), and the rest of the world.

 

1.89        “Tax(es)” means any and all federal, state, local, foreign,
and other net income, gross income, gross receipts, sales, use, ad valorem,
value added, transfer, franchise, profits, license, excise, lease, severance,
stamp, occupation, premium, customs, duties or other taxes, fees, assessments
or charges of any kind whatever, together with any interest and penalties
thereto imposed by any governmental or other taxing authority.

 

1.90         “Technology” means conceptions, ideas, innovations,
discoveries, inventions, processes, machines, biological materials, formulae,
equipment, compositions of matter, improvements, enhancements, modifications,
technological developments, know-how, show-how, methods, techniques, systems,
designs, production systems and plans, software, 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

15

 

documentation,
data, programs and information (irrespective of whether in human or
machine-readable form) and works of authorship, whether or not patentable,
copyrightable, or susceptible to any other form of legal protection.

 

1.91         “Termination Date” means the date of expiration of this Agreement
pursuant to Section 17.1 or the date of termination pursuant to any other
provision of this Agreement.

 

1.92         “Third Party” means an individual, corporation or other entity
other than the Parties or their Permitted Affiliates.

 

1.93         “Total Control” and cognates thereof mean direct or indirect ownership
of one hundred percent (100%) of the voting equity (other than a nominal number
of shares that may be owned by management or directors as directed by
applicable law).

 

1.94         “Valid Claim” means a claim in any issued, active, unexpired
patent which has not been withdrawn, cancelled, lapsed or disclaimed, or held
unpatentable, invalid or generally unenforceable by a non-appealed or
nonappealable final decision by a court or other appropriate body of competent
jurisdiction.

 

1.95         “Work Plan(s)” means a written description which sets forth in
reasonably specific detail the description and specification of the product to
be developed pursuant to a JRB-approved NPCD; the plans for research,
Development, clinical, regulatory, manufacturing and Commercialization
activities, including use of any Third Party to perform material portions of
such activities; the timeline, work plan budget, and expected distribution of
responsibilities for such activities (including identification of the proposed
Supplier and Distributor of the contemplated Alliance Product); the expected
commercial return from such product or project; the estimated cost of the
proposed Alliance Product; the estimated market size; and any information that
may impact the ability of either Party to Commercialize the proposed Alliance
Product, such as the availability or cost of raw materials or Third Party
intellectual property, contract restrictions or royalty obligations. A Work
Plan will generally be in the form attached hereto as Exhibit 1.95.

 

ARTICLE
II

EXCLUSIVITY

 

2.1           Exclusivity Obligations.
Except as otherwise provided in this Agreement, during the term of this
Agreement, the Parties will work exclusively with each other in all activities
pursuant to a JRB-approved NPCD — Feasibility, Development, submissions of
Regulatory Filings, manufacturing, and Commercialization activities in the
Exclusive Areas and with respect to the Alliance Products. In accordance with
the terms of this Agreement, each Party (a) will use its experience and
will exert commercially reasonable efforts to maximize sales of and profits
from Alliance Products, (b) will share relevant information with respect
to the Exclusive Areas; provided, however, that a Party will have no
obligation, unless required by law, to share information about a product or
service in the Exclusive Areas that such Party does not intend to Commercialize
before termination or expiration of this Agreement pursuant to Section 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

16

 

17.1 or 17.6, and (c) will
not exchange information, discuss any collaboration or work with a Third Party
which is a Commercial Entity regarding products or services in the Exclusive
Areas or regarding Alliance Products unless, prior to such exchange, discussion
or activity, the Party has given notice to the other Party of termination pursuant
to Section 17.6. The prohibition of Section 2.1(c) will not
apply to [***] unless they are Alliance Products or [***] that solely perform
[***].

 

2.2           Exceptions to Exclusivity.
Notwithstanding anything to the contrary in Section 2.1 above:

 

(a)        Each
Party will have the right to continue to perform, outside the Alliance Program,
its obligations under bona fide agreements with Third Parties in effect as of
the effective date of the Prior Alliance Agreement, such obligations in the
Alliance Field being listed in Exhibit 2.2 hereto (except for routine
confidentiality agreements, material transfer agreements and other standard
agreements executed by a Party in the ordinary course of business, which
agreements have no material impact on the Parties’ ability to perform their
obligations under this Agreement). Any material amendments or any extensions to
such agreements after the Effective Date will be subject to prior written
consent of the other Party, which consent will not be unreasonably withheld or
delayed; provided, however, that neither Party will be obligated to obtain the
prior written consent of the other Party to amend or extend the agreements
listed in Exhibit 2.2(a) if such amendment or extension does not
include activity in the Exclusive Areas.

 

(b)        Each
Party, without notice to or cooperation of the other Party, and solely at its
own cost, may independently conduct research and development directed to
products or services in the Exclusive Areas; provided, however, that any such
product or service must be the subject of a NPCD-Development proposed to the
JRB pursuant to Section 4.2 before any Development, Regulatory Filings,
manufacturing or Commercialization activities. A Party may conduct any
activities subject to this Section 2.2(b) without notice to the other
Party or JRB approval of such activity after notice to the other Party of
termination of this Agreement pursuant to Section 17.6.

 

(c)        Either
Party will have the right to continue to develop, manufacture and Commercialize
General Purpose Instruments or Instruments labeled for “Research Use Only” and General Purpose Reagents outside of the
Alliance Program.

 

2.3           Outside Exclusive Areas.
Except as otherwise provided in this Article II and Article IV of
this Agreement, each Party may work alone or with any Third Party outside the
Exclusive Areas and each Party may research, develop, manufacture and/or
Commercialize any product or service outside the Exclusive Areas; provided,
however,

 

(a)        a
Proposing Party (as defined in Section 4.2) conducting research or
Development for a product or service in the Conditionally Exclusive Areas must
submit an NPCD-Development to the JRB for review pursuant to Section 4.2
before commencing any submission of Regulatory Filing, manufacturing or
Commercialization activities, except for [***] in which a Third Party [***] is
involved, in which case the Proposing Party must use reasonable efforts to have
any [***] that results from such collaboration distributed through the Alliance
Program; and

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

17

 

(b)        if
the product or service is in the Optional Areas, the Proposing Party may, but
is not required to, submit an NPCD to the JRB for review pursuant to Section 4.2.

 

(c)        If
the non-Proposing Party accepts the NPCD described in Section 2.3(a) or
2.3(b), the subject product or service becomes an Alliance Product and is added
to the Exclusive Areas pursuant to Section 1.39(g).

 

(d)        If
the non-Proposing Party rejects the NPCD described in Section 2.3(a) or
2.3(b), the Proposing Party may develop and/or Commercialize the product or
service which is the subject of the rejected NPCD as a Non-Alliance Product on
its own or with a Third Party pursuant to Section 4.4(b). The Proposing
Party will not have any obligation to share revenues from the Commercialization
of such Non-Alliance Product or any right to seek reimbursement from the
non-Proposing Party for any expenses associated with such Non-Alliance Product;
provided, however, the Proposing Party will pay royalties to the non-Proposing
Party if the Non-Alliance Product uses any Alliance Technology or Alliance
Patent Rights; and further provided, the Proposing Party and its Affiliates
will pay to the non-Proposing Party, in accordance with Section 10.14, a
royalty on Net Sales of Non-Alliance Products at a rate not greater than [***]
percent ([***]%).

 

(e)        If
a Party wishes to Commercialize an Alliance Product outside the Alliance Field,
it must obtain the prior written consent of the other Party, which consent will
not be unreasonably withheld or delayed, except such written consent will not
be required to the extent such Alliance Product is used in a bona fide clinical
study with respect to a therapeutic product.

 

2.4           [***]. Until June 30,
2007, the Parties will work exclusively with each other to consider whether
products and services in the Alliance Field for [***]. Unless otherwise agreed
by the JRB pursuant to this Section 2.4, such products and services will
be excluded from the Alliance Field as of July 1, 2007. The Parties will
work together to complete an assessment of the strategy and costs to enter the
[***] in Europe and Japan, with such assessment to be completed by April 1,
2007. The JRB will review the assessment and determine by June 30, 2007 if
the Alliance Program will fund the Development of products or services to enter
such [***] in the Alliance Field in Europe and Japan. If the JRB approves
funding for the Development of such products or services, [***] applications
would continue to be part of the Alliance Field. If the JRB does not approve
such funding, [***] applications would be excluded from the Alliance Field as
of July 1, 2007, and each Party would be free to pursue, outside the
Alliance Field, the Development and Commercialization of [***] products and
services on its own or with a Third Party.

 

2.5           QSR Claims; Commercialization of
Non-Alliance Products and Reagents for Research Use Only.

 

(a)        The
Parties must Commercialize through the Alliance Program all Alliance Products
which have been designed or manufactured under the QSR Standard through the
Alliance Program.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

18

 

(b)        Each
Party may Commercialize directly or through a distributor any product in the
Alliance Field that is outside the Exclusive Areas and Conditionally Exclusive
Areas, provided that such product is a Non-Alliance Product. In addition, each
Party may Commercialize directly or through a distributor any primers or probes
outside the Alliance Field, provided that such primers or probes (i) are
prominently labeled “For Research Use Only. Not For Use In Diagnostic
Procedures” or any comparable label subsequently required by applicable
Regulatory Authority, (ii) are not claimed by the Party that they were
manufactured under the QSR Standard, except that they may be claimed to have
been manufactured under a certified quality system with traceable
documentation, and (iii) are not Commercialized by the Party in a manner
that Facilitates use as a Competing Product. Further, each Party will use
commercially reasonable efforts to cause its distributors to label or promote
such primers and probes in accordance with the terms of this Section 2.5(b).

 

(c)        Notwithstanding
Section 2.5(b) to the contrary, if a member of the JRB of one Party
learns or is given notice by the other Party that primers or probes distributed
by or for the one Party and labeled “For Research Use Only” or any comparable
label are being used by a Third Party purchaser “off label” as a Competing
Product, the Parties will discuss an appropriate course of action for such
alleged violation of Section 2.5(b), which may include (i) discontinuance
of sales of the specific primers and probes to such Third Party purchasers or (ii) sharing
with the other Party all profits derived from the sales of the primers and
probes that were used as Competing Products. “For Research Use Only” primers
and probes sold for use for the same Clinical Intent as an Alliance Product
will not be a Competing Product except as provided in Section 1.26.

 

(d)        In
the event the Parties cannot agree that a violation of Section 2.5(b) has
occurred, or on an appropriate course of action to remedy the violation, or if
the supplying Party fails to perform its obligations which are the agreed —upon
remedies for the violation, the other Party, by invoking the binding
alternative dispute resolution (“ADR”) proceeding in accordance with Article XVIII
of this Agreement, may seek a determination as to whether the activities of the
supplying Party or its Third Party purchasers are violations of Section 2.5(b) and
an appropriate remedy for such violation, which remedy shall make, to the
extent possible, the injured Party whole.

 

(e)        Section 2.5(c) will
not apply where the primers or probes being used by Third Party purchasers as
Competing Products were first distributed to such Third Party purchasers prior
to the NPCD-Development directed to the Alliance Product being approved by the
JRB. For the avoidance of doubt, Section 2.5(e) applies only to sales
of such primers or probes to those Third Party purchasers who purchased such
primers or probes prior to the JRB approval of the applicable NPCD-Development.

 

2.6           OEM Alliance Products. For
current and replacement [***] products (“OEM Alliance Products”)
which are not within the [***], which current OEM Alliance Products are set
forth in Exhibit 2.6, Abbott will pay to Applera, in accordance with Section 10.14(b),
a royalty of (a) [***] percent ([***]%) of Net Sales of all such [***] OEM
Alliance Products during the term of this Agreement; and (b) [***] percent
([***]%) of Net Sales of all such [***] OEM Alliance Products sold during
calendar year [***] and [***] percent ([***]%) of Net Sales of all such [***]
OEM Alliance Products sold from [***] through the remaining 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

19

 

term of this Agreement. As
consideration for such royalty payments, Applera will not sell or assist others
in selling products in the Alliance Field which are Competing Products with the
OEM Alliance Products. Abbott will bear all expenses associated with
Development, manufacture, and Commercialization of OEM Alliance Products
incurred after the Effective Date and Applera will not be charged for any such
expenses. For the purposes of this Section 2.6,  “replacement product”
is any product that detects the same analyte and essentially functions in the
same manner as a current OEM Alliance Product. For the avoidance of doubt, a
non-sequencing based [***] product is not a Competing Product with any OEM
Alliance Product. Any products which are subject to the royalty payments
pursuant to this Section 2.6 will not be Alliance Products for the
purposes of this Agreement.

 

ARTICLE III

JOINT REVIEW BOARD

 

3.1           Composition. The Joint Review
Board (the “JRB”) will comprise three (3) named
representatives of Abbott and three (3) named representatives of Applera.
Each Party will designate one (1) of its JRB representatives to serve as
co-chair of the JRB. Each Party will notify the other Party in writing of its
initial representatives to the JRB within ten (10) days after the
Effective Date, and each Party may substitute one (1) or more
representatives from time to time effective upon written notice to the other
Party. The members of the JRB may establish subcommittees to oversee particular
projects or activities from time to time, and such subcommittees will be
constituted as the JRB agrees.

 

3.2           Responsibilities. The JRB will
be responsible for:

 

(a)        reviewing
NPCDs proposed by either Party for inclusion in the Alliance Program and
determining whether such NPCDs and will become Alliance Products;

 

(b)        developing
and implementing the Initial Activities and all subsequent Work Plans and,
subject to Section 7.1, allocating responsibility for Alliance Program
activities between the Parties, taking into consideration their relevant
expertise and available resources;

 

(c)        monitoring
and reviewing the progress of the Alliance Program and the results thereof;

 

(d)        recommending
to the Parties any modifications to the Initial Activities and subsequent Work
Plans;

 

(e)        facilitating
an effective exchange of information between the Parties regarding the Alliance
Program;

 

(f)         establishing
procedures by which the Parties evaluate on an individual basis potential
professional publications which may disclose Confidential Information of the
other Party;

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

20

 

(g)        evaluating
additional technologies, assets, products or other commercial opportunities
that may be necessary or useful to the Alliance Program and recommending the
acquisition or in-licensing of these opportunities to the Parties;

 

(h)        approving
Alliance Accounting Policies and any subsequent changes thereto, budgets,
allowed budget deviations and levels of expenditure by the Parties in the
Alliance Program;

 

(i)         approving
termination of Alliance Products and NPCDs pursuant to Section 17.2;

 

(j)         approving
the disposition of an Alliance Product(s) to a Third Party, subject to
agreement by the Parties as to allocation of compensation for their respective
investment in such Alliance Product pursuant to Section 4.13;

 

(k)        approving
Party proposals regarding Development, acquisition or distribution of
Instruments pursuant to Article VIII;

 

(l)         managing
preparation by the Parties of and approving the quarterly statements of Revenues
and Allowable Expenses and of Net Investment, as set forth in Sections 9.1 and
9.2, respectively;

 

(m)       managing
preparation by the Parties of and approving quarterly and annual combined
statements of Revenues, Allowable Expenses and Net Investment of the Alliance
Program;

 

(n)        overseeing
the Commercialization activities of the Alliance Program;

 

(o)        determining
a Target Minimum Sales Price and recommending the average selling price for
each Alliance Product in each geographic area specified in Section 1.88;

 

(p)        managing
preparation by the Parties of and annually approving a rolling three-year
business plan that addresses each of the JRB responsibilities as set forth in
this Section 3.2;

 

(q)        consistent
with and subject to Articles XI, XII and XIII of this Agreement, overseeing
intellectual property used, created by or impacting the Alliance Program,
including, without limitation: (i) assigning responsibility for the
preparation, filing, prosecution and maintenance of Joint Alliance Patent
Rights; (ii) reviewing all invention disclosures arising under or relating
to the Alliance Program for the purposes of making patent application filing
recommendations to the Parties and for determining proper inventorship and
ownership of such inventions; (iii) establishing policies for the filing
of foreign patent applications arising from the Alliance Program; (iv) creating
and approving, as necessary, a budget for management of intellectual property
issues; (v) determining which Alliance Products should be marked with which
Patent Right numbers; and (vi) addressing any other intellectual property
issues referred to the JRB pursuant to the terms of this Agreement; and

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

21

 

(r)         reviewing
the [***] markets assessment set forth in Section 2.4 and determining by June 30,
2007 whether the Alliance Program will fund the Development of products or
services to enter such markets in the Alliance Field in Europe and Japan.

 

3.3           Meetings. Unless otherwise
mutually agreed to by the co-chairs, the JRB will meet at least once following
each calendar quarter during the term of this Agreement, on dates at least
forty-five (45) days after the end of each calendar quarter and at such times
as agreed to by the co-chairs of the JRB, alternating between Des Plaines,
Illinois, and Alameda, California, or such other locations as the Parties
mutually agree. Upon the mutual agreement of the co-chairs, any such meeting
may be conducted by telephone or videoconference. At such meetings, the JRB
will discuss the activities conducted under the Alliance Program and the
results thereof and any matters referred to it within the scope of its
responsibilities as set forth in Section 3.2. Each Party may permit such
visitors to meetings of the JRB as the Parties mutually agree. Each Party will
be responsible for its own costs in connection with the meetings of the JRB.

 

3.4           Decisions. The JRB will be
deemed to have made a decision only following written agreement of the
co-chairs. Any dispute or deadlock within the JRB will be finally resolved in
the manner specified in Article XVIII. To the extent reasonably necessary
to any decision, the JRB may retain appropriate expert assistance, the costs of
which will be shared equally by the Parties.

 

3.5           Minutes. Within ten (10) business
days following each JRB meeting, a representative to the JRB of the Party
hosting such meeting (who was present at such meeting) will prepare and provide
to each Party a copy of the minutes of such meeting which will summarize the
decisions of the JRB. Such minutes will be final and enforceable under this
Agreement only after being adopted by the written acceptance by the JRB
co-chairs.

 

3.6           In-License Decisions.

 

(a)        In
the event performance pursuant to the Alliance Program may require rights to
intellectual property, Materials and/or Technology from a Third Party, and the
JRB decides to pursue such rights, the JRB will decide what rights are
reasonably necessary and which Party will negotiate for such rights. The JRB
also will decide on allocation between the Parties of the costs associated with
obtaining and maintaining such rights. Such rights so obtained will be
considered Joint Alliance Technology or Joint Alliance Patent Rights, as
appropriate.

 

(b)        In
the event the JRB cannot agree whether the Parties should negotiate for or
obtain such rights, then either Party may, upon written notice to the other
Party, independently pursue such rights at its sole expense and such rights
will be Independent Patent Rights and Independent Technology, as the case may
be, of the acquiring Party. If, as a result, the acquiring Party is required to
pay monetary consideration to the Third Party for the sale or use of an
Alliance Product, the acquiring Party may seek to have such monetary
consideration included as Allowable Expenses. If the other Party disputes the
necessity of the license for the Alliance Product or the reasonableness of any
part of the monetary consideration, the acquiring Party may submit the issues
to ADR under Article XVIII of this Agreement. Whatever monetary 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

22

 

consideration
is determined by the ADR to be reasonable and necessary to permit sale or use
of the Alliance Product, up to the total payable by the acquiring Party to the
Third Party for sale or use of the Alliance Product, will be Allowable
Expenses. The acquiring Party will be solely responsible for any difference
between the monetary consideration determined by ADR and the monetary
consideration the acquiring Party agreed to pay the Third Party. In the event
the other Party does not pay any monetary consideration to the acquiring Party
during the Alliance Program for the license under this Section 3.6(b),
then the other Party will not have any rights under such license after
termination of this Agreement.

 

(c)        In
the event a Party acquires or has the opportunity to acquire from a Third Party
tissue or blood samples or other biological material that may be useful in
performance of the Alliance Program, and such material is available in excess
of material needed by the Party for Non-Alliance Products or products outside
of the Alliance Field, the Party may offer such Material to the JRB. Any such
offer must include a description of the material, a summary of its potential
usefulness to the Alliance Program, the monetary costs associated with
acquiring and using the offered material and a description of any contractual
restrictions on or obligations associated with using the offered material in
the Alliance Program. The JRB will decide to accept or reject the offer within
sixty (60) days after the required information is submitted to the JRB. If the
JRB accepts the offer, the monetary costs associated with acquiring and using
the offered material will be Allowable Expenses. If the JRB rejects the offer,
subject to the terms and conditions of this Agreement, the Party making the
offer may use the material for its own benefit and at its own cost.

 

ARTICLE
IV

ALLIANCE PROGRAM

 

4.1           Initial Program Efforts. At
its first meeting after the Effective Date, the JRB will terminate all pending
NPCDs outside the Exclusive Areas. Thereafter, each Party may bring NPCDs in
any area within the Alliance Field to the other Party as set forth below. The
NPCDs which were approved by the JRB as indicated in the minutes of the JRB for
its meeting of September 1, 2005, as listed on Exhibit 4.1, will
continue according to their existing Work Plans.

 

4.2           New Product Concept Documents:
Feasibility and Development. During the term of this Agreement, each Party is
entitled to propose NPCDs (the “Proposing Party”)
to the JRB that will be subject to the following procedures:

 

(a)        Feasibility.
The Proposing Party, at any time, may submit an NPCD — Feasibility to each
member of the JRB. If rejected or not acted on by the non-Proposing Party
within sixty (60) days after receipt, the Proposing Party may pursue the
proposed product or service pursuant to Section 4.4. If accepted by the
non-Proposing Party, the Proposing Party may explore the feasibility of such
proposed product or service for a period of up to twelve (12) months, with
joint funding from the other Party for such evaluation in the NPCD —
Feasibility. The outcome of such feasibility evaluation will result in one of
the following activities: (i) the Proposing Party submits an NPCD —
Development pursuant to Section 4.2(b) or (ii) the Parties
mutually agree not to further pursue the proposed product or service; provided,
however, the 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

23

 

Proposing
Party must submit an NPCD — Development if the feasibility evaluation has been
completed under an NPCD — Feasibility with joint funding and the Proposing
Party intends to develop the subject product or service in the Alliance Field.

 

(b)        Development.
The Proposing Party, either after completion of the feasibility study described
in an NPCD — Feasibility or without first submitting an NPCD — Feasibility, may
submit an NPCD — Development to the JRB. The Proposing Party will submit to
each member of the JRB an NPCD — Development and Work Plan for a proposed
product or service. Within sixty (60) days after receipt of the NPCD —
Development and Work Plan, the non-Proposing Party will make its final decision
whether to designate the proposed product or service as an Alliance Product,
and shall so notify the JRB in writing, whereupon the JRB immediately will
determine that such proposed product or service has become an Alliance Product.

 

(c)        After
the JRB has determined that a proposed product or service has become an
Alliance Product and added such Alliance Product to the R&D Plan, such
Alliance Product will be added to the Exclusive Areas unless or until the
project is terminated by the JRB pursuant to Section 17.2.

 

(d)        The
date on which the non-Proposing Party approves an NPCD in accordance with Section 4.2(a) or
4.2(b) will set the start date for calculating expenses incurred by the
Proposing Party, for the purpose of calculating the [***] share of Development
Costs, including costs of a feasibility evaluation pursuant to the accepted
NPCD-Feasibility where applicable, to be reimbursed to the Proposing Party. Any
expenses incurred by the Proposing Party prior to approval by the non-Proposing
Party of an NPCD in accordance with Section 4.2(a) or 4.2(b) will
not be shared by the Parties, and will be borne solely by the Proposing Party.

 

(e)        The
non-Proposing Party may reject an NPCD for any reason. Once a non-Proposing
Party declines to include a proposed product or service as part of the Alliance
Program, that Party cannot later include such proposed product or service in
the Alliance Program. The non-Proposing Party which rejected the NPCD may not
develop or Commercialize in the Exclusive Areas or Conditionally Exclusive Areas
the product or service which was the subject of the rejected NPCD unless such
rejecting Party submits its own NPCD to the JRB and such NPCD is accepted by
the other Party. However, if the rejected NPCD is directed to a product or
service in the Optional Areas, both the non-Proposing Party and the Proposing
Party may independently develop and Commercialize such product or service as
Non-Alliance Products in the Optional Areas.

 

(f)         If,
after rejection of any NPCD — Development, the Proposing Party fails to
diligently pursue Development of the Non-Alliance Product specified in the
rejected NPCD — Development within one (1) year after its rejection, then
such NPCD — Development will no longer be considered a rejected NPCD, and,
except for products or services in the Optional Areas, either Party must
resubmit the NPCD to the JRB for reconsideration before any rights pursuant to Section 4.4
may be available to the Parties.

 

4.3           Acquisition of Products or
Companies in the Alliance Field. If, during the term of this Agreement, a
Party acquires or plans to acquire from a Third Party, directly or as 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

24

 

part of an acquisition of a
Third Party, a product or service (“Acquired Product”)
that is in the Exclusive Areas or is a Competing Product, the Party must either
divest itself of such Acquired Product or reach agreement with the other Party
on terms by which the Acquired Product would become an Alliance Product. If the
Acquired Product is in the Conditionally Exclusive Areas, the acquiring Party
must offer to make the Acquired Product an Alliance Product under terms and
conditions to be negotiated with the other Party. In all events, whether the
Acquired Product is in the Exclusive Areas or Conditionally Exclusive Areas or
is a Competing Product, the acquiring Party will propose reasonable terms and
conditions to the non-acquiring Party that do not place the non-acquiring Party
in a less advantageous position as a result of the proposed acquisition of the
Acquired Product. If the Parties do not agree on such terms and conditions, the
matter will be resolved by binding ADR in accordance with Article XVIII.
If the Acquired Product is in the Optional Areas, then the acquiring Party may,
but is not obligated to, negotiate with the other Party to make the Acquired
Product an Alliance Product. If the Acquired Product is a General Purpose
Instrument or an Instrument labeled “For Research Only”, this Section 4.3
will not apply. If the Acquired Product is an Instrument registered with an
applicable Regulatory Authority, the provisions of Section 8.8(b) will
apply with respect to Instruments registered for use in the Exclusive Areas and
the Conditionally Exclusive Areas.

 

4.4           Rejected NPCD.

 

(a)        In
the event the non-Proposing Party rejects an NPCD in the Exclusive Areas, or
the JRB fails to make a decision regarding an NPCD in the Exclusive Areas
within the applicable time frame set forth in Section 4.2, then the
Proposing Party either may (i) proceed at its own cost with the research
and Development of the product or service specified in such rejected NPCD, so
long as it is not a Competing Product, or (ii) abandon the product or
service proposed in such NPCD. If the Proposing Party proceeds with the
research and/or Development of such product or service and it is
Commercialized, such product or service will become an Alliance Product as of
the date of first Commercialization. The rejecting Party will pay to the
Proposing Party, pursuant to Section 10.14(b)(vii) and (viii), [***]
percent ([***]%) of Incremental Net Sales of such Alliance Product until the
Proposing Party has recovered [***] percent ([***]%) of the Proposing Party’s
Development Costs for such Alliance Product, including any feasibility costs
where an NPCD-Feasibility was rejected by the other Party. The date on which
the NPCD is rejected by the other Party will set the start date for calculating
the [***] percent ([***]%) share of the Development Costs to be reimbursed to
the Proposing Party pursuant to this Section 4.4(a).

 

(b)        In
the event the non-Proposing Party rejects an NPCD in the Conditionally
Exclusive Areas or the Optional Areas, or the JRB fails to make a decision
regarding an NPCD in the Conditionally Exclusive Areas or the Optional Areas
within the applicable time frame set forth in Section 4.2, then, subject
to Section 4.5, the Proposing Party may proceed with the research,
Development, submission of Regulatory Filing, manufacturing and/or
Commercialization activities with respect to any product or service specified
in such NPCD as a Non-Alliance Product.

 

(c)        For
the avoidance of doubt, a Party may conduct research, Development, submission
of Regulatory Filing, manufacturing and/or Commercialization activities with
respect to products and services in the Optional Areas, except where such
product 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

25

 

or
service is a Competing Product, without first submitting to the JRB or
obtaining a rejection of an NPCD.

 

(d)        In
the event that the other Party rejects an NPCD-Feasibility in the Optional
Areas or the Conditionally Exclusive Areas and subsequently accepts an NPCD —
Development for the same product or service, the non-Proposing Party will pay
to the Proposing Party [***] percent ([***]%) of Incremental Net Sales of such
product or service in the same manner as set forth in Section 4.4(a) until
the Proposing Party has recovered [***] percent ([***]%) of its costs of the
applicable feasibility studies.

 

4.5           Non-Alliance Product.

 

(a)        The
rejecting Party will not take any action intended to prevent or frustrate the
Proposing Party’s ability to Commercialize a Non-Alliance Product. If a Non-Alliance
Product requires use of Alliance Products for which the other Party is the
Supplier, the other Party will continue to manufacture such Alliance Products
for the Proposing Party under terms and conditions similar to those applicable
to the sale of such Alliance Products to other customers, including providing
service and support as required by Section 7.5. The other Party will not
make a modification of its then-current Instruments or then-current Reagents
which has or is likely to have the effect of rendering incompatible the
Non-Alliance Product.

 

(b)        If,
pursuant to Section 4.2, a Party rejects an NPCD and the Proposing Party
wishes to Commercialize in the Conditionally Exclusive Areas such Non-Alliance
Product for a different or additional Clinical Intent than was specifically
identified in the rejected NPCD, then the Proposing Party must submit a new
NPCD, but only to the extent of the different or additional Clinical Intent.
This new NPCD will be subject to all of the terms and conditions regarding the
review process and disposition of an NPCD.

 

4.6           Work Plans. In conjunction
with its approval of an NPCD, the JRB will accept, modify or require the
Proposing Party to modify the proposed Work Plan submitted by the Proposing
Party. Once accepted by the JRB, a Work Plan may not be modified except as set
forth in writing and duly authorized by the JRB.

 

4.7           R&D Plan.

 

(a)        Within
thirty (30) days after the Effective Date, the Parties will have agreed on a
detailed R&D Plan, including the Initial Activities to be pursued pursuant
to the Alliance Program (the “Initial R&D Plan”),
as set forth in Exhibit 4.7(a)(i) attached hereto. In addition, the
Parties will have agreed on an initial budget for each of the first three (3) Contract
Years directed to Development Costs associated with the Initial R&D Plan
(the “Initial
R&D Plan Budget”), as set forth
on Exhibit 4.7(a)(ii). The Initial R&D Plan Budget will be binding on
the Parties for the first Contract Year and will [***] by the Parties, until
the JRB approves NPCDs and reallocates such Development Costs. The Initial
R&D Plan Budget for the second Contract Year will be [***] percent ([***]%)
of the Initial R&D Plan Budget for the first Contract Year, and for the
third Contract Year will be [***] percent ([***]%) of the Initial R&D Plan
Budget for the first Contract Year; these percentages will be binding on the
Parties unless otherwise modified by the JRB.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

26

 

(b)        The
Initial R&D Plan Budget will include maximum allowed spending in the
Exclusive Areas by each Party during each Contract Half Year and Contract Year
and will be allocated on an Alliance Product-by-Alliance Product basis..

 

(c)        Each
Party is responsible for any Development Costs incurred that exceeds its
maximum allowed levels during a Contract Half Year and Contract Year as set
forth in the Initial R&D Plan Budget and any subsequent R&D Plan
Budget. If a Party spends less than projected during a Contract Year, such
reduced spending will accrue to the benefit of both Parties during such
Contract Year; provided, however, if a Party spends less than projected in any
Contract Half Year during a Contract Year, its unspent funds will be carried
over to subsequent Contract Half Year within such Contract Year and will be
added to that Party’s subsequent Contract Half Year’s allowance within such
Contract Year. The Parties will exchange reports of actual Development Cost
spending under the R&D Plan in each Contract Half Year within forty-five
(45) days after the end of such Contract Half Year, and the Parties shall agree
on a binding R&D Plan Budget for the subsequent Contract Half Year. Each
Party will use its best efforts to support the R&D Plan in the Exclusive
Areas.

 

(d)        The
JRB will update the Initial R&D Plan by the first day of the second
Contract Year, for the following three Contract Years, including the Initial
R&D Plan Budgets by Contract Year and Contract Half Year. Thereafter, the
JRB shall update the R&D Plan and the R&D Plan Budget directed to
Development Costs at least annually by each subsequent January 1 during
the term of this Agreement,  for the
subsequent three (3)-Contract Years. The first Contract Year of each R&D
Plan will include fixed Development Cost limits allocated to each Party and
detailed responsibilities for each Party, and the second and third Contract
Years of each R&D Plan will contain general responsibilities and maximum
R&D Plan Budgets for such Contract Years.

 

(e)        Each
Party may request reimbursement from the Alliance Program of any Development
Costs incurred in excess of the amount allocated to that Party for a Contract
Year by written request to the JRB. Any such request must be supported by
appropriate evidence of such expenditures and the reasons therefor. The other
Party, through the JRB, in its sole discretion may reject any such request.

 

4.8           Technical Assistance. Promptly
following the designation of an Alliance Product, each Party will provide to
the other Party, pursuant to the applicable Work Plan, and in accordance with
the responsibilities of each Party, such Technology, including Confidential
Information, as reasonably necessary to conduct the Work Plan. The cost of
Materials provided by one Party to another pursuant to this Section 4.8
will be Allowable Expenses.

 

4.9           Conduct of the Alliance Program.
During the term of this Agreement, each Party will conduct its obligations
under the Alliance Program in accordance with the applicable Work Plan(s), and
will use commercially reasonable efforts to accomplish the objectives thereof.
Each Party will provide the personnel, Materials, equipment and other resources
reasonably necessary to conduct its obligations under the Work Plan(s) for
the Alliance Program. Subject to Section 2.3, each Party may employ Third
Parties as contractors, agents or sublicensees to perform its responsibilities
under a Work Plan; provided, however, if the Party proposes to disclose the
other Party’s Confidential Information to such Third Party, the Party must
first 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

27

 

obtain the other Party’s
approval in accordance with Articles X and XIV. Each Party will perform its
obligations under the Alliance Program (whether itself, or with or through a
contractor, agent or sublicensee) in accordance with high scientific and
professional standards, and in compliance in all material respects with the
requirements of applicable laws, regulations, current good laboratory practices
and the QSR Standard.

 

4.10         Records. Each Party will
maintain records, in sufficient detail and in a good scientific, professional
and business-like manner, appropriate for patent, manufacturing, quality and
Regulatory Approval purposes, which records must be complete and accurate and
must fully and properly reflect its work done, results achieved and costs and
expenses incurred in the performance of each Work Plan. Non-financial records
related to the performance of a Party’s obligations, and financial records
related to Revenues received and Allowable Expenses incurred within the
Alliance Program through the most recently completed calendar quarter, will be
made available to the other Party within forty-five (45) days of any reasonable
written request by such other Party. Each Party will maintain such records and
the information of the other Party contained therein in confidence in
accordance with Article XIV.

 

4.11         Reports. Each Party will keep
the other Party informed of the progress of its activities under each Work
Plan. Within forty-five (45) days following the last day of each Contract Half
Year during the term of this Agreement, and within thirty (30) days following
termination of each Work Plan, each Party will prepare, and provide to each
member of the JRB, a reasonably detailed written summary report which will
describe its work done and results achieved in the performance of each Work
Plan.

 

4.12         Commercialization of Alliance
Products. Commercialization of an Alliance Product may not occur until the
JRB agrees in writing that the Alliance Product is ready for Commercialization.
The Supplier designated in the applicable Work Plan pursuant to Section 4.6
will provide written specifications and copies of the product labeling to each
Party’s designee at a reasonable time prior to the decision on
Commercialization and will propose to the JRB the Target Minimum Sales Price
and an average selling price for the Alliance Product.

 

4.13         Disposition of Alliance Product.
A Party may propose to the JRB the disposition of an Alliance Product or a line
of Alliance Products to a Third Party. Any such proposal must include terms by
which the other Party receives compensation for its investment in the Alliance
Product(s) and for any Alliance Technology (to the extent it is
Confidential Information) or Alliance Patent Rights solely-owned by the other
Party that are required for Commercialization of the Alliance Product(s). The
other Party, pursuant to its participation in the JRB, may approve the proposal
or seek different terms. The other Party may also offer to acquire the Alliance
Product(s) on terms that reflect the Third Party’s offer and the other
Party’s investment in the Alliance Product(s). If the other Party acquires the
Alliance Product or line of Alliance Products, it will thereafter be a
Non-Alliance Product. If the Parties cannot agree on the disposition of the
Alliance Product or line of Alliance Products, the JRB must reject the
proposal. The JRB may elect to terminate the Alliance Product or line of
Alliance Products pursuant to Section 17.2.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

28

 

ARTICLE
V

REGULATORY APPROVALS

 

5.1           Regulatory Approvals. The Supplier
of an Alliance Product will be responsible for the preparation, filing,
presentation and maintenance of all Regulatory Filings and for obtaining
Regulatory Approval for such Alliance Product, unless otherwise agreed to by
the JRB. Notwithstanding the foregoing, the Parties will consult with each
other to develop a regulatory strategy for each Alliance Product and the
Supplier will in good faith consider recommendations of the other Party
regarding regulatory strategy for such Alliance Product.

 

5.2           Regulatory Communications. To
the extent practical in view of deadlines, the Supplier will provide the other
Party (if requested in writing by the other Party) with an opportunity, in
advance of submission to a Regulatory Authority, to review and comment on all
Regulatory Filings (including written responses to any Regulatory Authority
questions) regarding each Alliance Product. The Supplier will provide to the
other Party copies of all material written communications from the Supplier to
applicable Regulatory Authorities (in advance of filing if possible), copies of
all material written communications received by the Supplier from such
Regulatory Authorities promptly after receipt, and any adverse finding or
communication, oral or written, by such Regulatory Authority regarding each
Alliance Product.

 

5.3           Product Inserts and Labeling.
Unless otherwise agreed to by the JRB, the Supplier of an Alliance Product will
be responsible for the text and regulatory compliance of all package labels,
product inserts, operator manuals and end-user training materials used in
connection with the Commercialization of such Alliance Product. All labels and
labeling will prominently identify the Supplier as the manufacturer of such
Alliance Product and the Distributor for each Alliance Product. If the Supplier
and Distributor are the same Party, the JRB will determine how the other Party
will be identified on all labels and labeling. To the extent a Party is subject
to contractual obligations or restrictions as of the Effective Date that may
have an impact on the obligations set forth in this Section 5.3, that
Party will generally describe such obligations and restrictions to the JRB
prior to a JRB decision on Commercialization of an affected Alliance Product.

 

5.4           Inspection and Audit of Supplier.
The Supplier of an Alliance Product will allow representatives of the other
Party to inspect and audit each facility at which the Supplier manufactures
such Alliance Product, but only to the extent related to Alliance Products,
upon reasonable notice during normal business hours, not more than once in any
twelve (12) month period. The Supplier will use its commercially reasonable
efforts to notify the other Party within three (3) business days after any
Regulatory Authority notifies it of any impending inspection or audit of any
such facility. The Supplier will notify the other Party in writing of the
results of such inspection or audit promptly after such inspection or audit has
occurred. The Supplier will provide the other Party with copies of any
documentation of action resulting therefrom, and all correspondence relating
thereto.

 

5.5           Inspection and Audit of
Distributor. In the event a Regulatory Authority notifies the Distributor
of an impending audit and such audit involves any Alliance Product being
distributed by the Distributor, regardless of which Party is the Supplier for
such Alliance Product, 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

29

 

the Distributor will notify the
other Party promptly after receipt of such notice. The Distributor will notify
the other Party in writing of the results of such inspection or audit promptly
after such inspection or audit has occurred. The Distributor will provide the
other Party with copies of any documentation of action resulting therefrom, and
all correspondence relating thereto.

 

5.6           Localization. The Supplier of
an Alliance Product will provide translations in all languages as agreed to by
the JRB and implement such translations by modifying the documentation and
labeling of such Alliance Products and translating all screens and displays
into such languages so that they comply with the local regulatory requirements
for sale and clinical use in such countries. The Supplier of an Alliance
Product also will translate all such Alliance Product’s required technical
product literature, including, without limitation, operator manuals, service
manuals, training manuals and labeling into such languages as approved by the
JRB. Additional languages will be subject to mutual agreement of the Parties.

 

5.7           Regulatory Compliance And Related
Matters. Within ninety (90) days after the Effective Date,
quality/regulatory representatives from both Parties will meet to define and
document processes for exchange of customer complaints, trends or other
information concerning Alliance Products necessary to be shared between the
Parties to ensure compliance with the Quality System Regulation provisions of
the applicable Regulatory Authorities or other international agencies for
conformity to QSR Standard, ISO and other applicable regulatory requirements.
The document prepared pursuant to this Section 5.7 and subject to Section 5.8,
also will define how notices, corrective actions or recall of Alliance Products
will be handled. The recommendations of the quality/regulatory representatives
will become effective when approved by the JRB. These processes may be modified
from time to time in writing by the JRB.

 

5.8           Field Actions.

 

(a)        Any
Field Action with respect to an Alliance Product identified in Section 4.1
as having been an Existing Product will be the sole responsibility and at the
sole cost of the Party that provided the Existing Product to the Alliance
Program for the entire duration in which such product is an Alliance Product;
provided, however, in the event the Parties determine that such Field Action is
as a result of the gross negligence of the other Party, then in such case, the
other Party will be solely responsible for any Field Action resulting from such
gross negligence and at such Party’s sole cost. For purposes of this Agreement,
“Field Action” means any product quality related communication to
a customer or recall of the Alliance Product. In each instance, the Party
responsible for the Field Action will consult with the other Party in as much
in advance of the Field Action as is commercially reasonable.

 

(b)        Any
Field Action with respect to an Alliance Product that was not converted from an
Existing Product will be determined by the JRB and all associated costs will be
considered Allowable Expenses; provided, however, in the event the Parties
determine that a Field Action is as a result of the gross negligence of one
Party, then in such case, such Party will be solely responsible for any Field
Actions resulting from such gross negligence and at such Party’s sole cost,
which cost will not be considered Allowable Expense.

 

(c)        With
respect to Field Actions described in Section 5.8(b), in the event the JRB
fails within a timely manner (depending on the regulatory requirements and 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

30

 

breadth
and scope of the issue, as early as twenty-four (24) hours) to approve an
appropriate action plan to address a Field Action, either Party may initiate a
Field Action unilaterally, with the understanding that the initiating Party
will be responsible to pay all costs associated with such Field Action, subject
to possible modifications pursuant to this Section 5.8. If the initiating
Party determines that the costs for such Field Action should be either an
Allowable Expense or an expense of the other Party as a result of such Party’s
gross negligence, then the initiating Party may request the JRB to appoint a
neutral medical expert in the relevant area associated with the alleged cause
of such Field Action. The appointed neutral medical expert will assess whether
a Field Action was necessary and will determine as follows:

 

(i)    If the Field Action was necessary, then the
costs paid by the initiating Party should be considered Allowable Expenses; or

 

(ii)   If the Field Action was not necessary, then
the initiating Party must bear its own costs and such costs will not be
considered Allowable Expenses.

 

The determination of necessity by the neutral
medical expert is a binding and non-appealable decision.

 

(d)        In
the event either Party believes that the cause of the Field Action was as a
result of the gross negligence of the other Party, then a Party may take only
the issue of allocation of costs to ADR for a neutral to decide pursuant to Article XVIII.

 

5.9           Existing Products. The Parties
recognize that some of the provisions of this Article V may not apply to
some Alliance Products that are identified in Section 4.1 as having been
Existing Products. The Parties acknowledge and agree that any regulatory issues
and liability resulting from such regulatory issues associated with such
Alliance Products, which issues and liabilities arise from activities prior to such
Existing Product’s conversion to an Alliance Product, will be the sole
responsibility of the Party contributing such Existing Product.

 

ARTICLE
VI

MANUFACTURING RIGHTS

 

6.1           Manufacturing. During the term
of this Agreement, the JRB, in conjunction with acceptance of a Work Plan, will
determine which Party will manufacture (or have manufactured) each Alliance
Product or components thereof, taking into consideration the demonstrated
expertise and cost to manufacture of each Party in the manufacture of similar
products and any technology rights necessary to manufacture the Alliance
Products.

 

6.2           Manufacturing Practices.

 

(a)        The
Supplier of an Alliance Product will manufacture (or have manufactured) such
Alliance Product in conformity with its written specifications and in
accordance with all applicable laws and regulations. If a Supplier is unable to
supply pursuant to the terms of this Agreement an FDA-approved or FDA-cleared
Alliance Product due to non-compliance with FDA regulations, such event, subject
to Sections 6.2(b) and (c), will be deemed 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

31

 

a
material breach of this Agreement and the other Party may terminate this
Agreement pursuant to Section 17.4 or 17.5, as the case may be.

 

(b)        For
purposes of this Section 6.2, such inability to supply will only be deemed
material if: (i) the duration of the inability to supply is at least [***];
and either (ii) the Sales Revenue generated by the affected Alliance
Product is greater than [***] percent ([***]%) of the total Sales Revenue of
all Alliance Products, both as measured during the [***] period immediately
preceding the inability to supply; or (iii) the affected Alliance Product
provided at least [***] in Margin (as defined below) to the Alliance Program
during the [***] period immediately preceding the inability to supply. For
purposes of this Section 6.2, “Margin” means
Distribution Margin (as defined below) of the affected Alliance Product, less: (A) Marketing
and Advertising Expenses; (B) Selling and Promotion Expenses; and (C) General
and Administrative Expenses. For further purposes of this Agreement, “Distribution Margin” means Sales Revenue and Service Revenue less Cost
of Goods Sold.

 

(c)        As
a condition to asserting material breach pursuant to this Section 6.2, the
Party asserting material breach must have first in good faith provided the
other Party with assistance as reasonably requested by such other Party to
attempt to relocate the manufacturing of the affected Alliance Product to
either: (i) a manufacturing location of the Party asserting the material
breach; or (ii) a manufacturing location of a Third Party.

 

(d)        For
purposes of this Section 6.2, a Party wishing to exercise its right to
terminate pursuant to this Section 6.2, must provide the other Party with
written notice of termination within sixty (60) days after the date such right
accrued. Failure to provide written notice of termination within such sixty
(60)-day period precludes such Party from asserting material breach thereafter
for the same facts and circumstances giving rise to such right to terminate.
Further, the sixty (60) day cure period set forth in Sections 17.4 and 17.5, as
the case may be, will not be applicable to this Section 6.2.

 

6.3           Manufacturing Records. Upon
the reasonable request of the other Party, the Supplier of an Alliance Product
will provide the other Party with copies of, or access to, manufacturing
information, including batch records, process flows, analytical performance
data, quality assurance documents agreed to by the Parties pursuant to Sections
5.7 and 5.8 and other documentation, requested by the other Party regarding
manufacture and quality control of an Alliance Product. The requesting Party
will treat all such information disclosed as Confidential Information of the
Supplier subject to the provisions of Article XIV.

 

6.4           Warranty. The Supplier of an
Alliance Product will warrant to the other Party and to a bona fide purchaser
of such Alliance Product that all units of such Alliance Product supplied to
such purchaser conform with the applicable specifications, are free from
defects in material and workmanship and were designed and manufactured in
compliance with applicable laws and regulations. EXCEPT AS OTHERWISE EXPRESSLY
SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY OTHER WARRANTIES, EXPRESS
OR IMPLIED, WITH RESPECT TO ALLIANCE PRODUCTS. EACH PARTY DISCLAIMS ALL OTHER
WARRANTIES, EXPRESS AND IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

32

 

PARTICULAR PURPOSE AND
NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS.

 

6.5           Terms of Supply. The Supplier
and Distributor will agree on terms of supply of Alliance Products, such as a
transfer price at Supplier’s Cost of Goods Sold, as defined in Exhibit 1.13,
production and sale forecasts, delivery terms, risk of loss terms, and other
ordinary commercial terms. Unless they are the same Party, on the first
business day of each calendar month, the Distributor of an Alliance Product
will provide to the Supplier of that Alliance Product with a written, rolling
estimate of expected dispositions of each model of the Alliance Product and
parts thereof for each of the immediately succeeding four (4) calendar
quarters. Such estimates will not be binding on the Distributor but will be
used by the Supplier for production scheduling. If applicable, the Distributor
will promptly provide the Supplier with any material changes to the estimates
that may arise before the next monthly estimate.

 

ARTICLE
VII

SALES, MARKETING AND SUPPORT

 

7.1           Distributor. Unless otherwise
agreed to by the JRB, Abbott will be the worldwide Distributor for all Alliance
Products. Abbott may designate an Abbott Affiliate and a Third Party
distributor to distribute Alliance Products.

 

7.2           Selling Price. Each
Distributor Commercializing an Alliance Product in the Alliance Field, in its
sole discretion, will determine the final sales price of such Alliance Product;
provided, however, that the Distributor will use commercially reasonable
efforts to meet or exceed the average sales price and Target Minimum Sales Price
recommended by the JRB. In the event the Distributor does not achieve the
Target Minimum Sales Price recommended by the JRB on the sale of an Alliance
Product and to the extent the failure to achieve the Target Minimum Sales Price
is predominantly due to the bundling of an Alliance Product with other products
or providing discounts on Alliance Products in order to sell other products,
the Distributor will be responsible to the other Party for the shortfall. If
the Distributor and the other Party disagree as to the cause of the shortfall,
the Parties will submit the matter to the JRB for resolution. If the JRB cannot
resolve the matter, it will be resolved by binding ADR in accordance with Article XVIII.
As part of any such ADR proceeding, the other Party will be entitled to an
audit of applicable Distributor records limited to determining the reasons for
the shortfall. Any discount to the sales price of such Alliance Product will be
consistent with the overall discounting policy of the Distributor in connection
with the sale of its other diagnostic products and, when considered in relation
to the percentage discount applicable to the Distributor’s diagnostic products
which are sold together with or in connection with such Alliance Product, will
not materially adversely affect Sales Revenue. The pricing policy and structure
applied to Alliance Products will be the same as applied to other comparable
products and services offered by the Distributor in comparable markets, and any
discounts, rebate or pricing adjustments the Distributor establishes for
Alliance Products will not disproportionately reduce the price of Alliance
Products versus other Distributor products and services. The provisions of this
Section 7.2 will not apply to Non-Alliance Products, Competing Products or
any other product or service in which the Parties compete with each other.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

33

 

7.3           Marketing. Annually the
Distributor will prepare a marketing strategy for Alliance Products for which
it is the Distributor. Except for Existing Products converted to Alliance
Products pursuant to Section 4.1, prior to the introduction of each
Alliance Product that measures a new analyte, the Distributor will provide the
other Party with a copy of a marketing plan for such Alliance Product and with
a reasonable opportunity to comment on the marketing plan before it becomes
effective. The Distributor will conduct the promotion, marketing and sales
activities for each Alliance Product in accordance with the concepts outlined
in the marketing strategy. The Distributor will book all Alliance Product
sales, subject to the sharing of Revenues and Allowable Expenses in accordance
with Article IX hereof.

 

7.4           Diligence. The Distributor
will use commercially reasonable efforts to promote, market, sell and support
the sale of Alliance Products for which it is the Distributor, such efforts to
be no less than those used by such Party with respect to other products which
have the same or similar market potential. If the Distributor wishes to
discontinue promotion and sale of an Alliance Product, the Distributor will
give the other Party ninety (90) days advance written notice thereof. The other
Party, within such ninety (90)-day period, with the prior written consent of
the JRB, may elect to become the Distributor for such Alliance Product, in which
event, the original Distributor will cooperate in a transition to the other
Party designed to avoid adverse effects in the market for such Alliance
Product. If the other Party does not elect to become the Distributor for the
Alliance Product, the Alliance Product, at the end of the ninety (90)-day
period, will be considered terminated pursuant to Section 17.2 hereof.

 

7.5           Service and Support. The
Distributor will use commercially reasonable efforts to provide service and
support to customers purchasing the Alliance Products sold by such Distributor.
These efforts will be consistent with the efforts used by the Distributor with
respect to other diagnostic products it markets and distributes for which it
provides service and support and which have the same or similar market
potential, or as otherwise described in an approved NPCD.

 

ARTICLE
VIII

INSTRUMENTS

 

8.1           Instrument Commercialization.

 

(a)        Each
Party, alone or with any Third Party, may develop and Commercialize, directly
or indirectly, for any purpose any Instrument or any associated
application-specific software outside the Alliance Field or in the Optional
Areas. Such Instruments include, for example, Instruments for protein analysis.

 

(b)        Each
Party, alone or with any Third Party, may develop and Commercialize, directly
or indirectly, any Instrument for use in the Alliance Field, provided, such
Instrument is labeled “Research Use Only. Not For Use In Diagnostic Procedures”
or other comparable label restriction under applicable Regulatory Authority, or
is a General Purpose Instrument.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

34

 

(c)        Each
Party, alone or with any Third Party, may develop and Commercialize, directly
or indirectly, any Instrument registered with a Regulatory Authority for use in
the Exclusive Areas or Conditionally Exclusive Areas, provided, (i) sales
of such Instruments are solely to end users and (ii) the Party
Commercializing such Instruments does not Facilitate use as a Competing
Product.

 

(d)        For
the avoidance of doubt, it is the intent of the Parties that no Party may
Commercialize in the Exclusive Areas an Instrument registered with an
applicable Regulatory Authority in a manner inconsistent with obligations of
this Agreement that will damage the Alliance Program’s objectives of maximizing
sales of Alliance Products in the Exclusive Areas. If a Party believes the
other Party has intentionally deviated from the principle of this Section 8.1(d),
the first Party may provide notice thereof to the other Party and the Parties
will discuss resolution of the matter. If the first Party is not satisfied
after such discussion, such Party may initiate ADR proceedings in accordance
with Article XVIII.

 

8.2           Instrument Co-Promotion. A
Distributor of an Alliance Product may contract for the promotion in the
Alliance Field of Instruments that are then being offered for sale by any
manufacturer of Instruments. In the event the Instrument is offered for sale by
the other Party and was developed by that Party without funding by the Alliance
Program, (a) the Distributor may promote such Instrument only to customers
in the Alliance Field in conjunction with the sale of an Alliance Product, and (b) the
terms of the promotion contract will be as agreed by the Parties. The Party
supplying the Instrument will be free to sell the same Instrument independently
of the Distributor in any market. The Parties will not share any commission or
other compensation received by the Distributor for the promotion of Instruments
pursuant to this Section 8.2.

 

8.3           Instrument Distribution. A
Distributor of an Alliance Product may become a distributor in the Alliance
Field for Instruments (other than Instruments subject to Sections 8.2, 8.4 or
8.5) acquired from a manufacturer of such Instruments. If the manufacturer is
the other Party: (a) the Distributor may Commercialize such Instrument
only to customers in the Alliance Field in conjunction with the sale of an
Alliance Product; (b) the transfer price to the Distributor for the
Instrument will be no greater than the lowest offered by the manufacturer to
any Third Party for the same Instrument on comparable terms in the Alliance
Field; and (c) the terms of the distribution contract will be as agreed by
the Parties. The Party supplying the Instrument will be free to sell the same
Instrument independently of the Distributor in any market. The costs incurred
by the Distributor, including the transfer price of the Instrument and other
selling costs, will be Allowable Expenses and the revenue from the Distributor’s
sale of the Instrument will be included in Sales Revenue.

 

8.4           OEM Instruments. Either Party
may propose to the JRB entering into a contract with an Instrument manufacturer
for the manufacture and sale to one or both Parties for distribution in the
Alliance Field of a pre-existing Instrument modified by the manufacturer to
meet specifications approved by the JRB and funded through the Alliance Program
(“OEM Instrument”). Any such contract will preclude the manufacturer
from distributing the OEM Instrument in the Alliance Field or selling the OEM
Instrument to a Third Party for resale in the Alliance Field. If the
manufacturer is a Party, the price of the OEM Instrument will be the Party’s 

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

35

 

[***]. For purposes of this
Agreement, the OEM Instrument will be considered an Alliance Product.

 

8.5           Alliance Funded Instrument.
Either Party may propose to the JRB, pursuant to Section 4.2, the design
and Development of a new Instrument for the Alliance Program or a successor for
or an improvement of an Instrument that is an Alliance Product (“Alliance Instrument”). If the JRB approves the Alliance Instrument
proposal, the Parties will work exclusively together on Development and
Commercialization of such Alliance Instrument pursuant to an approved Work Plan
and associated budget. Any such Alliance Instrument approved by the JRB will be
an Alliance Product.

 

8.6           Instrument Funding. If, at the
time of JRB approval of an OEM Instrument proposal pursuant to Section 8.4
or an Alliance Instrument proposal pursuant to Section 8.5, Applera,
through its Applied Biosystems Group (“ABI”) states,
in writing, an intent to Commercialize the developed OEM Instrument or Alliance
Instrument outside the Alliance Program, the Parties will negotiate terms for
sharing all budgeted costs for the Development of such Instrument, but in no
event will Abbott’s share be greater than [***] percent ([***]%) of the total
costs, unless otherwise agreed by the Parties. In addition, Applera will bear
[***] associated with features of the Instrument requested by Applera for
customers outside the Alliance Field. If, at the time of JRB approval of an OEM
Instrument proposal pursuant to Section 8.4 or an Alliance Instrument
proposal pursuant to Section 8.5, ABI does not state, in writing, an
intent to Commercialize the developed OEM Instrument or Alliance Instrument,
Abbott will bear [***] percent ([***]%) and Applera will bear [***] percent
([***]%) of all budgeted costs for Development of the Instrument. In this case,
both Abbott and CDx may Commercialize such Instrument independently for use
with Non-Alliance Products and through the Alliance Program. However, ABI will
not have the right to Commercialize the OEM Instrument or Alliance Instrument
outside the Alliance Program unless the Parties negotiate an arrangement under
mutually acceptable terms in a separate agreement.

 

8.7           Rejected Instrument. If the
JRB rejects an OEM Instrument proposed pursuant to Section 8.4 or an
Alliance Instrument proposed pursuant to Section 8.5, or an Alliance
Instrument prior to Commercialization, the Proposing Party, alone or with a
Third Party, may continue Development of the proposed OEM Instrument or
Alliance Instrument. The Proposing Party will bear [***] incurred by it in
developing the OEM Instrument or Alliance Instrument, and in the case of an
Alliance Instrument previously funded by the Alliance Program, the Proposing
Party will bear [***] incurred subsequent to the JRB rejection. If the rejected
OEM Instrument or Alliance Instrument is Commercialized by the Alliance Program
for use in the performance of testing that uses Alliance Products in the
Exclusive Areas, the non-Proposing Party will pay to the Proposing Party,
pursuant to Section 10.14(b)(vii) and (viii), [***] percent ([***]%)
of Incremental Net Sales of Alliance Products sold for use on such rejected OEM
Instrument or Alliance Instrument until the Proposing Party is reimbursed [***]
percent ([***]%) of the Proposing Party’s Development Costs for the rejected
OEM Instrument or Alliance Instrument.

 

8.8           OEM Opportunity.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted
material has been filed separately with the Securities and Exchange Commission.

 

36

 

(a)        ABI
will be the preferred supplier of Alliance Instruments to the Alliance Program.
ABI will have a right to submit a bid to be the OEM manufacturer of any
Alliance Instrument, subject to the bidding process determined by the JRB. If
ABI meets or exceeds the specifications of such bid, and the bids of all other
companies which submit such bids, ABI will be awarded the rights to be the OEM
manufacturer of the subject Alliance Instrument pursuant to such bid.

 

(b)        In
the event ABI has an opportunity to be an OEM manufacturer for a Third Party in
connection with an Instrument to be registered with a Regulatory Authority for
use in the Exclusive Areas or Conditionally Exclusive Areas, ABI will inform
the JRB in writing of such opportunity and provide information, subject to Article XIV,
concerning the specifications of such Instrument as requested by the JRB. Once
such information is provided to the JRB by ABI, the JRB will have [***] to
determine if it wishes ABI to manufacture such Instrument exclusively for the
Alliance Program. If the JRB informs ABI that it wishes ABI to manufacture such
Instrument exclusively for the Alliance Program, ABI will negotiate terms with
the JRB for ABI to provide the Instrument exclusively to the Alliance Program.
If ABI and the JRB reach agreement, ABI may not manufacture such Instrument for
any Third Party. If the JRB and ABI do not reach agreement or the JRB fails to
act within [***] of ABI providing all requested information on such Instrument
specifications to the JRB, and the proposed Instrument is not subject to Section 8.9
below, ABI may elect to be the OEM manufacturer of such Instrument to a Third
Party, including a Third Party who Facilitates use of the Instrument as a
Competing Product; provided, however, that the terms of the agreement between
ABI and the Third Party are no better in terms of value to the Third Party than
the last best offer of the JRB.

 

8.9           Instruments for Performing Tests
in Exclusive Areas. In the event (a) the Instrument subject to Section 8.8(b) is
an Instrument that is intended for use within the Exclusive Areas, and (b) the
Alliance Program, pursuant to an Instrument supply agreement with ABI, is
purchasing or has made a commitment to purchase an Instrument registered with a
Regulatory Authority that has the [***] and is for sale or intended for sale in
the same [***] as the Instrument in the OEM opportunity, ABI cannot become an
OEM manufacturer of such Instrument for a Third Party whether or not the JRB
elects to have such Instrument manufactured by ABI for the Alliance Program.
ABI may request the JRB to waive the restriction of this Section 8.9 for
any particular OEM Instrument opportunity. For the avoidance of doubt, nothing
herein will restrict ABI from any commercial activities including OEM supply of
Instruments that are not registered with a Regulatory Authority or the sale of
any Instruments registered with a Regulatory Authority to an end-user so long
as such sale does not Facilitate a Competing Product.

 

8.10         Technology and Patent Rights.
Except pursuant to a separate agreement, a Party purchasing an Instrument from
the other Party will not get any right under the other Party’s Technology and
Patent Rights directed to Instruments to make or have made such Instrument.

 

[***] indicates material that
has been omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

37

 

ARTICLE IX

SHARING OF COSTS AND REVENUES

 

9.1           Quarterly Cost and Revenue Estimate. No later than
the second business day after the end of each of the first three calendar
quarters in a calendar year (end March, June and September) during the
term of this Agreement, the Parties will exchange estimated cost and revenue
statements for the calendar quarter just ended in a form substantially the same
as the form set forth in Exhibit 9.2, attached hereto. For each fourth
calendar quarter ending December 31, the Parties will exchange quarterly
cost and revenue estimates no later than the third business day of January in
the calendar year immediately following such fourth quarter.

 

9.2           Cost and Revenue Statements. Within forty-five (45)
days following the end of each calendar quarter during the term of this
Agreement, each Party will prepare and furnish to the other Party a written
statement, in reasonably specific detail, stated in United States dollars, of
Revenues and Allowable Expenses incurred during the preceding calendar quarter,
in a form substantially the same as the form set forth in Exhibit 9.2,
attached hereto. The Parties will agree on exchange rate calculations that each
Party will use when preparing these statements.

 

9.3           Statement of Net Investment. Within forty-five (45)
days following the end of each calendar quarter during the term of this
Agreement, each Party will prepare and furnish to the other Party a written
statement, in reasonably specific detail, setting forth, in United States
dollars, the Party’s balance of Net Investment in the Alliance Program as of
the end of the preceding calendar quarter, in a form substantially the same as
the form set forth in Exhibit 9.3, attached hereto. The balance of Net
Investment for each Party may not include the manufacturing equipment,
instruments and account receivables on the books of such Party as of the
execution date of the Prior Alliance Agreement.

 

9.4           Equalization Payments. Within thirty (30) days
following receipt of each statement rendered pursuant to Sections 9.2 and 9.3:

 

(a)        the Party
with the higher Revenue will pay to the Party with the lower Revenue [***] in
Revenue between the Parties;

 

(b)        the Party
with the lower actual Allowable Expenses will pay to the Party with the higher
actual Allowable Expenses [***] in actual Allowable Expenses between the
Parties;

 

(c)        the Party
with the lower Net Investment balance will pay the Party with the higher Net
Investment balance [***] in Net Investment between the Parties at the end of
such calendar quarter, except that the Party with the lower Net Investment
balance may, in lieu of making a payment [***] between the respective Net
Investments, elect to pay the other Party a financing fee equal to the weighted
average cost of capital of the other Party times [***] in Net Investment
between the Parties, times [***]. Weighted average cost of capital will be
calculated as cost of equity times (market value of equity/(market value of
equity + market value of debt)) + cost of debt times (1- tax rate) times (market
value of debt/(market value of equity + market 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

38

 

value of
debt)). For purposes of this Section 9.4(c), market value of debt equals
book value of debt, cost of debt equals the U.S. ten (10) year Treasury
rate, tax rate equals the marginal U.S. and applicable state tax rate of the
other Party, and cost of equity equals the long term equity premium per Goldman
Sachs with an assumed beta of 1 + cost of debt; and

 

(d)       the payments
due from/to a Party pursuant to Sections 9.4 (a) through (c) may be
offset against each other, such that a single payment may be made by one Party
to the other Party to fulfill the requirements of this Section 9.4.

 

9.5           Maximum Costs. The Parties agree to set a limit on
Development Costs, Marketing and Advertising Expenses, Selling and Promotion
Expenses and General and Administrative Expenses for each Contract Half Year,
and, unless otherwise agreed by the JRB, a Party exceeding its allocated
portion of such costs and expenses must absorb the overrun. The Parties’
agreement with respect to Development Costs is set forth in Section 4.7.
Similarly, every six (6) months, the Parties will agree for the following
two Contract Half Years on a limit for Marketing and Advertising Expenses and
Selling and Promotion Expenses (collectively, as a percentage of Net Sales of
Alliance Products (excluding OEM Alliance Products)), and General and
Administrative Expenses.

 

9.6           Modifying Terms. Upon the request of either Party,
the JRB will consider the definitions of Allowable Expenses and Net Investment,
and the components thereof, and, if approved by the JRB, the JRB will modify
the definitions and provide each Party with written notice of the modified
definitions and the date on which such modified definitions will become
effective.

 

9.7           Payment Terms. All payments hereunder will be in
United States dollars in immediately available funds and will be made by wire
transfer from a United States bank located in the United States to such bank
account as payee may designate in writing from time to time.

 

(a)        Any payments
or portions thereof due hereunder which are not paid on the date such payments
are due under this Agreement will bear interest at a rate equal to the lesser
of (i) the prime rate as published in The Wall Street Journal, Eastern
Edition, under the heading “Money Rates,”
on the first day of each calendar quarter in which such payments are overdue,
plus one (1) percentage point, and (ii) the maximum rate permitted by
law, calculated on the number of days such payment is delinquent, compounded
monthly using a three hundred sixty-five (365)-day year.

 

(b)        If at any
time legal restrictions prevent the prompt remittance of any monies owed with
respect to Revenues in any jurisdiction, the remitting Party will notify the
receiving Party and make such payments by depositing the amount thereof in
local currency in a bank account or other depository in such country in the
name of the receiving Party or its designee, and the remitting Party will have
no further obligations under this Agreement with respect thereto.

 

9.8           Record Keeping. Each Party will maintain, and will
use commercially reasonable efforts to cause its licensees, sublicensees,
contractors and agents to maintain, books 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

39

 

of account and accurate records relating to
Revenues, Allowable Expenses and Net Investments with respect to the Alliance
Program and all amounts payable or receivable under this Agreement, in
sufficient detail to permit the other Party to confirm the correctness of such
items. All books of account and records will be maintained for a period not less
than relevant time permitted for audit of such accounts and records pursuant to
Section 9.9 and for any applicable tax period pursuant to Section 9.10.

 

9.9           Audits.

 

(a)       Upon the
written request of a Party (the “Requesting Party”)
and not more than once in each calendar year, the other Party (the “Responding Party”) will permit an independent certified public
accounting firm of nationally recognized standing, selected by the Requesting
Party and reasonably acceptable to the Responding Party, at the Requesting
Party’s expense, to have access during normal business hours to such of the
records of the Responding Party as may be reasonably necessary to verify (i) compliance
with the terms of this Article IX and all associated definitions in Article I
and Exhibit 1.13, and (ii) the accuracy of the reports provided under
this Article IX, for any year ending not more than thirty-six (36) months
prior to the date of such request. Further, an audit may not cover a year that
was already the subject of a previous audit under this Agreement. The
Responding Party also will permit the accounting firm to visibly inspect any
tangible asset included within Net Investment. The accounting firm will
disclose to the Requesting Party only whether the reports and records are correct
or not and the specific details concerning any discrepancies. All other
information will be Confidential Information of the Responding Party and may
not be shared with the Requesting Party.

 

(b)        If such
accounting firm concludes that additional amounts were owed during the audited
period, the Party owing such amounts will pay such additional amounts within
thirty (30) days of the date the Requesting Party delivers to the Responding
Party such accounting firm’s written report so concluding. The fees charged by
such accounting firm will be paid by the Requesting Party; provided, however, (i) if
the audit discloses that the actual Revenues for such period are more than one
hundred five percent (105%) of the Revenues reported for such period, then the
Responding Party will pay the reasonable fees and expenses charged by such
accounting firm, and (ii) if the audit discloses that the Allowable
Expenses of the Responding Party reported for such period are more than one
hundred five percent (105%) of the actual Allowable Expenses of the Responding
Party for such period, then the Responding Party will pay the reasonable fees
and expenses charged by such accounting firm, but the total of such fees and
expenses payable by the Responding Party will not be more than Fifty Thousand
dollars ($50,000).

 

9.10         Tax Matters.

 

(a)        The Parties
understand and agree that the activities and other undertakings evidenced by
this Agreement result in a partnership for purposes of federal income taxation
and for the purposes of certain state and/or local income tax laws which
incorporate or follow federal income tax principles as to tax partnerships. For
every other purpose of this Agreement, however, and not withstanding any other
provision in this Agreement, expressed or implied, to the contrary, the Parties
understand and agree that their legal relationship to each other under
applicable law with respect to all activities is as set forth in Section 19.6
and is not 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

40

 

one of
partnership; that the liabilities of the Parties will be several and not joint
or collective except as might otherwise be provided for and pursuant to this
Agreement.

 

(b)        The Parties
intend that solely for Tax purposes and pursuant to the provisions of
Subchapter K of Chapter 1 of Subtitle A of the Internal Revenue Code of 1986,
as amended (the “Code”), the alliance created by this Agreement will be
treated as a partnership for United States income tax purposes and each Party
agrees not to elect to be excluded from the application of said Subchapter K.
The Parties further intend that pursuant to the provisions of those state
and/or local income tax laws that incorporate or follow federal income tax
principles as to tax partnerships, the alliance created by this Agreement will
be treated as a partnership for Tax purposes and each Party agrees not to elect
to be excluded from the application of such provisions. As such, the Parties
agree to have the partnership file all required federal, state and local
Partnership Tax Returns and to make any appropriate elections, including an election
to deduct currently research and Development expenditures incurred by the
partnership pursuant to Section 174(a) of the Code.

 

(c)        The effective
date of the partnership will be the effective date of the Prior Alliance
Agreement, and the partnership will continue in full force and effect from and
after such date until terminated as provided in this Agreement.

 

(d)        Solely for
income tax purposes, each Party will be considered and deemed to own an
interest in the profits, losses and capital of this partnership as determined
under the provisions of this Agreement.

 

(e)        For purposes
of reporting on federal, state and/or local Partnership Tax Returns, each Party
will keep accounts on the accrual method of accounting. The taxable year of the
partnership for purposes of reporting on federal, state and/or local
Partnership Tax Returns will be the fiscal year ending June 30. Within
ninety (90) days after the end of each fiscal year, a Tax representative from
each Party will provide the other Party with a schedule of partnership Revenue
and Allowable Expenses reportable by the partnership for its taxable year.

 

(f)         Audits of
each Party’s records will be performed pursuant to the provisions of Section 9.9.

 

(g)        Abbott will
be responsible for filing any and all federal, state and/or local Partnership
Tax Returns covering operations reportable by the partnership and pursuant to
this Agreement. Abbott agrees to use its best efforts in the preparation and
filing of such Partnership Tax Returns, acting on behalf of itself and Applera,
but in doing so, Abbott will incur no liability to Applera with regard to such
Partnership Tax Returns or elections relating thereto. Each Party will fill out
Tax information requests so that Abbott can accurately and timely prepare the
appropriate Partnership Tax Returns. Abbott will send to Applera a copy of the
Partnership Tax Returns at least thirty (30) days prior to the due date,
including extensions of time, for filing such Partnership Tax Returns, and
Applera will approve of such Partnership Tax Returns at least fifteen (15) days
prior to the due date. Abbott and Applera agree to resolve in good faith any
issues arising as a result of the review of such returns. The due date for
filing the Partnership Tax Returns may be extended by the tax matters partner
as defined in Section 6231(a)(7) of the Code (“TMP”) if either Party requests such an extension. Both
Parties agree to 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

41

 

share
equally the expenses of hiring an independent certified public accountant to
prepare the Partnership Tax Returns.

 

(h)        All
correspondence relating to the preparation and/or filing of any and all
federal, state and/or local Partnership Tax Returns of the partnership will be
mailed to Abbott or Applera at the address provided in Section 9.10 (q) or
as otherwise agreed in writing by the Parties. Applera agrees to provide to
Abbott on a timely basis all information required and necessary to enable
Abbott to fulfill and satisfy its obligations and responsibilities.

 

(i)         Abbott is
designated the TMP. The designation as TMP will be effective only for
operations conducted by the Parties pursuant to this Agreement. The TMP will
not bind Applera to any agreement, extend the statute of limitations, settle
any outstanding audit, litigate any unsettled audit issues, choose a forum for
litigation, appeal an adverse lower court decision, file a Request for
Administrative Adjustment, make any election with respect to federal, state or
local income tax law, or take any other actions affecting Tax matters without
obtaining the prior written concurrence of Applera. The TMP will inform
Applera, on a timely basis, of any Tax matters, including, but not limited to,
progress of any Internal Revenue Service (“IRS”) audit,
receipt of a Revenue Agent’s Report, and notice of an Appeals Conference.
Neither Party will enter into a settlement agreement with the IRS with respect
to any partnership item, as defined by Section 6231(a)(3) of the
Code, or file a notice of inconsistent treatment under Section 6222(b) of
the Code without first notifying the other Party within thirty (30) days of
such proposed action. Applera will furnish the TMP, within thirty (30) days of
receipt of the request, such information as the TMP may reasonably request to
permit it to provide the IRS with sufficient information for purposes of
Sections 6223 and 6050K of the Code. Both Parties agree that filing Partnership
Tax Returns requires the use of a federal identification number. Abbott, as
TMP, will file an application with the IRS to obtain a federal identification
number for the partnership. Both Parties will agree on a name for the
partnership.

 

(j)         Both Parties
agree that the TMP may engage, upon Applera’s prior written consent, which
consent will not be unreasonably withheld or delayed, an outside consultant to
assist in settling or litigating any outstanding partnership audit issues with
the IRS or any other taxing authority. Such expenses are expenses of the
partnership and will be shared equally by the Parties. This provision will be
applicable for any audits of the partnership during the term of this Agreement
and any audits that occur after termination of the partnership under the terms
of this Agreement.

 

(k)        All items of
income, gain, loss, deduction and credit will be allocated to each Party as set
forth in this Agreement. All items of tax credit will be allocated in the same
proportion as the corresponding item of income or deduction. All tax credit
recapture and depreciation recapture will be allocated to each Party in the
same proportion as the corresponding credit and depreciation was allocated. Any
item of income, gain, loss or deduction with respect to any property deemed
contributed to the partnership by a Party will, solely for income tax purposes,
be allocated between the Parties so as to take into account any variation
between the adjusted basis of such property for federal income tax purposes and
its fair market value as of the date of contribution in accordance with Section 704(c) of
the Code and Treasury Regulation Section 1.704-3. In the event that the
IRS upon audit imputes, under Section 482 of the Code, any item of income,
gain, loss, deduction or credit to either Party as a result of the 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

42

 

Party’s
actual or deemed furnishing of property, products, facilities or services under
this or any other agreement between Applera or Abbott and the partnership, the
correlative item of income, gain, loss, deduction or credit of the partnership
resulting from such imputation will be specially allocated to the Party to
which the item of income, gain, loss, deduction or credit is imputed. It is the
intention of this section to place the Parties in the same economic position as
if such adjustment under Section 482 of the Code had not been made.

 

(l)         All
allocation methods described herein for income, gain, loss or deduction will be
utilized for allocation of income, gain, loss, or deduction for financial
accounting purposes, including financial capital accounts, as well as for
income tax purposes. Each Party will have a capital account that will be
maintained in a manner that will comply with the provisions of Treasury
Regulation Section 1.704-1(b)(2)(iv), as amended from time to time.
Appropriate adjustments will be made in each Party’s capital account to
effectuate any audit adjustment imposed by any tax authorities on any item of
income, gain, loss, deduction or credit.

 

(m)       The
partnership will terminate upon the effective termination of this Agreement by
any Party or as provided by law. Upon termination, the partnership will
dissolve and distribute any and all partnership assets and liabilities in
accordance with the Party’s positive capital accounts and the terms of this
Agreement. Should either Party have a deficit in its capital account at the
time of dissolution of the partnership, such Party will contribute sufficient
funds to the partnership to eliminate such deficit. Distributions upon
dissolution and contributions to restore deficits in capital accounts will be
made by the end of the taxable year during which the dissolution of the
partnership occurs, or, if later, within ninety (90) days after the date of
such dissolution. It is the intention of the Parties that the partnership will
terminate for federal and state income tax purposes at such time that the
activities of the Parties evidenced by this Agreement are no longer deemed to be
partnership activities for any such purpose.

 

(n)        It is the
intention of the Parties that their capital accounts will be determined in a
manner so that allocations in this Agreement will have, or be deemed to have,
substantial economic effect under Section 704(b) of the Code and
Treasury Regulations thereunder. Furthermore, it is the intention of the
Parties to comply with all requirements of Section 704(b) of the Code
and Treasury Regulations thereunder regarding the treatment of any item of
income, gain, loss, deduction or credit not specifically addressed in this
Agreement.

 

(o)        Each Party
will cooperate (and cause their respective Affiliates to cooperate) with the
other Party in connection with matters relating to the preparation and filing
of Partnership Tax Returns and the examination of Partnership Tax Returns by
any taxing authority. Such cooperation will include making all information and
documents in their possession relating to the partnership available to the
other Party. Applera will also make available to Abbott, as reasonably
requested and available, personnel (including officers and employees and agents
of Applera or its Affiliates) responsible for preparing, maintaining and
interpreting information and documents relevant to the partnership, and
personnel reasonably required as witnesses or for purposes of providing
information or documents in connection with any administrative or judicial
proceedings relating to Tax matters of the partnership. The Party receiving
information or documents provided under this Section 9.10 will keep such
information or documents confidential, except as may otherwise be necessary in
connection with the filing of Partnership Tax Returns or in connection with any
administrative or judicial proceedings.

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

43

 

Each Party will preserve and keep all records relating to the assets
and activities of the partnership for so long as the contents thereof may
become material in the administration of any matter under the Code or other
applicable Tax law, but in any event, until the later of (i) the
expiration of any applicable statute of limitations with respect to any
Partnership Tax Return and (ii) the expiration of the applicable statute
of limitations of both Parties (for all Tax returns which include the Party’s
share of partnership items).

 

Each Party will be responsible for its own Tax liabilities resulting
from (i) payments received under this Agreement and (ii) its share of
partnership items and partnership allocations determined pursuant to the
provisions of this Agreement. Any income or other Taxes which a Party is
required by law to pay or withhold on behalf of a receiving Party with respect
to royalties or other payments payable to a receiving Party under this
Agreement will be deducted from the amount of such royalties or other payments
due, and paid or withheld as appropriate by the paying Party on behalf of the
receiving Party. Any such Tax required by law to be paid or withheld will be an
expense of, and borne solely by, the receiving Party. The paying Party will
furnish the receiving Party with the best available evidence of such payment or
amount withheld as soon as practicable after such payment is made or such
amount is withheld. The Parties will reasonably cooperate in completing and
filing documents required under the provisions of any applicable tax laws or
under any other applicable law in connection with the making of any required
tax payment or withholding tax in connection with any claim for exemption from,
or a reduction in the rate of withholding, or in connection with any claim to a
refund of or credit for any such payment.

 

(p)        The Parties
agree that any Taxes that are imposed upon the partnership by any governmental
entity or political subdivision thereof are an expense of the partnership. Such
expenses will pass through to the partners in accordance with the terms of this
Agreement and, in particular, the principles of this Section 9.10.

 

(q)        Mailing
address for correspondence relevant to this Section 9.10:

 

If to Abbott:

 

Tax Division D-367/AP6D

100 Abbott Park Road

100 Abbott Park Road

Abbott Park, IL 60064-6057

Attn: Vice President, Taxes

 

If to Applera:

 

Applera Corporation

 

301 Merritt 7

P.O. Box 5435

Norwalk, CT 06856-5435

Attn: Vice President, Corporate Tax

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

44

 

ARTICLE X

OWNERSHIP, LICENSE AND TECHNOLOGY TRANSFER

 

10.1         Abbott Independent Rights. Nothing in this Agreement
is intended to change ownership or Control of Abbott Independent Technology or
Abbott Independent Patent Rights. Subject to Sections 10.11 and 11.1, Abbott
and its Affiliates may Exploit all Abbott Independent Technology and Abbott
Independent Patent Rights in any field and territory without restriction;
provided, however, during the term of this Agreement, Abbott will give the JRB
advance written notice of any intention to license any Abbott Independent
Technology or Abbott Independent Patent Rights in the Exclusive Areas and
Conditionally Exclusive Areas.

 

10.2         Applera Independent Rights. Nothing in this Agreement
is intended to change ownership or Control of Applera Independent Technology or
Applera Independent Patent Rights. Subject to Sections 10.10 and 11.1, Applera
and its Affiliates may Exploit all Applera Independent Technology and Applera
Independent Patent Rights in any field and territory without restriction;
provided, however, during the term of this Agreement, Applera will give the JRB
advance written notice of any intention to license any Applera Independent
Technology or Applera Independent Patent Rights in the Exclusive Areas and
Conditionally Exclusive Areas.

 

10.3         Abbott Alliance Technology and Alliance Patent Rights.
Abbott will own all right, title and interest in and to all Abbott Alliance
Technology and all Abbott Alliance Patent Rights; provided, however, during the
term of this Agreement, neither Abbott nor its Affiliates may Exploit any Abbott
Alliance Technology or Abbott Alliance Patent Rights except as follows:

 

(a)        Abbott and
its Affiliates may use Abbott Alliance Technology and Abbott Alliance Patent
Rights in the Exclusive Areas in the performance of Abbott’s obligations
pursuant to this Agreement.

 

(b)        Abbott and
its Affiliates, if Abbott is an acquiring Party pursuant to Section 4.3 or
a Proposing Party pursuant to Section 4.4, may independently or with a
Third Party use Abbott Alliance Technology and Abbott Alliance Patent Rights
for Non-Alliance Products, provided Abbott pays to Applera royalties on Net
Sales of such Non-Alliance Products in accordance with Section 10.14(b) at
the rate determined for Section 2.3(d).

 

(c)        Abbott and
its Affiliates may use Abbott Alliance Technology and Abbott Alliance Patent
Rights for its or a Third Party’s (under contract with Abbott or its
Affiliates) research, Development, manufacture, use and Commercialization of
products and services outside the Alliance Field.

 

(d)        Abbott and
its Affiliates may not grant any right or license to use Abbott Alliance
Technology or Abbott Alliance Patent Rights in the Exclusive Areas without the
prior approval of Applera, and all revenue and other consideration (e.g.,
cross-license rights or supply or distribution rights) received by Abbott or
its Affiliates in consideration for any such approved license will constitute
Licensing Revenue. Upon written notice to Applera, Abbott or its Affiliates may
grant to a Third Party a nonexclusive right and license to use Abbott Alliance 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

45

 

Technology
or Abbott Alliance Patent Rights in the Alliance Field but outside the
Exclusive Areas; provided, however, that Abbott pays to Applera in accordance
with Section 10.14, [***] percent ([***]%) of all revenue and other
consideration (e.g., cross-license rights or supply or distribution rights)
received by Abbott or its Affiliates in consideration for such license.

 

(e)        Upon written
notice to Applera, Abbott or its Affiliates may grant to a Third Party a
nonexclusive right and license to use Abbott Alliance Technology or Abbott
Alliance Patent Rights outside the Alliance Field without accounting to
Applera.

 

(f)         In
settlement of a lawsuit or alternate dispute resolution procedure involving
enforcement of an Abbott Alliance Patent Right against a Third Party, Abbott or
its Affiliates may grant license rights to the Third Party under the Abbott
Alliance Patent Rights in dispute in the Alliance Field but outside the
Exclusive Areas, provided: (i) the Third Party grants license rights to
Abbott under Third Party Patent Rights in dispute, if any; (ii) Abbott
uses commercially reasonable efforts to obtain sufficient rights to bring the
Third Party Patent Rights within Abbott Independent Patent Rights; and (iii) any
revenue received by Abbott from the Third Party as consideration for activities
in the Alliance Field after the Effective Date covered by the Abbott Alliance
Patent Rights will be shared as provided in Section 10.3(d).

 

(g)        Notwithstanding
the provisions of this Section 10.3, Abbott may Exploit without limitation
or restriction any Abbott Alliance Technology that is not Confidential
Information.

 

10.4         Applera Alliance Technology and Alliance Patent Rights.
Applera will own all right, title and interest in and to all Applera Alliance
Technology and all Applera Alliance Patent Rights; provided, however, during
the term of this Agreement, neither Applera nor its Affiliates may Exploit any
Applera Alliance Technology or Applera Alliance Patent Rights except as
follows:

 

(a)        Applera and
its Affiliates may use Applera Alliance Technology and Applera Alliance Patent
Rights in the Exclusive Areas in the performance of Applera’s obligations
pursuant to this Agreement.

 

(b)        Applera and
its Affiliates, if Applera is an acquiring Party pursuant to Section 4.3
or a Proposing Party pursuant to Section 4.4, may independently or with a
Third Party, use Applera Alliance Technology and Applera Alliance Patent Rights
for Non-Alliance Products, provided Applera pays to Abbott royalties on Net
Sales of such Non-Alliance Products in accordance with Section 10.14(b) at
the rate determined for Section 2.3(d).

 

(c)        Applera and
its Affiliates may use Applera Alliance Technology and Applera Alliance Patent
Rights for its or a Third Party’s (under contract with Applera or its Affiliates)
research, Development, manufacture, use and Commercialization of products and
services outside the Alliance Field.

 

(d)        Applera and
its Affiliates may not grant any right or license to use Applera Alliance
Technology or Applera Alliance Patent Rights in the Exclusive Areas without the
prior approval of Abbott, and all revenue and other consideration (e.g.,
cross-license rights or supply or distribution rights) received by Applera or
its Affiliates in consideration for any such 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

46

 

approved
license will constitute Licensing Revenue. Upon written notice to Abbott,
Applera or its Affiliates may grant to a Third Party a nonexclusive right and
license to use Applera Alliance Technology or Applera Alliance Patent Rights in
the Alliance Field but outside the Exclusive Areas; provided, however, that
Applera pays to Abbott in accordance with Section 10.14, [***] percent
([***]%) of all revenue and other consideration (e.g., cross-license rights or
supply or distribution rights) received by Applera in consideration for such license.

 

(e)        Upon written
notice to Abbott, Applera or its Affiliates may grant to a Third Party a
nonexclusive right and license to use Applera Alliance Technology or Applera
Alliance Patent Rights outside the Alliance Field without accounting to Abbott.

 

(f)         In
settlement of a lawsuit or alternate dispute resolution procedure involving
enforcement of an Applera Alliance Patent Right against a Third Party, Applera
or its Affiliates may grant license rights to the Third Party under the Applera
Alliance Patent Rights in dispute in the Alliance Field but outside the
Exclusive Areas, provided: (i) the Third Party grants license rights to
Applera under Third Party Patent Rights in dispute, if any; (ii) Applera
uses commercially reasonable efforts to obtain sufficient rights to bring the
Third Party Patent Rights within Applera Independent Patent Rights; and (iii) any
revenue received by Applera from the Third Party as consideration for
activities in the Alliance Field after the Effective Date covered by the Applera
Alliance Patent Rights will be shared as provided in Section 10.4(d).

 

(g)        Notwithstanding
the provisions of this Section 10.4, Applera may Exploit without
limitation or restriction any Applera Alliance Technology that is not
Confidential Information.

 

10.5         Joint Alliance Technology and Joint Alliance Patent
Rights. Applera and Abbott will jointly own all right, title and interest
in and to all Joint Alliance Patent Rights and Joint Alliance Technology and
during the term of this Agreement, neither Party nor its Affiliates will have
the right to Exploit any Joint Alliance Patent Rights and Joint Alliance
Technology except as follows:

 

(a)        A Party may
use the Party’s interest in Joint Alliance Patent Rights and Joint Alliance
Technology in the Exclusive Areas in the performance of such Party’s
obligations pursuant to this Agreement.

 

(b)        A Party, if
it is an acquiring Party pursuant to Section 4.3 or a Proposing Party
pursuant to Section 4.4, may independently, or with a Third Party, use its
interest in Joint Alliance Patent Rights and Joint Alliance Technology for
Non-Alliance Products, provided such Party pays to the other Party royalties on
Net Sales of such Non-Alliance Products in accordance with Section 10.14(b) at
the rate determined for Section 2.3(d).

 

(c)        Without
approval of the other Party, a Party may use Joint Alliance Patent Rights and
Joint Alliance Technology for its or a Third Party’s (under contract with such
Party) research, Development, manufacture, use and Commercialization of
products and services outside the Alliance Field.

 

(d)        A Party and
its Affiliates may not grant any right or license to use that Joint Alliance
Technology or Joint Alliance Patent Rights in the Exclusive Areas without the 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

47

 

prior
approval of the other Party, and all revenue and other consideration (e.g.,
cross-license rights or supply or distribution rights) received by such Party
or its Affiliates in consideration for any such approved license will
constitute Licensing Revenue. A Party may grant to a Third Party a nonexclusive
right and license to use the Party’s interest in Joint Alliance Patent Rights
and Joint Alliance Technology in the Alliance Field but outside the Exclusive
Areas; provided, however, that the granting Party pays to the other Party in
accordance with Section 10.14, [***] percent ([***]%) of all revenue and
other consideration (e.g., cross-license rights or supply or distribution
rights) received by the granting Party in consideration for such license.

 

(e)        A Party may
grant to a Third Party a nonexclusive right and license to use the Party’s
interest in Joint Alliance Patent Rights outside the Alliance Field without
accounting to the other Party.

 

(f)         In
settlement of a lawsuit or alternate dispute resolution procedure involving
enforcement of a Joint Alliance Patent Right against a Third Party, the Third
Party may be granted license rights under the Joint Alliance Patent Rights in
dispute in the Alliance Field but outside the Exclusive Areas, provided the
Third Party grants license rights on the same terms to each Party under any
Third Party Patent Rights in dispute at least to the extent of the Alliance
Field.

 

(g)        Notwithstanding
the provisions of this Section 10.5, each Party may Exploit without
limitation or restriction any Joint Alliance Technology that is not
Confidential Information.

 

10.6         Employee Assignment and Disclosure. To the extent
permissible under applicable law, each Party will cause each employee and
contractor conducting work on such Party’s behalf under this Agreement to sign
a contract that (a) compels prompt disclosure to the Party of all
Technology Derived by such employee or contractor during any performance under
the Alliance Program and (b) automatically assigns to the Party all right,
title and interest in and to all such Technology. Each Party will require each
employee and contractor conducting work on such Party’s behalf under this
Agreement to maintain records in sufficient detail and in a good scientific
manner appropriate for patent purposes to properly reflect all work done.

 

10.7         Transfer of Applera Technology. Applera will use
commercially reasonable efforts to make available to Abbott all Applera
Independent Technology and Applera Alliance Technology that is reasonably
necessary for Abbott to perform its obligations under this Agreement. Without
the prior written consent of Applera, neither Abbott nor its Affiliates may use
any Applera Independent Technology or Applera Alliance Technology that is
Applera Confidential Information for any purpose not expressly authorized by
the terms of this Agreement. Moreover, Applera will disclose and make available
to Abbott and its Affiliates, upon Abbott’s request and at Abbott’s sole
expense, Applera Alliance Technology to the extent licensed to Abbott or its
Affiliates pursuant to Section 10.10(a) or 10.13 of this Agreement.

 

10.8         Transfer of Abbott Technology. Abbott will use
commercially reasonable efforts to make available to Applera all Abbott
Independent Technology and Abbott Alliance Technology that is reasonably
necessary for Applera to perform its obligations under this Agreement. Without
the prior written consent of Abbott, neither Applera nor its Affiliates may 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

48

 

use any Abbott Independent Technology or
Abbott Alliance Technology that is Abbott Confidential Information for any
purpose not expressly authorized by the terms of this Agreement. Moreover,
Abbott will disclose and make available to Applera and its Affiliates, upon
Applera’s request and at Applera’s sole expense, Abbott Alliance Technology to
the extent licensed to Applera or its Affiliates pursuant to Section 10.11(a) or
10.12 of this Agreement.

 

10.9         No Title Transfer. The transfer to a Party of any
physical item that embodies any Independent Technology or Alliance Technology
owned by the transferring Party will not be, and will not be construed to be, (a) a
sale, lease, offer to sell or lease or other transfer of title or ownership to
the receiving Party of such Independent Technology or Alliance Technology, or (b) a
license to the receiving Party (except as expressly provided in this Agreement)
under such Independent Technology or Alliance Technology.

 

10.10       Applera License Grant to Abbott in the Alliance Field.
Subject to the terms and conditions of this Agreement,

 

(a)        Applera
hereby grants to Abbott and its Affiliates a worldwide, nonexclusive license,
with no right to grant sublicenses, under Applera Independent Patent Rights,
Applera Independent Technology, Applera Alliance Patent Rights and Applera
Alliance Technology in the Exclusive Areas solely to the extent necessary for
Abbott: (i) to perform its obligations expressly set forth in this
Agreement; and (ii) to Commercialize Alliance Products during the term of
this Agreement.

 

(b)        The license
granted in Section 10.10(a)(i) and (ii) will be royalty-free
during the term of this Agreement, except and only to the extent of royalties
due to Third Parties for use of Applera Independent Technology or Applera
Independent Patent Rights.

 

(c)        Applera
hereby grants to Abbott and its Affiliates a worldwide, royalty-bearing,
nonexclusive license, with no right to grant sublicenses, under Applera
Alliance Patent Rights and Applera’s Deliverable Alliance Technology solely to
the extent necessary to permit Abbott and its Affiliates to Commercialize
Non-Alliance Products. This license will be subject to royalties in accordance
with Section 10.14 on Net Sales of such Non-Alliance Products at the rate
determined in Section 2.3(d) and will survive expiration or
termination of this Agreement.

 

(d)        Applera
hereby grants to Abbott and its Affiliates a worldwide, royalty-bearing,
nonexclusive license, with no right to grant sublicenses, under Applera
Independent Patent Rights and under Applera Independent Technology that was
previously used by Abbott or its Affiliates in Commercialization of an Alliance
Product, solely to the extent necessary to permit Abbott and its Affiliates to
Commercialize Non-Alliance Products that had been subject to rejected NPCDs in
the Conditionally Exclusive Areas. Abbott will pay Applera in accordance with Section 10.14(b) a
royalty on Net Sales of such Non-Alliance Products at the rate determined in Section 2.3(d).
The license granted in this Section 10.10(d) will survive expiration
or termination of this Agreement. No license is granted under any Applera
Independent Patent Rights or Applera Independent Technology for products or
services in the Optional Areas or outside the Alliance Field.

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

49

 

(e)        Notwithstanding
the provisions of this Section 10.10, Abbott may Exploit without
limitation, restriction or payment any Applera Independent Technology that,
through no fault of Abbott, is not Confidential Information.

 

10.11       Abbott License Grant to Applera in the Alliance Field.
Subject to the terms and conditions of this Agreement,

 

(a)        Abbott hereby
grants to Applera and its Affiliates a worldwide, nonexclusive license, with no
right to grant sublicenses, under Abbott Independent Patent Rights, Abbott
Independent Technology, Abbott Alliance Patent Rights and Abbott Alliance
Technology in the Exclusive Areas solely to the extent necessary for Applera: (i) to
perform its obligations expressly set forth in this Agreement; and (ii) to
Commercialize Alliance Products during the term of this Agreement.

 

(b)        The license
granted in Section 10.11(a)(i) and (ii) will be royalty-free
during the term of this Agreement, except and only to the extent of royalties
due to Third Parties for use of Abbott Independent Technology or Abbott
Independent Patent Rights.

 

(c)        Abbott hereby
grants to Applera and its Affiliates a worldwide, royalty-bearing, nonexclusive
license, with no right to grant sublicenses, under Abbott Alliance Patent
Rights and Abbott’s Deliverable Alliance Technology solely to the extent
necessary to permit Applera and its Affiliates to Commercialize Non-Alliance
Products. This license will be subject to royalties in accordance with Section 10.14
on Net Sales of such Non-Alliance Products at the rate determined in Section 2.3(d) and
will survive expiration or termination of this Agreement.

 

(d)        Abbott hereby
grants to Applera and its Affiliates a worldwide, royalty-bearing, nonexclusive
license, with no right to grant sublicenses, under Abbott Independent Patent
Rights and under Abbott Independent Technology that was previously used by
Applera or its Affiliates in Commercialization of an Alliance Product, solely
to the extent necessary to permit Applera and its Affiliates to Commercialize
Non-Alliance Products that had been subject to rejected NPCDs in the
Conditionally Exclusive Areas. Applera will pay Abbott in accordance with Section 10.14(b) a
royalty on Net Sales of such Non-Alliance Products at the rate determined in Section 2.3(d).
The license granted in this Section 10.11(d) will survive expiration
or termination of this Agreement. No license is granted under any Abbott
Independent Patent Rights or Abbott Independent Technology for products or
services in the Optional Areas or outside the Alliance Field.

 

(e)        Notwithstanding
the provisions of this Section 10.11, Applera may Exploit without
limitation, restriction or payment any Abbott Independent Technology that,
through no fault of Applera, is not Confidential Information.

 

10.12       Abbott License Grant to Applera Outside the Alliance Field.
In consideration of Applera’s joint funding pursuant to this Agreement, Abbott
hereby grants to Applera and its Affiliates the following worldwide,
royalty-bearing licenses outside the Alliance Field under the following license
terms:

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

50

 

(a)        for products,
other than therapeutic products, outside the Alliance Field, a nonexclusive
license, as determined in accordance with the procedures specified in Section 10.14(c),
under Abbott’s Deliverable Alliance Technology and any Abbott Alliance Patent
Rights, with a royalty rate negotiated and determined taking into account the
factors identified in Section 10.14(a), and in any event of not more than
[***] percent ([***]%) on Net Sales of products which incorporate or use such
Deliverable Alliance Technology or the manufacture, use, sale, offer for sale
or import of which is covered by a Valid Claim of the Abbott Alliance Patent
Rights, such license to be subject to the terms and conditions specified in Section 10.14(b);

 

(b)        the licenses,
except if terminated pursuant to Section 17.4, will survive expiration or
termination of this Agreement. No royalty will be payable for use of Abbott’s
Deliverable Alliance Technology that, through no fault of Applera, is not
Abbott Confidential Information; and

 

(c)        for
therapeutic products, there is no license absent separate agreement by the
Parties.

 

10.13       Applera License Grant to Abbott Outside the Alliance Field.
In consideration of Abbott’s joint funding pursuant to this Agreement, Applera
hereby grants to Abbott and its Affiliates the following worldwide,
royalty-bearing licenses outside the Alliance Field under the following license
terms:

 

(a)        for products,
other than therapeutic products, outside the Alliance Field, a nonexclusive
license, as determined in accordance with the procedures specified in Section 10.14(c),
under Applera’s Deliverable Alliance Technology and any Applera Alliance Patent
Rights, with a royalty rate negotiated and determined taking into account the
factors identified in Section 10.14(a), and in any event of not more than
[***] percent ([***]%) on Net Sales of products which incorporate or use such
Deliverable Alliance Technology or the manufacture, use, sale, offer for sale
or import of which is covered by a Valid Claim of the Applera Alliance Patent
Rights, such license to be subject to the terms and conditions specified in Section 10.14(b);

 

(b)        the licenses,
except if terminated pursuant to Section 17.5, will survive expiration or
termination of this Agreement. No royalty will be payable for use of Applera’s
Deliverable Alliance Technology that, through no fault of Abbott, is not
Applera Confidential Information; and

 

(c)        for
therapeutic products, there is no license absent separate agreement by the
Parties.

 

10.14       Royalty Rate Factors and License Terms. Each royalty
obligation under Sections 2.3(d), 4.4(a), 10.10(c) and (d), 10.11(c) and
(d), 10.12, 10.13 and 17.7(b) will be governed by this Section 10.14
as follows:

 

(a)        In each case
the royalty rate will be negotiated by the Parties but will not be greater than
the rate specified, or in the event the Parties cannot reach agreement on 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

51

 

the royalty
rate by negotiation and the issue is referred to ADR under Article XVIII,
the following factors will be considered in determining the royalty rate:

 

(i)    the strength of the intellectual property
subject to the license;

 

(ii)   the profitability of the products to which
such intellectual property would be applicable;

 

(iii)  whether the intellectual property is
foundational to the product or merely incidental;

 

(iv)  the market royalty rate, if any, for licenses
to intellectual property of similar scope for related or alternative
technologies;

 

(v)   the ease with which the intellectual property
can be avoided or designed around;

 

(vi)  whether the licensee will need to obtain
licenses to intellectual property controlled by Third Parties in order to
Commercialize a royalty bearing product;

 

(vii) whether the license is exclusive,
semi-exclusive or nonexclusive;

 

(viii)                whether the royalty rate will be
dependent upon achievement of specified sales thresholds; and

 

(ix)   such other factors as are usual and customary
in determining a reasonable royalty (e.g., the Georgia-Pacific factors).

 

(b)        Licenses
subject to this Section 10.14 will include the following terms and
conditions:

 

(i)    if the license being negotiated is other
than exclusive, the royalty rate will be subject to adjustment to be at least
as favorable to the licensee and its Affiliates as the royalty rate provided to
any other of the licensor’s licensees under the same rights for comparable
products in comparable markets (most favored licensee protection);

 

(ii)   the royalty rate will be additive to any
royalty owed to a Third Party (Third Party royalties additional);

 

(iii)  Third Party royalties owed will be passed
through by the licensor without mark-up (no mark-up on any pass through);

 

(iv)  if a product is subject to more than one
license which is subject to this Section 10.14 or, for a given license, a
product is subject to 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

52

 

multiple patents or technology
grants, then the royalty rate will be the highest rate applicable for a given
license, but royalties will not be cumulative, except for any Third Party
royalties (no royalty stacking);

 

(v)   the term for royalty payments will be: (A) for
licenses under Patent Rights, until expiration of the last to expire of the
licensed patents on products which, but for the license, would infringe a Valid
Claim of the licensed patents; and (B) for licenses under Technology, for
a period of [***] commencing from the first Commercialization of any product
which is made using or otherwise embodies the Technology, but only if and for
so long as Technology is Confidential Information;

 

(vi)  net sales will be calculated in the same
manner as Net Sales;

 

(vii) royalty payments will made in accordance with Section 9.7
within seventy-five (75) days after the end of each calendar quarter for sales
during such preceding calendar quarter, and each royalty payment will be
accompanied by a written report of net sales of the applicable products or
services sold during the preceding calendar quarter and the royalties due;

 

(viii)                the Party and its Affiliates
paying royalties will keep records sufficient to determine royalties due and
will make them available for audit in accordance with Sections 9.8 and 9.9; and

 

(ix)   such other terms and conditions as are usual
and customary.

 

(c)        The terms and
conditions for licenses under Sections 2.3(d), 4.4(a), 10.10(c) and (d),
10.11(c) and (d), 10.12, 10.13 and 17.7(b) will be negotiated and
determined in accordance with the following procedures:

 

(i)    the Parties will negotiate for a period of
three (3) months commencing from written notice by the prospective
licensee to the prospective licensor. The royalty factors and terms set forth
in Sections 10.14(a) and 10.14(b) will be used as guidance to the
Parties; and

 

(ii)   if after completion of the three (3) month
negotiation period the Parties are unable to reach agreement, the issue of the
license terms will be submitted to ADR pursuant to Sections 18.1 through 18.5,
with each side required to submit its last, best proposed terms to the neutral.
The neutral will select one of the Parties’ proposals and the prospective
licensee will have the option of either electing to enter into an agreement
with the terms of the selected proposal or to forever forgo its right to a
license.

 

(d)        Royalties
paid by one Party to the other Party in accordance with this Section 10.14,
for purposes of the Alliance Program, will not be considered as Revenue of the
receiving Party or Allowable Expenses for the paying Party.

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

53

 

ARTICLE XI

 

PATENT RIGHTS MAINTENANCE AND
ENFORCEMENT

 

11.1         Independent Patent Rights. Each Party will have the
exclusive right, but not the obligation, at its sole expense, to prepare, file,
prosecute, maintain and abandon all of its Independent Patent Rights. A Party
will give the other Party sixty (60) days advance written notice of its
intention to assign to a Third Party any of its Independent Patent Rights to
the extent reasonably related to the Exclusive Areas and the Conditionally
Exclusive Areas. To the extent the JRB determines an Independent Patent Right
claims the manufacture, use, sale, offer for sale or import of an Alliance
Product as of the date of assignment of such Independent Patent Right to a
Third Party, the Party assigning the Independent Patent Right will reserve for
itself and the other Party a nonexclusive, royalty-free, worldwide, irrevocable
license to Commercialize the Alliance Product during the term of this Agreement
and after termination pursuant to Sections 17.7(b)(ii) and (iii). Assigned
Independent Patent Rights will be subject to licenses granted prior to such
assignment pursuant to Sections 10.10 and 10.11 with respect to Non-Alliance
Products. Expenses associated with preparation, filing, prosecution and
maintenance of Independent Patent Rights will not be Allowable Expenses.

 

11.2         Alliance Patent Rights. Each Party will have the
exclusive right, but not the obligation, at its sole expense, to prepare, file,
prosecute and maintain all of its Alliance Patent Rights. All reasonable costs
and fees incurred by a Party in connection with preparation, filing,
prosecution and maintenance of Alliance Patent Rights in a Major Market Country
will be Allowable Expenses. To the extent any Alliance Patent Right is or
becomes reasonably necessary for or important to performance by either Party of
any aspect of the Alliance Program or reasonably necessary for or important to
manufacture or Commercialization of an Alliance Product, the Party owning such Alliance
Patent Right will exercise commercially reasonable efforts consistent with good
faith business practices to maintain ownership or Control of such Alliance
Patent Rights.

 

(a)        To the extent
a Party elects not to file for an Alliance Patent Right in a Major Market
Country or elects to abandon any Alliance Patent Right already filed in any
country, that Party will notify the other Party in writing not less than sixty
(60) days prior to the date such election is irrevocable without additional
cost, and will offer the other Party the opportunity to assume, at the other
Party’s sole expense, the right to file for, prosecute and maintain such
Alliance Patent Right in such country. If the other Party accepts the offer by
written notice to the first Party, the first Party will assign such Alliance
Patent Right to the other Party and will reasonably assist the other Party in
assuming the filing, prosecution and maintenance of such Alliance Patent Right
in such country. Such Alliance Patent Right thereafter will be the other Party’s
Independent Patent Rights.

 

(b)        With respect
to each United States patent application that is an Alliance Patent Right, not
less than sixty (60) days before filing any application for corresponding
patent protection in foreign countries, the Party owning the Alliance Patent
Right will give to JRB a copy of the priority application and written notice of
the foreign countries selected for filing. The JRB, in writing within thirty
(30) days after such notice, may reject any selected country outside the Major
Market Countries and may request filing of applications in 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

54

 

additional
foreign countries. The Party will file in such additional countries and may
file in the rejected countries. All reasonable costs associated with filing,
prosecution and maintenance of applications in Major Market Countries and in
any such additional countries requested by the JRB will be Allowable Expenses.
Expenses associated with filing, prosecution and maintenance in rejected
countries will be borne solely by the filing Party.

 

(c)        At least once
annually, each Party will provide to the other Party a written report of the
status of each pending and issued Alliance Patent Right.

 

11.3         Joint Alliance Patent Rights. The JRB will determine
which Party will control the preparation, filing, prosecution and maintenance
of each Joint Alliance Patent Right (“Controlling Party”).
The Controlling Party will prepare, file, prosecute and maintain all such Joint
Alliance Patent Rights in each of the Major Market Countries and such other
countries as the JRB approves, and the reasonable expenses thereof will be
Allowable Expenses.

 

(a)        If the
Controlling Party elects not to apply for a Joint Alliance Patent Right in any
country (other than a Major Market Country or such other countries as the JRB
approves) or elects to abandon any Joint Alliance Patent Right already filed in
any country, the Controlling Party will notify the other Party in writing not
less than sixty (60) days prior to the date such election is irrevocable
without additional cost, and will offer the other Party the opportunity to
assume, at the other Party’s sole expense, the right to file for, prosecute and
maintain such Alliance Patent Right in such country. If the other Party accepts
the offer by written notice to the Controlling Party, the Controlling Party
will assign its interest in such Joint Alliance Patent Right to the other Party
and will reasonably assist the other Party in assuming the filing, prosecution
and maintenance of such Joint Alliance Patent Right in such country. Such Joint
Alliance Patent Right thereafter will be the other Party’s Independent Patent
Rights.

 

(b)        With respect
to filing, prosecution and maintenance of each Joint Alliance Patent Right, the
Controlling Party will provide to the other Party: (i) a copy of the
patent application sufficiently prior to filing to permit the other Party
reasonable opportunity to review and make reasonable comments thereon; (ii) a
copy of the patent application promptly after such filing; (iii) copies of
all substantive communications received from patent office(s) with respect
to such filings; and (iv) copies of all substantive communications to be
sent to the patent office(s) with respect to such filings sufficiently
before a due date to permit the other Party to review and make reasonable
comments thereon.

 

(c)        The other
Party, when requested by the Controlling Party, will use commercially
reasonable efforts to assist the Controlling Party in preparing, filing or
maintaining the patent applications and patents within the Joint Alliance
Patent Rights. The reasonable expenses associated with providing such
assistance will be Allowable Expenses.

 

11.4         Alliance Patent Rights Enforcement Outside Exclusive
Areas. A Party will have the exclusive right, but not the obligation, at
its sole expense, to enforce all of its Alliance Patent Rights outside the
Exclusive Areas in the Alliance Field. Any recovery realized as a result of
such suit, claim or action or related settlement may be retained by the Party;
provided, however, that if a settlement grants rights under the Alliance Patent
Rights to the accused Third Party, Section 10.3(f) or 10.4(f) will
apply. Expenses incurred in any such enforcement will not 

 

[***] indicates material that has been omitted pursuant to a request for
confidential treatment. The omitted material has been filed separately with the
Securities and Exchange Commission.

 

55

 

be Allowable Expenses. To the extent the
alleged infringement or the scope of the settlement is outside the Alliance
Field, there will be no sharing between the Parties of any expenses or
recoveries.

 

11.5         Alliance Patent Rights Enforcement in the Exclusive Areas.
Each Party will promptly notify the other Party in writing if it learns of any
actual, alleged or threatened infringement of any Alliance Patent Right by a
Third Party in the Exclusive Areas. The Party owning the affected Alliance
Patent Right will have the first right, but not the obligation, at its own
expense, to bring suit (or take other appropriate legal action) against any
actual, alleged or threatened infringement of the Alliance Patent Right by a
Third Party in the Exclusive Areas, including the defense and settlement, to
the extent such infringement is in the Exclusive Areas. If the owning Party
does not initiate an infringement action or otherwise take affirmative measures
to abate any such actual, alleged or threatened Third Party infringement of the
Alliance Patent Right within ninety (90) days of the later of: (a) receiving
notification from the other Party under this Section 11.5 of such
infringement; (b) sending notice to the other Party under this Section 11.5
of such infringement; or (c) receiving a written request from the other
Party to take action with respect to such infringement, then the other Party
will have the right, but not the obligation, at its own expense, to bring suit
(or take other appropriate legal action) against any such actual, alleged or
threatened infringement of the Alliance Patent Right by a Third Party in the
Exclusive Areas, including the defense and settlement thereof. In the event
either Party brings an infringement action in accordance with this Section 11.5,
such Party will notify the other Party in writing at least fifteen (15) days
prior to filing such action and the other Party will provide reasonable
assistance and authority to file and bring the action, including, if required
to bring such action, being joined as a party plaintiff; provided, however,
that neither Party will be required to transfer any right, title or interest in
or to any of its Alliance Patent Rights to the other Party or a Third Party to
confer standing on a Party hereunder. In addition, if either Party brings an
infringement action hereunder, the other Party will have the right to be
represented separately in such action by counsel of its own choice, at its own
expense. Any recovery realized as a result of such suit, claim or action or
related settlement will first be applied pro rata to reimburse the Parties’
reasonable costs and expenses in connection with such suit, claim or action,
and any remaining amounts will be Licensing Revenue. Reasonable expenses not
offset will be Allowable Expenses; provided, however, that the Party not
bringing the infringement action may, by written notice to the other Party
within sixty (60) days from receipt of the notice of intent to file such
action, elect to opt-out from any monetary recovery resulting from such action,
including any settlement proceeds, and in such case, the reasonable expenses of
the Party prosecuting the action will not be Allowable Expenses.

 

11.6         Joint Alliance Patent Rights Enforcement. Each Party,
at its own expense, will have the right, but not the obligation, to initiate an
action to enforce a Joint Alliance Patent Right against accused infringer(s) outside
the Alliance Field. The Party initiating the action will notify the other Party
and identify the accused infringer(s). The other Party will cooperate in any
such action by (i) agreeing to be named as party to the action solely to
the extent necessary to maintain the action, and (ii) not granting any
license under the Joint Alliance Patent Right to the identified accused
infringer(s) until after such action is finally resolved. No Party will
settle the action without the other Party’s prior written consent, which
consent will not be unreasonably withheld or delayed, if the terms of
settlement would deprive the other Party of its rights in the asserted Joint
Alliance Patent Rights. Any recovery realized as a result of such suit, claim
or 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

56

 

action or related settlement will first be
applied pro rata to reimburse the Parties’ reasonable costs and expenses in
connection with such suit, claim or action, and any remaining amounts will be
retained by the Party initiating the action. Reasonable expenses not offset
will not be Allowable Expenses. A Party wishing to enforce a Joint Alliance
Patent Right against infringement in the Alliance Field will notify the JRB in
writing and identify the accused infringer(s). If the JRB approves of the
action, any monetary recovery will be considered Licensing Revenue and all
reasonable expenses incurred in the enforcement action will be Allowable
Expenses. If the enforcement action for infringement in the Alliance Field is
not approved by the JRB, the Party wishing to enforce a Joint Alliance Patent
Right may still bring the action, but such Party will be solely responsible for
all expenses incurred in the enforcement action and will be solely entitled to
retain any monetary recovery. In either case, the other Party will cooperate in
any such action by (i) agreeing to be named as party to the action solely
to the extent necessary to maintain the action, and (ii) not granting any
license under the Joint Alliance Patent Right to the identified accused
infringer(s) until after such action is finally resolved. Any settlement
will be subject to Section 10.5(f), and no Party will settle the action
without the other Party’s prior written consent, which consent will not be
unreasonably withheld or delayed, if the terms of settlement would deprive the
other Party of its rights in the asserted Joint Alliance Patent Rights.

 

11.7         Defense of Third Party Infringement Actions. Each
Party will promptly notify the other Party in the event of a claim or suit by a
Third Party alleging infringement of a Third Party patent based on use of
Alliance Technology or manufacture, use, sale, offer for sale or import of an
Alliance Product by a Party or customer. Promptly after such notice, the
Parties will confer. The Party against whom the action is filed will defend and
control the defense, and the other Party will cooperate with the defending
Party. If the alleged infringement is in the Alliance Field: (a) all
reasonable costs associated with the defense of the action will be Allowable
Expenses; (b) any payment as damages or in settlement allocated to sales
of Alliance Products during the term of this Agreement which are recognized as
Revenue will be approved by the JRB pursuant to Section 3.6 and if
approved will be Allowable Expenses; and (c) any settlement that requires
payment to the Third Party for the prospective right to Commercialize the
Alliance Product in the Alliance Field will require approval of the JRB
pursuant to Section 3.6. Each Party will individually bear the risks and
costs of infringing Third Party Patent Rights for its activities which are
either outside the term of this Agreement or outside the Alliance Field for any
product such Party manufactures or Commercializes.

 

11.8         Non-Alliance Product Infringement Issues. Each Party
will have the exclusive right, at its sole expense, to defend and control the
defense of any action alleging infringement of a Third Party’s patent by such
Party’s Non-Alliance Products.

 

ARTICLE XII

 

TRADEMARKS

 

12.1         Trademark Usage. Subject to continuing compliance
with applicable quality control standards, each Party will permit use of its
trademark or trade name with each Alliance Product to appropriately acknowledge
its contribution to the research, Development, manufacture or distribution
thereof. The JRB will determine the trademarks, trade names and domain names to
be used in connection with promotion, distribution and sale of each Alliance 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

57

 

Product (collectively, the “Marks”). In addition to trademarks, trade names or domain
names owned by a Party and used to Commercialize Alliance Products (“Party Marks”), the JRB may adopt new trademarks, trade names or
domain names for Alliance Products (“New Marks”).
Either Party may propose a New Mark to the JRB for approval. Prior to
submission to the JRB, such Party must first determine the availability of such
New Mark in the Major Market Countries. Neither the Supplier nor the
Distributor thereof may alter, remove or modify such Marks, or affix any other
trademark to such Alliance Product, without the prior written consent of the
JRB.

 

12.2         Labels. Each Alliance Product will be distributed in
the original packages under the original labels with the original inserts
provided by Supplier, unless otherwise agreed to by the JRB. The Distributor
thereof may alter, remove or modify such packages, labels or inserts, or add
any other packaging, label or insert to such Alliance Product if necessary to
comply with local requirements, but the Distributor may not alter, remove or
modify Marks used on such packages, labels or inserts without the prior written
consent of the JRB.

 

12.3         Party Trademark Rights. Each permitted use of a Party
Mark, to the extent used in the Alliance Program, will clearly indicate the
respective Party’s ownership of the Mark. Except as permitted by the JRB
pursuant to Section 12.1, nothing in this Agreement is intended to grant
to either Party any license or interest in the Party Marks of the other Party.
Each Party acknowledges the other Party’s claim of ownership of Party Marks of
such other Party. A Party’s use of the other Party’s Party Marks will inure to
the benefit of and be on behalf of the owner thereof. To the extent enforceable
under applicable law, a Party will not challenge the ownership of any Party
Mark, and a Party will not take any action that is inconsistent with, or may
impair, the other Party’s right, title and interest to its Party Marks. Neither
Party will represent to any Third Party that it has any ownership interest in
such Party Marks of the other Party.

 

12.4         New Trademark Rights. The Parties will have the right
to use New Marks relating to any Alliance Product solely in connection with the
promotional, marketing and sales activities of the Alliance Program. The
Distributor for a particular Alliance Product will own the New Marks associated
therewith. The Distributor will be responsible for obtaining and maintaining
registration of and for enforcing and defending such New Marks. All costs
associated with the search for and the registration, maintenance, defense and enforcement
of any approved New Mark will be considered Allowable Expenses. In the event
the Distributor transfers an Alliance Product to the other Party for
distribution pursuant to Section 7.4, the Distributor will assign to the
other Party all New Marks associated with the transferred Alliance Product and
goodwill associated therewith. In the event an Alliance Product is terminated
pursuant to Section 17.2, the JRB will decide, on a case by case basis,
whether one Party may own the New Mark associated with the terminated Alliance
Product in the post-termination period for a nominal royalty to be paid to the
other Party, or whether it is better to prohibit either Party from using the
New Mark and let the New Mark go unused and be subject to Third Party use under
applicable law.

 

12.5         Trademark Challenges. Each Party will promptly notify
the other Party in writing of any challenges to the validity or allegations of
infringement or unauthorized use of any of the Party Marks of the other Party
that are used in connection with the Alliance Program,  actual or threatened, that may come to such
Party’s attention. Unless the JRB otherwise 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

58

 

determines, each Party will be responsible
for and will assume all expenses of the defense and enforcement of its Party
Marks.

 

12.6         Post-Termination Rights. Upon termination or
expiration of this Agreement, the Distributor may continue to use the Marks on
the terms agreed to previously by the Parties solely in connection with
promotion, marketing, distribution and sale of Alliance Products permitted
after such termination or expiration as provided in Article XVII. Except
as provided in the preceding sentence, each Party will discontinue all use of
Party Marks owned by the other Party on termination or expiration of this
Agreement. Upon termination or expiration of this Agreement, each Party will
cooperate with the other Party and execute any and all documents requested for
the purpose of canceling any registered user or other rights with respect to
the other Party’s Party Marks that such Party may have acquired in operating
hereunder.

 

ARTICLE XIII

 

COPYRIGHTS

 

13.1         Copyright License. To the extent a Party’s
Copyrighted Works are included in its Independent Technology and Alliance
Technology, the Party hereby grants to the other Party licenses of the scope
granted under the corresponding Independent Technology and Alliance Technology
pursuant to Article X. Copyrighted Works that are part of Joint Alliance
Technology will be subject to Section 10.5.

 

13.2         Copyright Marking. The Supplier will ensure that any
Copyrighted Works associated with Alliance Products are marked with appropriate
copyright markings and accompanied with appropriate restrictive licenses, and
the Distributor may not remove such markings and licenses. Each Party may copy
and distribute to its sales representatives Alliance Product advertising,
literature and other materials prepared by or on behalf of a Party for the
purpose of fulfilling its obligations under this Agreement.

 

13.3         Copyright Infringement. Upon becoming aware of any
infringement of any of the other Party’s copyrights that are used in connection
with the Alliance Program, such Party will promptly notify the other Party in
writing of any such infringement and will provide the other Party with
reasonable assistance in initiating and prosecuting any legal action against
any infringer of the other Party’s copyrights.

 

ARTICLE XIV

 

CONFIDENTIALITY

 

14.1         Confidentiality. Subject to this Article XIV,
each Party will: (a) maintain in confidence the Confidential Information of
the other Party; (b) have the right to use the Confidential Information of
the other Party solely for the purpose of performing its obligations and
exercising its rights under this Agreement; (c) not use or grant to others
the use of the Confidential Information of the other Party except as expressly
permitted hereby; and (d) not disclose the Confidential Information of the
other Party except on a need-to-know basis to such Party’s directors, officers,
employees, agents, consultants and contractors, to the extent such 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

59

 

disclosure is reasonably necessary in
connection with such Party’s activities as expressly authorized by this
Agreement. Each Party will ensure that any of its directors, officers,
employees, agents, consultants and contractors having access to the other Party’s
Confidential Information is under a contractual obligation to the Party to hold
in confidence and not use such Confidential Information, except as permitted
under this Agreement. To the extent that disclosure to any person is authorized
by this Agreement, prior to disclosure, a Party will obtain written agreement
of such person to hold in confidence and not disclose, use or grant the use of
the Confidential Information of the other Party except as expressly permitted
under this Agreement. Each Party will notify the other Party promptly upon
discovery of any unauthorized use or disclosure of the other Party’s
Confidential Information. In performance of its obligation under this Section 14.1,
each Party will exercise the same degree of care as it exercises with respect
to its own proprietary information.

 

14.2         Terms of Agreement. No Party may disclose any terms
or conditions of this Agreement to any Third Party without the prior consent of
the other Party; provided, however, that a Party may disclose, under terms of
confidentiality equivalent to those in this Article XIV, the terms or
conditions of this Agreement (a) on a need-to-know basis to its legal and
financial advisors to the extent such disclosure is reasonably necessary, and (b) to
a Third Party in connection with: (i) a private placement equity
investment in such Party greater than Ten Million dollars ($10,000,000); (ii) a
merger, consolidation or similar transaction by such Party; or (iii) the
sale or other transfer of all or substantially all of such Party’s assets to
which this Agreement pertains. Notwithstanding the provisions of this Section 14.2,
a Party may disclose to potential customers and partners general aspects of
this Agreement, provided that no financial terms of this Agreement are
disclosed.

 

14.3         Permitted Disclosures. The confidentiality
obligations under this Article XIV will not apply to the extent that a
Party is required to disclose information (a) by applicable law,
regulation or order of a governmental agency or a court of competent
jurisdiction, or (b) pursuant to the rules and regulations of any
exchange or market on which a Party’s securities are traded or listed;
provided, however, that: (i) in the case of any such disclosure being
required under legal, regulatory or judicial process, such Party will: (A) provide
written notice thereof to the other Party; (B) consult with the other
Party with respect to such disclosure and use all reasonable efforts to provide
the other Party with sufficient opportunity to object to any such disclosure or
to request confidential treatment thereof; and (C) disclose only that
portion of Confidential Information or other information disclosed of which is
restricted hereunder that it determines (based on advice of its legal counsel)
is legally required to be disclosed, and will exercise its commercially
reasonable efforts to obtain reliable assurance that confidential treatment
required hereby will be accorded such information; and (ii) in the case
any Party determines (based on advice of its legal counsel) that it is required
to make a disclosure permitted under this Section 14.3, other than as a
result of legal, regulatory or judicial process, such Party will use all
reasonable efforts to provide the other Party with sufficient opportunity to
object to any such disclosure or request confidential treatment thereof. The
confidentiality obligations of this Article XIV also will not apply to the
content of professional publications that have been approved for publication
pursuant to the requirements of the procedure to be established by the JRB
pursuant to Section 3.2(f).

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

60

 

14.4         Disclosure to Investors and Rating Agencies.
Notwithstanding Sections 14.2 and 14.3, each Party may disclose the financial
results of the Alliance Program to its current and potential investors
(including securities analysts) and rating agencies. The scope of such
disclosure will be of the type ordinarily disclosed by corporations in the
healthcare field to investors and rating agencies. For avoidance of doubt, each
Party may disclose Alliance Program end user sales, which sales include
end-user sales of Alliance Products plus OEM Alliance Products, and its share
of operating profit or loss, as calculated in Section 9.2, in its
quarterly earnings releases and related filings with the U.S. Securities and
Exchange Commission. The disclosing Party will provide the other Party with two
(2) business days’ prior notice of any extraordinary financial disclosure.

 

14.5         Term of Obligations. The obligations of Sections 14.1
and 14.3 will expire five (5) years after termination or expiration of
this Agreement. Within such five (5) year period, either Party may notify,
in writing, the other Party of Confidential Information considered to be a
trade secret of the notifying Party, in which event, the other Party will
comply with the terms of Sections 14.1 and 14.3 with respect to such identified
trade secret so long as it retains the characteristics of Confidential
Information.

 

ARTICLE XV

REPRESENTATIONS AND WARRANTIES

 

15.1         Representations. Each Party represents and warrants
to the other Party as of the Effective Date as follows:

 

(a) except as otherwise identified in writing and
delivered to the other Party prior to the Effective Date, the execution,
delivery to the other Party and performance by it of this Agreement and its
compliance with the terms and provisions of this Agreement do not and will not
conflict, in any material respect, with, or result in a breach of, any of the
terms or provisions of: (i) any other contractual obligations of such
Party, except as more specifically described on Exhibit 2.2 hereto; (ii) the
provisions of its charter, operating documents or bylaws; or (iii) any
order, writ, injunction or decree of any court or governmental authority
entered against it or by which it or any of its property is bound except where
such breach or conflict would not materially impact the Party’s ability to meet
its obligations hereunder;

 

(b) this Agreement is a legal and valid obligation
binding upon such Party and enforceable in accordance with its terms except as
(i) enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting the enforcement of
creditors’ rights and (ii) equitable principles of general applicability;

 

(c) such Party is a corporation duly organized,
validly existing and in good standing under the laws of the state or other
jurisdiction of incorporation or formation and has full corporate power and
authority to enter into this Agreement and to carry out the provisions hereof
except where failure to be in good standing would not materially impact the
Party’s ability to meet its obligations hereunder;

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

61

 

(d) such
Party is duly authorized, by all requisite corporate action, to execute and
deliver this Agreement and the execution, delivery and performance of this
Agreement by such Party does not require any shareholder action or approval,
and the person executing this Agreement on behalf of such Party is duly
authorized to do so by all requisite corporate action; and

 

(e) no
consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any federal, state or local
governmental authority is required on the part of such Party in connection with
the valid execution, delivery and performance of this Agreement, except for any
filings under any applicable securities, trade, or competition laws and except
where the failure to obtain any of the foregoing would not have a material
adverse impact on the ability of such Party to meet its obligations hereunder.

 

15.2         Represented by Counsel. Each Party represents that it
has been represented by legal counsel in connection with this Agreement and
acknowledges that it has participated in the drafting hereof. In interpreting
and applying the terms and provisions of this Agreement, the Parties agree that
no presumption will apply against the Party which drafted such terms and
provisions.

 

15.3         Disclaimer Of Warranties. EXCEPT AS EXPRESSLY SET
FORTH IN SECTION 15.1, NEITHER PARTY MAKES ANY REPRESENTATIONS OR
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTIES
OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO ANY
ALLIANCE PRODUCTS, ALLIANCE TECHNOLOGY, ALLIANCE PATENT RIGHTS, OR ANY OF ITS
INDEPENDENT TECHNOLOGY OR INDEPENDENT PATENT RIGHTS. ADDITIONALLY, EACH PARTY
EXPRESSLY DISCLAIMS ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED,
THAT THE MANUFACTURE, USE, SALE, OFFER FOR SALE, IMPORT, COPYING OR
DISTRIBUTION OF ANY ALLIANCE PRODUCT OR OTHER PRODUCT OR METHOD SUBJECT TO THIS
AGREEMENT WILL NOT INFRINGE OR MISAPPROPRIATE THE INTELLECTUAL PROPERTY RIGHTS
OF ANY THIRD PARTY. ALL TECHNOLOGY PROVIDED BY ONE PARTY TO THE OTHER PARTY
PURSUANT TO THIS AGREEMENT IS PROVIDED “AS IS.”

 

ARTICLE XVI

INDEMNIFICATION

 

16.1         By Abbott. Abbott will indemnify and hold harmless
Applera, its Affiliates and their respective directors, officers, employees and
agents (“Applera
Indemnitees”) from and against all
losses, liabilities, damages and expenses, including reasonable attorneys’ fees
and costs (collectively, “Liabilities”), incurred as a result of any claims,
demands, actions or other proceedings by any Third Party to the extent
resulting from: (a) the material breach of any representation, warranty or
covenant by Abbott under this Agreement; (b) the use by Abbott of any
Technology of Applera or Confidential Information of Applera provided hereunder
(except to the extent indemnified by Applera under clause (c) of Section 16.2);
(c) subject to Sections 11.7 and 11.8, the infringement of any
intellectual property rights of a Third Party by Abbott 

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

62

 

Existing Products prior to but not after
becoming Alliance Products; or (d) the negligence or willful misconduct of
Abbott. The obligation to indemnify pursuant to Section 16.1(a) will
expire three (3) years after expiration or termination of this Agreement.
The indemnity obligations pursuant to Sections 16.1(b), (c) and (d) will
continue so long as a cause of action giving rise to the right of
indemnification may be brought by the Applera Indemnitees.

 

16.2        By Applera. Applera will indemnify and hold harmless Abbott,
its Affiliates and their respective directors, officers, employees and agents (“Abbott
Indemnitees”) (For purposes of this Article XVI, the term “Indemnitee” may refer to either or both the Applera
Indemnitees and the Abbott Indemnitees, as the context may indicate) from and
against all Liabilities, incurred as a result of any claims, demands, actions
or other proceedings by any Third Party to the extent resulting from: (a) the
material breach of any representation, warranty or covenant by Applera under
this Agreement; (b) the use by Applera of any Technology of Abbott or
Confidential Information of Abbott provided hereunder (except to the extent
indemnified by Abbott under clause (c) of Section 16.1); (c) subject
to Sections 11.7 and 11.8, the infringement of any intellectual property rights
of a Third Party by Applera Existing Products prior to but not after becoming
Alliance Products; or (d) the negligence or willful misconduct of Applera.
The obligation to indemnify pursuant to Section 16.2(a) will expire
three (3) years after expiration or termination of this Agreement. The
indemnity obligations pursuant to Sections 16.2(b), (c) and (d) will
continue so long as a cause of action giving rise to the right of
indemnification may be brought by the Abbott Indemnitees.

 

16.3         Procedure. If a Party or Indemnitee intends to claim
indemnification under this Article XVI, it will promptly notify the other
Party (the “Indemnitor”) in writing of any claim, demand, action or other
proceeding for which the Indemnitee intends to claim such indemnification, and
the Indemnitor may participate in, and, to the extent the Indemnitor so
desires, assume the defense of such claim, demand, action or proceeding with
counsel mutually satisfactory to the Parties; provided, however, that an
Indemnitee will have the right to retain its own counsel, with the fees and
expenses to be paid by the Indemnitor, if representation of such Indemnitee by
the counsel retained by the Indemnitor would be inappropriate due to actual or
potential differing interests between the Indemnitee and any other Party
represented by such counsel in such proceeding. The obligations of this Article XVI
will not apply to amounts paid in settlement of any claim, demand, action or
other proceeding if such settlement is effected without the consent of the
Indemnitor, which consent will not be unreasonably withheld or delayed. The
failure to deliver written notice to the Indemnitor within a reasonable time
after the commencement of any such action, if prejudicial to its ability to
defend such action, will relieve the Indemnitor of any obligation to the
Indemnitee under this Article XVI. The Indemnitee will reasonably
cooperate with the Indemnitor and its legal representatives in the
investigation of any claim, demand, action or other proceeding covered by this Article XVI.

 

16.4         Insurance. During the term of this Agreement and so
long as Alliance Products are being sold or used, each Party will maintain
comprehensive general liability, property damage, and product liability
insurance, through insurance carriers with an A.M. Best Rating of A-VII or
better rating. Such insurance coverage will be maintained with policy limits to
reasonably cover the obligations and the scope of activities contemplated
herein, and will name the other Party as an additional insured. Each Party
will, at the reasonable request of the other Party, provide the other Party
with evidence of such insurance coverage. Notwithstanding 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

63

 

the foregoing, and only upon written notice
to Applera of its agreement to provide protection of the scope contemplated by
this Section 16.4, Abbott may self-insure against each risk identified in
this Section 16.4 in amounts not less than the amounts identified as
appropriate hereunder.

 

ARTICLE XVII

TERM AND TERMINATION

 

17.1         Expiration. This Agreement will commence on the
Effective Date and, unless earlier terminated pursuant to this Article XVII,
will continue in effect until June 24, 2017.

 

17.2         Termination of an Alliance Product or NPCD. The JRB
will have the right to terminate an Alliance Product (including a JRB-approved
NPCD project), without terminating this Agreement in its entirety. An Alliance
Product may only be terminated by the JRB at the end of a Contract Year. The
Party requesting termination of the Alliance Product by the JRB (“Requesting Party”) must provide the non-Requesting Party with at
least one Contract Half Year’s prior written notice of its request to
terminate.

 

(a) If the
terminated Alliance Product had been in the Conditionally Exclusive Areas or
the Optional Areas prior to JRB approval of the NPCD or the terminated Alliance
Product was an OEM Instrument or Alliance Instrument subject to
Section 8.4 or 8.5, the non-Requesting Party may Commercialize the
terminated Alliance Product as a Non-Alliance Product subject to the terms of
Sections 2.3(d) and 4.4(b).

 

(b) If the
terminated Alliance Product had been in the Exclusive Areas,
Section 1.26(a)-(f), prior to JRB approval of the NPCD, upon termination
of an Alliance Product under this Section 17.2, except to the extent
necessary to perform its obligations pursuant to continuing other Alliance
Products under the Alliance Program, each Party will promptly return to the
other Party (unless otherwise approved by the JRB and except for one copy for
archival purposes only) all physical embodiments of any of the other Party’s
Independent Technology, Confidential Information and Copyrighted Works that
were provided by the other Party under this Agreement and that are unique to
the terminated Alliance Product.

 

17.3         Termination by Mutual Agreement. The Parties may
agree to terminate this Agreement at any time on mutually agreed upon terms.

 

17.4         Termination by Abbott. Abbott may terminate this
Agreement by a written notice to Applera that identifies a material breach by
Applera of its material obligations hereunder, and such termination will be
effective sixty (60) days after the written notice unless the identified breach
has been cured by Applera in the interim. If the breach has been cured prior to
expiration of the sixty (60)-day cure-period, the notice of termination will be
void. In lieu of seeking termination of this Agreement, Abbott may seek
compensatory damages and/or equitable relief as a remedy of an uncured material
breach by Applera.

 

17.5         Termination by Applera. Applera may terminate this
Agreement by a written notice to Abbott that identifies a material breach by
Abbott of its material obligations hereunder, and such termination will be
effective sixty (60) days after the written notice unless the identified breach
has been cured by Abbott in the interim. If the breach has been cured prior 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

64

 

to expiration of the sixty (60)-day
cure-period, the notice of termination will be void. In lieu of seeking
termination of this Agreement, Applera may seek compensatory damages and/or
equitable relief as a remedy of an uncured material breach by Abbott.

 

17.6         Other Termination. For calendar year [***], either
Party may give notice by no later than [***] of its intent to terminate this
Agreement, and upon such notice, this Agreement will terminate on [***]. In
determining Total Operating Profit of the Alliance Program for purposes of this
Section 17.6, all non-recurring, extraordinary items having a value of
more than [***] shall be excluded from the calculation. For the purposes of this
Agreement, “Total
Operating Profit” means, with
respect to the Alliance Program, the combined Revenue of the Parties less the
combined Allowable Expenses of the Parties. For the purposes of this Section 17.6,
Revenue includes Alliance Products and OEM Alliance Products.

 

17.7         Rights and Obligations. The following rights and
obligations will apply on and after the Termination Date:

 

(a) On the Termination Date, the Parties will enter
into a [***] tail down period (“TDP”). During
this period, each Party may continue to sell: (i) any Alliance Products
that it was a Distributor for and that was Commercialized prior to the
Termination Date; and (ii) any Alliance Products that it was designated by
the JRB as Distributor for and Regulatory Approval was filed for prior to the
Termination Date. After the expiration of the relevant TDP, each Party may
continue to sell the Alliance Products described in Sections
17.7(a)(i) and (ii) subject, to the extent applicable, to the license
grants hereunder.

 

(b) Effective as of the Termination Date:

 

(i)    Each Party hereby grants a worldwide,
royalty-bearing, nonexclusive license, as determined in accordance with the
terms and procedures specified in Section 10.14, with no right to grant
sublicenses, under its solely-owned Alliance Patent Rights and Deliverable
Alliance Technology to the other Party to Exploit (without the right to grant
further licenses) any product or service in the Alliance Field. The license
granted herein will continue until the last to expire of the granting Party’s
Alliance Patent Rights. The license granted herein does not require any
additional disclosure of Alliance Technology to the other Party. The royalty
for licenses granted pursuant to this Section 17.7(b)(i) will be
negotiated and determined taking into account the factors identified in Section 10.14(a),
and in any event the greater of [***] percent ([***]%) of Net Sales of products
sold or services rendered pursuant to such licenses or the TDP Royalty (as
defined in Section 17.7(c)), to the extent applicable pursuant to Section 17.7(c).

 

(ii)   Each Party hereby grants a worldwide,
royalty-bearing, nonexclusive license, as determined in accordance with the
terms and procedures specified in Section 10.14, with no right to grant
sublicenses under its Independent Patent Rights to the other Party solely to
the extent necessary to Exploit (without the right to grant further licenses): (A) the
license granted in Section 17.7(b)(i); (B) Joint Alliance Patent
Rights in the Alliance Field; and (C) 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

65

 

the
other Party’s solely-owned Alliance Patent Rights in the Alliance Field. The
royalty for licenses granted pursuant to this
Section 17.7(b)(ii) will be negotiated and determined taking into
account the factors identified in Section 10.14(a), and in any event, will
not be more than [***] percent ([***]%) of such Net Sales of products sold or
services rendered pursuant to such licenses plus any pass through royalty rates
due to Third Parties or the TDP Royalty, to the extent applicable pursuant to
Section 17.7(c).

 

(iii)  Each Party hereby grants to the other Party a
worldwide, royalty-bearing, nonexclusive license, as determined in accordance
with the terms and procedures specified in Section 10.14, with no right to
grant sublicenses, under the granting Party’s Independent Patent Rights and
Independent Technology to the extent, and only to the extent, such Independent
Patent Rights or Independent Technology were used by the other Party prior to
the Termination Date in Commercialization of a Non-Alliance Product of the
other Party or an Alliance Product, to Exploit (without the right to grant
further licenses) solely in the Alliance Field those products or services that
are: (A) first Commercialized by the other Party after the Termination
Date; (B) not subject to the licenses granted under Section 17.7(b)(ii);
and (C) not a Competing Product (“New Post-Termination Products”). The Parties will negotiate the applicable
royalty rate on Net Sales of such New Post-Termination Products in the Alliance
Field; provided, however, that the royalty rate will be negotiated and
determined taking into account the factors identified in Section 10.14,
and in any event not more than [***] percent ([***]%) of such Net Sales, plus
any royalties due to Third Parties for use of such Independent Patent Rights or
Independent Technology.

 

(iv)  Each Party who is a Supplier of an Alliance
Product as of the Termination Date will promptly disclose to the other Party
(to the extent not already disclosed) all Technology, including batch records
for each Alliance Product, used by the Supplier prior to the Termination Date
in manufacturing the Alliance Product. The Supplier also will, to the extent
permitted, grant to the other Party any intellectual property rights reasonably
necessary to permit the other Party to use the manufacturing Technology.

 

(c)        In
consideration for the post-termination rights granted in Sections 17.7(a) and
(b) and the value each Party contributed to the Alliance Program, each
Party will pay to the other Party a percentage on Division Margin, as defined
in Exhibit 17.7(c), of all Alliance Products, of all Post-Termination
Competing Products and, for the first [***] after Commercialization of only
those Post-Termination Acquired Products that are subject to Section 17.7(d)(i)(A),
any of which are sold or otherwise disposed of in the Alliance Field by such
Party, in the amounts and for the periods of time as set forth in Exhibit 17.7(c) (“TDP Royalty”), unless otherwise provided to the contrary.

 

(d)        For purposes
of this Article XVII, with respect to a Party that Commercializes a
Post-Termination Acquired Product that is also a Competing Product, one of the
following scenarios will occur:

 

[***]
indicates material that has been omitted pursuant to a request for confidential
treatment. The omitted material has been filed separately with the Securities
and Exchange Commission.

 

66

 

(i)    if the Party acquiring a Post-Termination
Acquired Product is also the Distributor of the competing Alliance Product and
such acquisition is closed within the first [***] after the Termination Date,
then the acquiring Party must provide prompt written notice to the other Party
regarding the Post-Termination Acquired Product, and the other Party, within
thirty (30) days after receipt of such notice, may elect, by providing written
notice to the acquiring Party, either:

 

     (A)     to
accept TDP Royalties on both the Post-Termination Acquired Product that is a
Competing Product and the competing Alliance Product for the [***] following
acquisition, unless the Parties mutually agree that such period be shorter, and
then at the end of the [***] period, or such other mutually agreed upon period,
such other Party would control the competing Alliance Product and the acquiring
Party would control the Post-Termination Acquired Product and neither product
will be subject to any further TDP Royalties; or

 

     (B)      to
immediately control the competing Alliance Product. In the event the other
Party makes an election under this Section 17.7(d)(i)(B), there will be a
[***] transition of the competing Alliance Product to the other Party, during
which time the other Party will continue to receive TDP Royalties on sales by
the Distributor of such competing Alliance Product (but will not receive any TDP
Royalties on the Post-Termination Acquired Product) and thereafter the
competing Alliance Product will not be subject to any further TDP Royalties;

 

(ii)   if the Party acquiring a Post-Termination
Acquired Product is also the Distributor of the competing Alliance Product and
such acquisition is closed after the [***] after the Termination Date, then the
acquiring Party must provide prompt written notice to the other Party regarding
the Post-Termination Acquired Product, and the other Party will immediately
control the competing Alliance Product; provided, however, there will be a
[***] transition of the competing Alliance Product to the other Party, during
which time the other Party will continue to receive TDP Royalties on sales by
the Distributor of such competing Alliance Product (but will not receive any
TDP Royalties on the Post-Termination Acquired Product) and thereafter the
competing Alliance Product will not be subject to any further TDP Royalties; or

 

(iii)  if the Party acquiring a Post-Termination
Acquired Product is not the Distributor of the competing Alliance Product, then
the acquiring Party must provide prompt written notice to the Distributor
regarding the Post-Termination Acquired Product, and the Distributor will
immediately control the competing Alliance Product and neither product will be
subject to any further TDP Royalties.

 

[***] indicates material that has been omitted
pursuant to a request for confidential treatment. The omitted material has been
filed separately with the Securities and Exchange Commission.

 

67

 

In no event will Section 17.7 apply to Post-Termination Acquired
Products that are not Competing Products. For the avoidance of doubt, neither
Party will be subject to any obligations regarding Target Minimum Sales Price
after the Termination Date.

 

(e)        In the event
termination is pursuant to Section 17.4 or 17.5 for breach of this
Agreement, any amounts payable pursuant to Section 17.7(c) by the
Party in breach of this Agreement to the other Party will be increased by [***]
percent ([***]%) (e.g., [***] times the applicable rate of the TDP Royalty) and
any amounts payable by the other Party to the Party in breach of this Agreement
will be decreased by [***] percent ([***]%) (e.g., [***] times the applicable
rate of the TDP Royalty).

 

(f)         A Party who
was a Supplier will continue to manufacture Alliance Products for the other
Party under terms and conditions similar to those regarding the supply of such
Alliance Products during the term of this Agreement, including providing
service and support as required by Section 7.5, and will ensure that any
such Alliance Product will not be incompatible with the other Party’s
then-current Instruments or then-current Reagents, depending on whether the
Alliance Product is a Reagent or an Instrument for a period of [***] following
the Termination Date; except that:

 

(i)    A Party who was a Supplier may discontinue
manufacturing any Alliance Product that is not an Instrument for any reason
following termination or expiration of this Agreement, upon providing the other
Party with [***] prior written notice; and

 

(ii)   A Party who was a Supplier of an Instrument
pursuant to Section 8.4 or 8.5 may, upon providing the other Party with
[***] prior written notice, discontinue supplying such Instrument following the
Termination Date if the annual number of such Instruments purchased from the
Supplier by the other Party falls below [***] percent ([***]%) of the level of
those such Instruments purchased from the Supplier by the other Party during
the [***] period prior to sending such notice. The Supplier may also, by [***]
prior written notice to the other Party, discontinue providing service and
parts for the Instrument whose supply to the other Party is being discontinued.

 

(g)        A Party who
was a Supplier will use commercially reasonable efforts to deliver all final
orders during the [***] wind-down period for Alliance Products under Section 17.7(f)(i) and
the [***] wind-down period for Alliance Products under Section 17.7(f)(ii) whose
supply to the other Party is being discontinued. Upon any such discontinued
supply of an Alliance Product, the Supplier, if requested in writing by the
other Party, will license and transfer to the other Party at that other Party’s
sole expense, royalty-free (subject to any pass through) and without the right
to sublicense, all Technology, including software source code and documentation
that is reasonably necessary to allow such other Party to support its own
manufacture of the Alliance Product in the future. The Party who was a Supplier
will be under no obligation to implement Product Innovations requested by the
other Party after the Termination Date. “Product Innovation”
means a modification that would require [***]. However, the Party who was a
Supplier will be obligated to implement reasonable Product Improvements
requested 

 

[***] indicates material
that has been omitted pursuant to a request for confidential treatment. The
omitted material has been filed separately with the Securities and Exchange
Commission.

 

68

 

by and at
the expense of the other Party. “Product Improvement”
means a modification that does not require [***].

 

(h)        Subsequent to
the Termination Date: (i) the Parties will continue to share in the
revenue from licenses granted during the term of this Agreement pursuant to
Sections 10.3(d), 10.4(d) and 10.5(d) for the duration of any royalty
or other payment obligation under such licenses; and (ii) each Party will
be permitted, upon prior written notice to the other Party, to grant licenses
in the Alliance Field to its solely-owned Alliance Patent Rights and Alliance
Technology and to Joint Alliance Patent Rights and Joint Alliance Technology:
provided, however, that revenue derived from such licenses: (A) in the
Exclusive Areas will be Licensing Revenue to be shared equally by the Parties; (B) in
the Alliance Field outside the Exclusive Areas will be shared by the Parties
pursuant to Sections 10.3(d), 10.4(d) or 10.5(d), as applicable; and (C) outside
the Alliance Field will not be shared by the Parties.

 

(i)    The intention of the TDP is to provide each
Party consideration for the rights granted in this Section 17.7 and for
its relative contribution to the Alliance Program. Accordingly each Party
agrees not to take action after the Termination Date that is intended to or has
the effect of disrupting or frustrating the purposes of the TDP and Section 17.7.

 

17.8         Termination for Force Majeure. In the event
performance by a Party is excused pursuant to Section 19.9 for a
continuous period of nine (9) months, the other Party will have the option
of terminating this Agreement upon written notice to the excused Party.

 

17.9         Termination for Change of Control.

 

(a)        If a Party, a
New Party (as defined in Section 17.9(b)(v)) it creates pursuant to Section 17.9(b) or
its permitted assignee pursuant to Section 19.5, is subject to a Change of
Control (as defined in Section 17.9(b)) during the term of this Agreement,
the following provisions will apply:

 

(i)    If within nine (9) months after such
Change of Control the Change of Control has actually, materially and adversely
affected the rights or reasonably contemplated benefits of the other Party
pursuant to this Agreement (an “Actual Adverse Effect”),
then the other Party may within such nine (9) months terminate this
Agreement by giving written notice to the Party subject to the Change of
Control specifying in reasonable detail the Actual Adverse Effect upon which
such termination is based.

 

(A)      If such Change of Control does not result
in an Actual Adverse Effect within nine (9) months after such Change of
Control, but the other Party believes in good faith that the Change of Control
is likely to result in an Actual Adverse Effect within twenty-one (21) months
after such Change of Control, then the other Party may, within nine (9) months
after such Change of Control, give notice to the Party subject to the Change of
Control of its belief regarding such likely Actual Adverse Effect, specifying
in reasonable detail (1) 

 

[***] indicates material
that has been omitted pursuant to a request for confidential treatment. The
omitted material has been filed separately with the Securities and Exchange
Commission.

 

69

 

the rights and/or benefits that the
other Party believes may be affected, and (2) the reasons that the other
Party believes such rights and/or benefits may be affected.

 

(B)       If the other Party sends a notice
pursuant to Section 17.9(a)(ii)(A), this Agreement will terminate on the
date which is twenty-one (21) months after the Change of Control if, as of such
date, the Change of Control has caused an Actual Adverse Effect and such Actual
Adverse Effect occurred either (1) in the manner and for the reasons
specified in the notice to the Party which was the subject of the Change of
Control under Section 17.9(a)(ii)(A) or (2) in a manner and for
reasons reasonably related to the manner and reasons specified in such notice.

 

(ii)   Notwithstanding the foregoing Sections
17.9(a)(i) and (ii), no termination of this Agreement under this Section 17.9
will be effective with respect to any event, facts or circumstances alleged to
be a Change of Control if the Party subject to the alleged Change of Control,
within sixty (60) days after receipt of the notice from the other Party
pursuant to Section 17.9(a)(i), establishes that there was no Change of
Control.

 

(b)        For purposes
of this Agreement, “Change
of Control” will mean with respect
to either Party: (i) the acquisition by a Third Party of twenty percent
(20%) or more of the combined voting power of the then outstanding voting
securities of the Party entitled to vote generally in the election of directors
(the “Combined
Voting Power”); provided, however,
that the acquisition by a Third Party that is a Passive Investor of twenty
percent (20%) or more of the Combined Voting Power will not be deemed a Change
of Control for purposes of this Agreement unless and until such Third Party
ceases to be a Passive Investor; (ii) over any twenty-four (24) month
period, individuals who constitute the board of directors of the Party as of
the beginning of the period (the “Incumbent Board”)
cease for any reason to constitute at least a majority thereof, provided that
any person becoming a director during such period whose election or nomination
for election by the Party’s stockholders was approved in advance by a vote of
at least a majority of the Incumbent Board (either by a specific vote or by
approval of the proxy statement of the Party in which such person is named as a
nominee for director without objection to such nomination) will be, for
purposes of this Section 17.9(b)(ii), considered as though such person
were a member of the Incumbent Board; (iii) the sale or transfer of a
substantial portion of the assets of the Party that are related to that Party’s
performance pursuant to this Agreement, directly or indirectly through the sale
or transfer of ownership interests in the assets or the entity owning such
assets, other than to a Permitted Affiliate of that Party (where for these
purposes a “substantial portion” of the assets related to performance pursuant
to this Agreement will mean assets material to a Party’s performance pursuant
to this Agreement); or (iv) a merger or combination with a Third Party
resulting in a Party’s stockholders ceasing to own at least sixty percent (60%)
of the equity voting power of the merged or combined enterprise.

 

Notwithstanding the foregoing, it will not be a Change of Control if: (v) a
Party transfers or otherwise disposes of a substantial portion (as defined
above and further refined below) of the assets related to that Party’s
performance pursuant to this Agreement to an entity formed by that Party or a
Permitted Affiliate (the “New Party”)
and then spins off to its stockholders all or a portion of the equity of that
entity (a “Spin Off”); and (vi) the New Party 

 

[***] indicates material that has been
omitted pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

 

70

 

becomes a Party to this Agreement (it being
understood for purposes of this Section 17.9 that no consent of the other
Party shall be required therefor); provided, however, that so long as the Party
doing the Spin Off owns at least thirty-five percent (35%) of the issued and
outstanding equity of the New Party, from and after the consummation of the
Spin Off, a Change of Control will be deemed to have occurred if any of the
events referred to in Sections 17.9(b)(i) through (iv) above occurs
with respect to either the Party doing the Spin Off or the New Party. For the
purposes of this Section 17.9(b), it is understood that, with respect to
intellectual property rights, a New Party will be deemed to have received a “substantial
portion” of the assets related to a Party’s performance pursuant to this
Agreement if that New Party has or receives all rights owned or Controlled by
the Party doing the Spin Off as of the date of the Spin Off (whether by
assignment or exclusive or nonexclusive license) that are necessary for that
New Party’s performance pursuant to this Agreement.

 

(c)        In the event
this Agreement is terminated pursuant to this Section 17.9, each Party
will be entitled to the rights and subject to the obligations created in
Sections 17.7(a), (b), (c), (d), (f) and (g).

 

(d)        For purposes
of this Agreement, a Change of Control of CDx will be deemed a Change of
Control of Applera.

 

(e)        Notwithstanding
anything to the contrary contained in this Agreement (including Section 19.5),
in the event of a Spin Off pursuant to Section 17.9(b), the Party doing
the Spin Off, from and after the date of the Spin Off, will no longer be
subject to any obligations or have any rights under this Agreement, including
any right to use any Alliance Technology and Alliance Patent Rights; provided
that the Party doing the Spin Off is released from such obligations only if and
so long as the following conditions are met:

 

(i)    after the Spin Off, the New Party must have
all material physical assets that were used by the Party doing the Spin Off
exclusively in its performance under this Agreement as of the date of the Spin
Off;

 

(ii)   the Party doing the Spin Off will not solicit
any employee of the New Party for two (2) years after the date of the Spin
Off; provided, however, that (A) a general advertisement of job
opportunities will not be deemed solicitation, (B) this restriction will
not apply to cases where an employee of the New Party initiates employment
discussions with the Party doing the Spin Off, and (C) this restriction
will not apply to former employees of the Party doing the Spin Off who are no
longer employed by the New Party;

 

(iii)  after the Spin Off, the New Party will own or
Control all Alliance Technology and all Alliance Patent Rights that the Party
doing the Spin Off owned or Controlled prior to the Spin Off and the Party
doing the Spin Off will not retain any rights under any such Alliance Patent
Rights or Alliance Technology;

 

(iv)  after the Spin Off, the New Party and the
other Party acting as part of the Alliance Program, in accordance with the
terms of this 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

71

 

Agreement, will own all Alliance
Products that existed before or will exist after the date of the Spin Off and
the Party doing the Spin Off will have no rights to any such Alliance Product;

 

(v)   the Party doing the Spin Off, as part of the
Spin Off, will grant to the New Party a worldwide, irrevocable, nonexclusive
license in the Exclusive Areas (subject to Section 8.10) on the same terms
as immediately prior to the Spin Off under all Independent Technology and
Independent Patent Rights owned or Controlled by the Party doing the Spin Off
as of the date of the Spin Off that is sufficient to permit the New Party to
exercise all rights and perform all obligations under this Agreement after the
Spin Off, including (A) the right to grant the other Party or Third
Parties rights necessary to permit research, Development and Commercialization
of Alliance Products, and (B) the right to make, have made, use, sell,
offer for sale and import all Alliance Products of the Alliance Program before
and after the date of the Spin Off; and

 

(vi)  except as may be agreed separately by the JRB
after the Spin Off, the Party doing the Spin Off will not be entitled to any
revenue from Alliance Program activities after the date of the Spin Off or
pursuant to any post-termination provisions of Section 17.7 (it being
understood that this Section 17.9(e)(vi) will not apply to any
economic interest resulting from any retained equity interest in the New Party
by the Party doing the Spin Off).

 

17.10       Termination for Insolvency. A Party may terminate this
Agreement by providing thirty (30) days prior written notice to the other Party
in the case of any adjudication of bankruptcy or insolvency, appointment of a
receiver by a court of competent jurisdiction, assignment for the benefit of
creditors, or institution of liquidation proceedings by or against the other
Party. Neither Party will deem termination pursuant to the application of this Section 17.10
to be a breach of this Agreement by a Party.

 

17.11       Product Inserts and Labeling. Post termination or
expiration of this Agreement, each Party will be responsible for providing the
Supplier with the text and documentation regarding any applicable regulatory
compliance of all package labels, product inserts, operator manuals and
end-user training materials used in connection with the Commercialization of
such Alliance Products. All labels and labeling will prominently identify the
appropriate Party as the manufacturer of an Alliance Product.

 

17.12       Return Material. Except to the extent necessary to
perform its rights and obligations pursuant to Section 17.7, each Party
will promptly return to the other Party (unless otherwise mutually agreed in
writing by the Parties and except for one copy for archival purposes only) all
physical embodiments of any of the other Party’s Independent Technology,
Confidential Information and Copyrighted Works, that were provided by such
other Party under this Agreement.

 

17.13       Share Net Investment. During the TDP, each Party will
continue to provide to the other Party Net Investment data as specified in Section 9.2.
Equalization payments will continue to be made as specified in Section 9.3,
factored as follows: (a) [***] percent 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

72

 

([***]%) for the [***] of the TDP; (b) [***]
percent ([***]%) for the [***] of the TDP; (c) [***] percent ([***]%) for
the [***] of the TDP; and (d) [***] percent ([***]%) for the [***] of the
TDP. At the expiration of the TDP, investment equalization held by each Party
will be returned to the other Party within sixty (60) days after such
expiration.

 

17.14       Liabilities. Termination of this Agreement will not
release either Party from any obligation or liability which may have accrued at
the time of termination, or preclude either Party from pursuing all rights at
law and in equity with respect to any default under this Agreement.
Notwithstanding the foregoing, neither Party will be liable for punitive,
exemplary or consequential damages incurred by the other Party arising out of any
default under this Agreement.

 

17.15       Post-Termination Activities.

 

(a)        Each Party
will render a post-termination report as required by Sections 4.11, 9.1, and
9.2 within the period specified in such provisions after the date of
termination or expiration of this Agreement. Each Party will be entitled to
conduct one audit in accordance with Section 9.9 within ninety (90) days
after the date of termination or expiration. To the extent surviving
termination, each Party will continue to comply with the terms of all licenses
granted to it in accordance with Section 10.14.

 

(b)        During the
relevant TDP, within sixty (60) days after the end of each fiscal calendar
quarter, each Party will furnish the other Party with a written statement, in
reasonably specific detail, stating in United States dollars for the
immediately preceding fiscal calendar quarter or part thereof, the Division
Margin as described in Section 17.7(c) and the royalties accrued
thereunder. Each such statement will be accompanied by payment of the amount
payable, if any, pursuant to Section 17.7(c).

 

(c)        During the
relevant TDP, each Party will keep records in accordance with Section 9.6
and will be entitled to an annual audit in accordance with Section 9.7
solely to the extent necessary to establish and confirm amounts payable
pursuant to Section 17.7.

 

17.16       Survival. Termination of this Agreement will be without
prejudice to any rights that may have accrued to the benefit of a Party prior
to such expiration or termination. Without limiting the foregoing, Articles I,
V, VI (except for Section 6.2), IX, XVI, and XVIII, and Sections 4.10,
4.11, 7.1, 7.4, 7.5, 10.9 through 10.13, 10.14, 11.1 through 11.3, 11.5, 11.6,
11.7, 12.6, 13.1, 14.1, 14.2, 14.3, 14.5, 17.7, 17.11 through 17.16, 19.1,
19.5, 19.7, 19.8, 19.9, 19.10, and 19.15 will survive any expiration or
termination of this Agreement to the extent necessary to effect the purposes
thereof.

 

ARTICLE XVIII

DISPUTE RESOLUTION

 

18.1         Disputes. Any dispute, controversy or claim initiated
by either Party arising out of, resulting from, or relating to this Agreement,
or the performance by either Party of its obligations under this Agreement
(other than bona fide Third Party actions or proceedings filed or instituted in
an action or proceeding by a Third Party against a Party to this Agreement), 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

73

 

whether before or after termination of this
Agreement, unless resolved pursuant to Section 18.2 or 18.3, will be
finally resolved by binding alternative dispute resolution (“ADR”) in accordance with this Article XVIII.

 

18.2         JRB Resolution. Before initiating arbitration, the
dispute will be brought to the attention of the JRB, which will attempt in good
faith to achieve a resolution. Either Party may convene a special meeting of
the JRB for the purpose of resolving disputes.

 

18.3         Executive Officer Resolution. If the JRB is unable to
resolve such a dispute within twenty-eight (28) days after the first
presentation of such dispute to the JRB or if the dispute arises by failure of
the JRB to reach a decision as provided in Section 3.4, the Parties will
send written notice of the dispute to their respective presidents (or their
executive officer designees) of the affected subsidiaries, divisions, or
business units. The respective officers will attempt to resolve such dispute by
good faith negotiations within twenty-eight (28) days after receipt of such
notice. If the Parties fail to resolve the dispute or their representatives
fail to meet or speak directly within twenty-eight (28) days of the notice of
the dispute, then either Party may refer the matter to ADR proceeding as
provided herein.

 

18.4         Notice of ADR. To begin any such ADR, a Party will
provide written notice to the other Party of the issues to be resolved by such
ADR. Within fourteen (14) days after receipt of such notice, the other Party
may, by written notice to the Party initiating the ADR, add additional issues
to be resolved within the same ADR.

 

18.5         Designation of Neutral. Within fourteen (14) days
following receipt of the notice required by Section 18.4, the Parties will
select a mutually acceptable neutral to preside in the resolution of any
dispute in such ADR proceeding. If the Parties are unable to agree on a
mutually acceptable neutral within such period, either Party may request the
President of the CPR Institute for Dispute Resolution (the “CPR”), 366 Madison Avenue, 14th Floor, New York, New
York 10017, to select a neutral pursuant to the following procedures:

 

(a)        The CPR will
submit to the Parties a list of not less than five (5) candidates within
fourteen (14) days after receipt of the request, along with a Curriculum Vitae
for each candidate. No candidate will be a current or past employee, director,
or shareholder of either Party.

 

(b)        Such list
will include a statement of disclosure by each candidate of any circumstance
likely to affect his or her impartiality.

 

(c)        Each Party
will number the candidates in order of preference (with the number one (1) signifying
the greatest preference) and will deliver the list to the CPR within seven (7) days
following receipt of the list of candidates. If a Party believes a conflict of
interest exists regarding any of the candidates, the Party will provide a
written explanation of the conflict to the CPR along with its list showing its
order of preference for the candidates. Any Party failing to return a list of
preferences on time will be deemed to have no order of preference.

 

(d)        If the
Parties collectively have identified fewer than three (3) candidates
deemed to have conflicts, the CPR will designate as the neutral the candidate
for whom the Parties collectively have indicated the greatest preference. If a
tie results between two 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

74

 

candidates,
the CPR may designate either candidate. If the Parties collectively have
identified three (3) or more candidates deemed to have conflicts, the CPR
will review the explanations regarding conflicts, and, in its sole discretion,
may either (i) immediately designate as the neutral the candidate for whom
the Parties collectively have indicated the greatest preference, or (ii) issue
a new list of not less than five (5) candidates, in which case the
procedures set forth in subsections 18.5(a) through (d) will be
repeated.

 

18.6         ADR Rules. Any such ADR will be conducted under the
then current CPR Rules for Non-Administrated Arbitration by a single neutral,
except that the Parties agree that there will be no discovery. Any such ADR
will be governed by the Federal Arbitration Act, 9 U.S.C. §§ 1-16. Any
arbitration will be held in Denver, Colorado.

 

18.7         Hearing. No earlier than twenty-eight (28) days but
no later than sixty (60) days after the selection, the neutral will hold a
hearing to resolve each of the issues identified by the Parties.

 

18.8         Evidence for Hearing. At least seven (7) days
prior to the hearing, each Party will submit the following to the other Party
and the neutral:

 

(a)        a copy of all
exhibits on which such Party intends to rely in any oral or written
presentation to the neutral;

 

(b)        a list of any
witnesses such Party intends to call at the hearing, and a short summary of the
anticipated testimony of each witness;

 

(c)        a proposed
ruling on each issue to be resolved, together with a request for a specific
damage award or other remedy for each issue. The proposed rulings and remedies
may not contain any recitation of the facts or any legal arguments and may not
exceed one (1) page per issue; and

 

(d)        a brief in
support of such Party’s proposed rulings and remedies, provided that the brief
may not exceed twenty (20) pages. This page limitation will apply
regardless of the number of issues raised in the ADR proceeding.

 

Except as expressly set forth in Sections 18.8(a) through (d), no
discovery will be required or permitted by any means, including depositions,
interrogatories, requests for admissions, or production of documents.

 

18.9         Hearing Procedure. The hearing will be conducted on
not more than two (2) consecutive days and will be governed by the
following rules:

 

(a)        Each Party
will be entitled to five (5) hours of hearing time to present its case.
The neutral will determine whether each Party has had the five (5) hours
to which it is entitled.

 

(b)        Each Party
will be entitled, but not required, to make an opening statement, to present
regular and rebuttal testimony, documents or other evidence, to cross-examine
witnesses, and to make a closing argument. Cross-examination of witnesses will
occur 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

75

 

immediately
after their direct testimony, and cross-examination time will be charged
against the Party conducting the cross-examination.

 

(c)        The Party
initiating the ADR will begin the hearing and, if it chooses to make an opening
statement, will address not only issues it raised but also any issues raised by
the responding Party. The responding Party, if it chooses to make an opening
statement, also will address all issues raised in the ADR. Thereafter, the
presentation of regular and rebuttal testimony and documents, other evidence,
and closing arguments will proceed in the same sequence.

 

(d)        Except when
testifying, witnesses will be excluded from the hearing until closing
arguments.

 

(e)        Settlement
negotiations, including any statements made therein, will not be admissible
under any circumstances. Affidavits prepared for purposes of the ADR hearing
also will not be admissible. As to all other matters, the neutral will have
sole discretion regarding the admissibility of any evidence.

 

18.10       Post-Hearing Briefs. Within seven (7) days
following completion of the hearing, each Party may submit to the other Party
and the neutral a post-hearing brief in support of its proposed rulings and
remedies, provided that such brief may not contain or discuss any new evidence
and may not exceed ten (10) pages. This page limitation will apply
regardless of the number of issues raised in the ADR proceeding.

 

18.11       Ruling by Neutral. The neutral will rule on each
disputed issue within fourteen (14) days following completion of the hearing.
Such ruling will adopt in its entirety the proposed ruling and remedy of one of
the Parties on each disputed issue but may adopt one Party’s proposed rulings
and remedies on some issues and the other Party’s proposed rulings and remedies
on other issues. The neutral may not issue any written opinion or otherwise
explain the basis of the ruling.

 

18.12       Allocation of Expenses. The neutral will be paid a
reasonable fee plus expenses. These fees and expenses, along with the
reasonable legal fees and expenses of the prevailing Party (including all
expert witness fees and expenses), the fees and expenses of a court reporter,
and any expenses for a hearing room, will be paid as follows:

 

(a)        If the neutral
rules in favor of one Party on all disputed issues in the ADR, the losing
Party will pay one hundred percent (100%) of such fees and expenses.

 

(b)        If the
neutral rules in favor of one Party on some issues and the other Party on
other issues, the neutral will issue with the rulings a written determination
as to how such fees and expenses will be allocated between the Parties. The
neutral will allocate fees and expenses in a way that bears a reasonable
relationship to the outcome of the ADR, with the Party prevailing on more
issues, or on issues of greater value or gravity, recovering a relatively
larger share of its legal fees and expenses.

 

18.13       Binding Result. The rulings of the neutral and the
allocation of fees and expenses will be binding, non-reviewable, and
non-appealable, and may be entered as a final 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

76

 

judgment in any court having jurisdiction.
All submissions to the ADR will be Confidential Information of the submitting
Party and the results of the ADR will be Confidential Information of each
Party.

 

18.14       Statute of Limitations. In no event will a demand for
ADR be made after the date when institution of a legal or equitable proceeding
based upon such claim, dispute or other matter in question would be barred by
the applicable statute of limitations.

 

ARTICLE XIX

MISCELLANEOUS

 

19.1         Governing Law. This Agreement will be governed by,
interpreted and construed in accordance with the laws of Delaware, without
regard to the conflict of laws principles thereof.

 

19.2         Publicity. Each Party may distribute the initial
press release. Other press releases or other similar public communication by
either Party relating to this Agreement, will be subject to Article XIV
and must be approved in advance by the other Party, which approval will not be
unreasonably withheld or delayed, except for those communications required by
applicable law (which will be provided to the other Party as soon as
practicable after the release or communication thereof). Neither disclosures of
information for which consent has previously been obtained, nor information of
a similar nature to that which has been previously disclosed publicly with
respect to this Agreement, will require advance approval.

 

19.3         No Implied Licenses. Except to the extent and only to
the extent necessary to enable a Party to conduct its obligations under this
Agreement, only licenses and rights granted expressly herein will be of legal
force and effect and no license or other right will be created hereunder by
implication, estoppel or otherwise.

 

19.4         Waiver. No waiver by a Party hereto of any breach or
default of any of the covenants or agreements herein set forth will be deemed a
waiver as to any subsequent and/or similar breach unless the waiver is in a
writing signed by authorized representatives of both Parties.

 

19.5         Assignment. Except as permitted by Section 17.9,
neither Party may assign any right or delegate any obligation hereunder, except
as otherwise expressly provided in this Agreement, other than to a Permitted
Affiliate, without the prior written consent of the other Party, such consent
not to be withheld if the proposed assignment or delegation would not be
reasonably expected to materially diminish such Party’s rights and reasonably
contemplated benefits under this Agreement (any refusal to provide consent on
this basis must be in writing and must include a reasonably detailed
explanation of the basis for the refusal). Any permitted assignee will assume
all obligations of its assignor under this Agreement and a Change of Control in
the assignee will be deemed to be a Change of Control in the assignor for
purposes of Section 17.9. Any purported assignment in violation of this Section 19.5
will be void. The terms and conditions of this Agreement will be binding upon
and inure to the benefit of the successors and permitted assigns of the
Parties.

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

77

 

19.6         Independent Contractors. The relationship of the
Parties hereto is that of independent contractors. The Parties hereto are not
deemed to be agents, partners or joint ventures of the others for any purpose
as a result of this Agreement or the transactions contemplated thereby.

 

19.7         Further Actions. Each Party agrees to: (a) execute,
acknowledge and deliver such further documents and instruments; (b) grant
such rights; and (c) perform all such other acts as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement.

 

19.8         Notices. All requests and notices required or
permitted to be given to the Parties hereto will be given in writing, will
expressly reference the section(s) of this Agreement to which they
pertain, and will be delivered to the other Party, effective on receipt, at the
appropriate address as set forth below or to such other addresses as may be
designated in writing by the Parties from time to time during the term of this
Agreement.

 

If to Applera and/or CDx:

 

Celera Diagnostics LLC

1401 Harbor Bay Parkway

Alameda, California 94502

Attn: President

 

with a copy to:

 

Applera Corporation

301 Merritt 7

Norwalk, Connecticut 06851

Attn: Senior Vice President and General Counsel

 

If to Abbott:

 

Abbott Molecular Inc.

1300 East Touhy Avenue

Des Plaines, Illinois 60018

Attn: President

 

with a copy to:

 

Abbott Laboratories

100 Abbott Park Road, D-322/AP6D

Abbott Park, Illinois 60064-6049

Attn: Divisional Vice President, Domestic Legal Operations

 

19.9         Force Majeure. Nonperformance of a Party (other than
for the payment of money) will be excused to the extent that performance is
rendered impossible by strike, fire, earthquake, flood, acts of terrorism,
governmental acts or orders or restrictions, failure of suppliers, or any other
reason where failure to perform is beyond the reasonable control and not 

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

78

 

caused by the negligence, intentional conduct
or misconduct of the nonperforming Party; provided, however, that the
nonperforming Party will use commercially reasonable efforts to resume
performance as soon as reasonably practicable.

 

19.10       No Consequential Damages. IN NO EVENT WILL A PARTY BE
LIABLE FOR SPECIAL, INCIDENTAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES
ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER,
INCLUDING, WITHOUT LIMITATION, LOST PROFITS ARISING FROM OR RELATING TO ANY
BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN
THIS SECTION 19.10 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION
RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER ARTICLE XVI ABOVE.

 

19.11       Third Party Rights. Notwithstanding anything to the
contrary in this Agreement, the grant of rights by each Party under this
Agreement will be subject to and limited in all respects by the terms of
agreements with Third Parties by which such Party acquired any Control of
intellectual property rights, and all rights granted under this Agreement will
be limited to the extent of such Party’s Control.

 

19.12       Complete Agreement. This Agreement, together with these
exhibits, constitutes the entire agreement between the Parties regarding the
subject matter hereof, and all prior representations, understandings and
agreements regarding the subject matter hereof, either written or oral, expressed
or implied, are superseded and will be and are of no effect; provided, however,
rights and obligations under the Prior Alliance Agreement will continue to the
extent they are not inconsistent with this Agreement. Nothing in this Agreement
is intended to affect or modify the terms of or relationship established by the
Instrument Supply Agreement dated September 24, 2004 or the Source Code
License dated September 24, 2004, both between Abbott and Applera, through
the Applied Biosystems Group. Amendment Nos. 2 and 2a to the Prior Alliance
Agreement survive the execution of this Agreement as further amended by the
Parties and set forth in Exhibit 19.12, attached hereto.

 

19.13       Counterparts. This Agreement may be executed in
counterparts, each of which will be deemed to be an original and together will
be deemed to be one and the same agreement.

 

19.14       Headings. The captions to the several articles and
sections hereof are not a part of this Agreement, but are included merely for
convenience of reference only and are not intended to affect its meaning or
interpretation.

 

19.15       Severability. Should any part or provision of this
Agreement be held unenforceable or in conflict with the law of any
jurisdiction, the validity of the remaining parts or provisions will not be
af­fected by such holding. In the event a part or provision of this Agreement
held unenforceable or in conflict with law affects consideration to either
Party, the Parties agree to negotiate in good faith amendment of such part or
provision in a manner consistent with the intention of the Parties as expressed
in this Agreement.

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

79

 

19.16       Amendment. This Agreement may be amended or modified
only by a written document signed by authorized representatives of both
Parties.

 

19.17       Controlling Document. In the event there is a conflict
between the terms or conditions of this Agreement and the terms and conditions
of Exhibit 8.2, the terms and conditions of this Agreement will control.

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be
executed by their respective duly authorized officers as of the day and year
first above written.

 

	
  APPLERA
  CORPORATION

  	
  ABBOTT
  LABORATORIES

  
	
  By:

  	
  /s/
  Kathy Ordoñez

  	
   

  	
  By:

  	
  /s/
  Edward Michael

  	
   

  
	
   

  	
  (Signature)

  	
   

  	
  (Signature)

  
	
  Kathy
  Ordoñez

  	
  Edward
  Michael

  
	
  (Printed
  Name)

  	
  (Printed
  Name)

  
	
  Senior
  Vice President

  	
  Corporate
  Vice President

  
	
  (Title)

  	
  (Title)

  
	
  January 9,
  2006

  	
  1/9/06

  
	
  Date

  	
  Date

  
						

 

 

	
  CELERA DIAGNOSTICS, LLC.

  
	
  By:

  	
  /s/ Kathy Ordoñez

  	
   

  
	
   

  	
  (Signature)

  

Kathy Ordoñez

(Printed Name)

President

(Title)

January 9, 2006

Date

 

[***] indicates material that has been omitted pursuant to a request
for confidential treatment. The omitted material has been filed separately with
the Securities and Exchange Commission.

 

80

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]